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ABSTRACT  
 
Chronic diseases and conditions such as liver and heart diseases are among the most 
common, costly, and preventable of all health problems. As of 2012 in the U.S., about half of all 
adults—117 million people—had one or more chronic health conditions. Aortic aneurysm and 
liver fibrosis are among the most common chronic diseases which are generated by the formation 
and deposition of excess extracellular matrix proteins (largely type I collagen) as a result of a 
reparative process, represents one of the most major global health problems. Collagen type I is one 
of the major diagnostic biomarkers and therapeutic targets for many chronic diseases including 
heart and liver diseases. Early diagnosis, noninvasive detection and staging of these diseases, 
remain as one of the major clinical barriers which can lead to effective treatment and stop further 
progression toward major clinical consequences. MRI as one the popular imaging modalities has 
several unique advantages for monitoring slow progression and detection of disease with high 
resolution without using radiation, however, there is an unmet medical need to develop MRI 
contrast agents with desired sensitivity and collagen specificity.   In this dissertation, the successful 
design of a protein-based contrast agent with collagen type I targeting capability 
(ProCA32.collagen1) is reported to diagnose and stage liver and heart diseases in many mouse 
models of caner, fibrosis and aortic aneurysm. ProCA32.collagen1 exhibits the highest relaxivity 
values for r1 (34 ± 0.12 mM
-1.s-1) and r2 (50 ± 0.16 mM
-1.s-1) per Gd3+ at 1.4 T and r1 (21.3 ± 0.5 
mM-1.s-1) and r2 (108.5 ± 1.2 mM
-1.s-1) at 7.0 T. ProCA32.collagen1 can detect both early (Ishak 
3 of 6) and late stage mouse liver fibrosis as well as early stage nonalcoholic steatohepatitis  (Ishak 
1 of 6) in different models with strong metal binding affinity and selectivity. The targeted contrast 
agent is also capable of detecting disease heterogeneity with high collagen type I binding affinity 
with dissociation constant of Kd=1.42  0.2 M. ProCA32.collagen1 has largely reduced dose and 
strong resistance against transmetallation (104-1012-fold higher metal selectivity for Gd3+ over Ca2+ 
and Zn2+) compared to existing contrast agents. ProCA32.collagen1 is expected to have strong 
translational potential to improve detection of different diseases at early stages with high 
confidence, and subsequently monitor disease progression and patient response to treatment.  
 
 
 
 
INDEX WORDS: MRI Contrast Agent, Protein Design, Gadolinium, Collagen Type I, Chronic 
Diseases, Liver Fibrosis, Aortic Aneurysm, Early Diagnosis,  
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1 INTRODUCTION 
 
 Magnetic resonance imaging (MRI) and contrast agents 
Magnetic resonance imaging (MRI) is an imaging modality and diagnostic technique in 
current clinical medicine. MRI as a diagnostic imaging modality has so many advantages such as 
its noninvasiveness, using no radiation, excellent spatial resolution, and soft tissue contrast. MRI 
is one of the premiere techniques resulting in important anatomical information. In addition, 
combination of MRI with other techniques leads to contrast in MRI which can provide noticeable 
images from the same anatomical region. As can example, MRI pulse sequences can be applied to 
create contrast between different tissues based on their proton density difference, T1 or T2 
relaxation times, water diffusion rates, and chemical shifts based on difference between water and 
lipids [2-6]. 
One of the major challenges associated with MRI is the lack of adequate sensitivity. In 
clinical imaging field, the primary importance is observing hydrogen atoms from water that are 
present in tissue at the concertation of approximately 90 M. In order to create more contrast to aid 
the MRI modality, usually a compound is necessary to affect properties of the 90 M water protons 
and this effect should be in a level that a noticeable change is reached. These compounds are called 
MRI contrast agents [6]. They can be categorized into three general subgroups of paramagnetic, 
superparamagnetic, or ferromagnetic compounds that will shorten the relaxation times of water 
protons. All contrast agents can shorten both T1 and T2 relaxation times, however based on 
whether the agent increases the transverse relaxation rate (1/T2) by roughly the same amount that 
it increases the longitudinal relaxation rate (1/T1) or whether 1/T2 is altered to a much greater 
extent, they can be classified into two groups of T1 agents and T2 agents, respectively [6, 7]. 
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In T1 agents, T1 lowering effect is dominant which increases the signal intensity; these are 
positive contrast agents. The T2 agents mainly increase the 1/T2 property and results in reduction 
in signal intensity, therefore, they are called negative contrast agents [6, 8]. One of the examples 
of paramagnetic agents with T1 effect are gadolinium-based contrast agents. Ferromagnetic iron 
oxide particles can be named as contrast agents with high T2 effect. The majority of contrast agents 
being used in clinical field are based on gadolinium complexes, however there are some instances 
of manganese- and iron-based contrast agents approved for clinical use. It has been reported that 
there are more than 10 million MRI studies being performed with gadolinium every year [6]. 
The interaction of contrast agent with the water hydrogen will affect relaxation properties of 
nuclei that creates the contrast which is different from contrast in other imaging modalities such 
as X-ray and nuclear imaging agents where the effect observed is more related to the concentration 
of the imaging agent. The concentration of water is much higher than the contrast agent, therefore, 
the agent must act as a catalyst to relax the water protons for the effect to be observed. The 
relaxivity is one of most important properties of a contrast agent which can be defined as the ability 
of an agent to change relaxation rate, and it is represented as r1 or r2, where r1 refers to longitudinal 
relaxation (1/T1) and r2 refers to transverse rate (1/T2). In other words, relaxivity is the change in 
relaxation rate after a contrast agent (∆(1/T)1) is applied which is normalized to the concentration 
of contrast agent or metal ion (M), Eqn (1-1).  
        (1-1) 
 
 
Different contrast agents have different relaxivity values and therefore have different sensitivities. 
Commercial and clinical contrast agents usually lack enough sensitivity and are effective at high 
concentrations ( 0.1 mM), therefore there has been an unmet medical need to increase their 
sensitivity [6]. 
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 Clinical Gd3+-based MRI contrast agents: Advantages and limitations 
Gadolinium-based contrast agent (GBCA) are used in approximately 25–30% of all MRI 
scans [9, 10]. The contrast agent creates a brighter or darker image specifically in the area of 
diseased tissue. The first approved contrast agent was Gd-DTPA (gadopentetate dimeglumine, 
Magnevist®) introduced in 1988. The first generation of contrast agents produced were for 
different purposes such as extracellular fluid (ECF) agents, liver imaging and agent that were given 
orally for gastrointestinal imaging. Currently, several agents are in clinical trials and one has been 
recently approved for MR angiography [11]. In preclinical stage, there has been continues efforts 
to create gadolinium-based contrast agents in molecular imaging. 
All GBCAs are used by intravenous (i.v.) administration. The route in which the contrast 
agent is being administered plays an indispensable role on biodistribution and safety. The majority 
of GBCAs are approved at a dose of ~ 0.1 mmol Gd/kg, however, for MR angiography two or 
three times higher dosage is required. Some newly developed agents such as gadofosveset and 
gadoxetic acid can be used at lower doses (0.03 mmol/kg and 0.025 mmol/kg, respectively). The 
injection dosage of contrast agent is also important since it affects the Gd3+ levels the subject 
receives. Furthermore, it can impact the exposure and how fast the compound is eliminated [11].  
Since the first approval of clinical MRI contrast agent, gadopentetate dimeglumine (Magnevist), 
in 1987, they have been successful in MR imaging of different types of tissues, diagnostics, 
characterization of tumors and other diseased tissues. In different cases of diseases, the change in 
permeability of blood vessels is crucial for the function of these MRI contrast agents. For instance, 
stroke, liver fibrosis, neuron degenerative diseases and so on are all have change in permeability 
of blood vessels. These clinical contrast agents can function as probes for organs such as liver, 
kidney, and gall bladder [8]. 
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Currently, all clinically approved MRI contrast agents based on Gd3+, the primary structure 
has a Gd3+ encapsulated by organic chelators, such as diethylenetriaminepentaacetic acid (DTPA) 
and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (Table 1.1). Usually, the 
coordination site of Gd3+ has up to 8 nitrogen and oxygen atoms contributed by the chelator to 
function as Gd3+ binding ligands. Furthermore, there is one water molecule exist in Gd3+ 
coordination site in clinical MRI contrast agent which interacts with Gd3+ through the Gd-O 
interactions. Charge and structure of chelators are important factors for Gd3+ coordination, 
therefore as a result, clinically approved Gd3+ MRI contrast agents are categorized into four 
groups: ionic linear contrast agents (examples: Magnevist, Multihance, Abalavar and Eovist), 
non-ionic linear contrast agents (examples: Ominiscan and Optimark), ionic cyclic contrast agents 
(examples: ProHance and Gadovist) and non-ionic cyclic contrast agents (example: Dotarem). 
Multihance and Eovist are organ (liver) specific agents, however, most of the clinical MRI contrast 
agents are extracellular contrast agents which are eliminated through kidney. Extracellular contrast 
agents can be successfully used for imaging of the whole body, structural changes in blood vessels 
and central nervous system (CNS). Since Eovist and Multihance are liver agents, hepatocytes in 
liver are responsible for their uptake (~50 %) and 5 % is eliminated by biliary excretion. These 
two contrast agents are widely used for liver imaging, such as primary liver cancer (hepatocellular 
carcinoma), liver metastases from other organs, and liver fibrosis [8, 12]. 
With the advent of MRI contrast agents, contrast enhanced MRI attracted great attention 
and became one of the most popular imaging modalities in the clinical field. For instance, the 
diagnosis of different liver diseases such as liver metastases and fibrosis heavily depends on 
imaging techniques, such as MRI, CT, ultrasound and PET, however, MRI is the best diagnostic 
tool among them. With the use of contrast agents, MRI is able to detect small lesions in liver 
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metastases with detection limit of ~ 2 cm or larger. Although other imaging modalities such as 
ultrasound may detect lesions as small as 2 mm, it faces important challenges such as surgery and 
limitations regarding the location of tumors since they need to be on the surface of the liver in 
order to be detected [13]. In addition, for detection of diseases such as liver fibrosis, MRI has the 
capacity to cover the whole liver in order to assess its heterogeneity [14]. Clinical MRI contrast 
agents can also play critical roles in MRI assisted surgery and biopsy and MRI guided therapy for 
different types of diseases, such as liver cancer [15].  
Despite evolving the whole MRI field with their advantages, clinically approved contrast 
agents have their own limitations. Since they are small-molecule chelators with small molecular 
mass, clinical MRI contrast agents usually have a short half-life time (half-life of approximately 
0.5-3 minutes in the blood of mice and elimination half-life of about 1.5 hours in humans [16, 17]. 
Optimization of MRI contrast agent’s properties are extremely important since it would directly 
affect the time window of MRI data collection and eliminate repeated dose injections. In addition, 
the application of these contrast agents can be widened to potential biological targets for molecular 
imaging which would significantly increase and improve their detection limits. For instance, this 
number is ~30 μM in mouse skeletal muscle for the contrast agent, [Gd(HPDO3A)(H2O)]. Overall, 
clinical MRI contrast agents have the following limitations: low relaxivity, low metal selectivity, 
high toxicity which causes Nephrogenic Systemic Fibrosis (NSF) due to high injection dosage, 
and they are non-specific and lack targeting capability with short half-life. All of these limitations 
have driven the need to develop contrast agents with significantly improved relaxivity, optimized 
retention time, and high targeting capabilities [16, 18, 19]. 
Other important characteristic of contrast agents are their toxicity and pharmacokinetics 
which have been well-studied in 1980s. Studies have shown that these contrast agents were proven 
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to be safer than iodinated contrast agents used in CT and X-ray. Despite their good safety profiles, 
clinical MRI contrast agents usually need high injection dosage of 0.025-0.3 mmol/kg and a 
concentration in mM range to be considered effective for contrast in tissues. In principal, the 
injection dosage and concentration can be lowered if the longitudinal relaxivity (r1) is increased or 
optimized. Since high concentrations are being utilized, these agents are facing concerns regarding 
the renal toxicity due to release of free Gd3+ from the most commonly used contrast agent, 
gadolinium-diethylene-triaminepentaacetic acid (Gd-DTPA). There are increased reports of 
nephrogenic systemic fibrosis (NSF) associated with Gd-DTPA, as well as a complication found 
in patients with end-stage renal failure (GRF < 30 ml min-1) [20-23]. 
Table 1.1 Clinical MRI Contrast Agents Based on Gd3+ [1, 24-26]. 
Generic Name Chemical Formula Trade Name r1,Plasma 
Relaxivity 
1.5T, 
37○C 
(mM-1s-1) 
r2,Plasma 
Relaxivity 
1.5T, 
37○C 
(mM-1s-1) 
Formulation 
Concentration 
Standard 
dose 
(mmol/kg) 
Gadopentetate 
dimeglumine 
[Gd(DTPA)(H2O)]2- Magnevist 4.1 4.6 0.5 M 0.1 
Gadodiamide [Gd(DTPA-
BMA)(H2O)] 
Omniscan 4.3 5.2 0.5 M 0.1 
Gadoversetamide [Gd(DTPA-
BMEA)(H2O)] 
Optimark 4.7 5.2 0.5 M 0.1 
Gadoterate 
meglumine 
[Gd(DOTA)(H2O)]- Dotarem 3.6 4.3 0.5 M 0.1 
Gadoteridol [Gd(HP-
DO3A)(H2O)] 
ProHance 4.1 5.0 0.5 M 0.1 
Gdobutrol [Gd(HP-
butrol)(H2O)] 
Gadovist 5.2 6.1 1.0 M 0.1 
Gadoxetic acid 
disodium 
[Gd(EOB-
DTPA)(H2O)]2- 
Eovist 
(Primovist) 
6.9 8.7 0.25 M 0.025 
Gadobenate 
dimeglumine 
[Gd(BOPTA)(H2O)]2- Multihance 6.3 8.7 0.5 M 0.1 
Gadofosveset 
trisodium 
Diphenylcyclohexyl 
phosphodiester-Gd-
DTPA 
Ablavar 27.7 72.6 0.25 M 0.03 
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 Important criteria of an MRI Contrast Agent 
There are several criteria that need to be considered in order to have an ideal contrast agent. 
One of the most important requirements for a contrast agent is to have minimum toxicity. In 
addition, thermodynamic and kinetic properties should be taken into consideration to have good 
stability and reasonable elimination half-life. Another important characteristic is the metal binding 
affinity and selectivity to minimize the adverse effects of the release of free Gd3+ into the body. 
Since other physiological metals such as Ca2+ and Zn2+ are present in high concentrations in the 
body, they have the ability to compete with Gd3+ in the contrast agent and cause its release, 
therefore, a high metal selectivity for paramagnetic metal ions (e.g. Gd3+ and Mn3+) against 
physiological metal ions is needed [27, 28]. High relaxivity, especially longitudinal relaxation (r1), 
is another important criterion required to achieve images with high dose efficiency and high 
contrast-to-noise ratio (CNR). Proper vascular retention time, permeability and perfusion is also 
crucial to allow the contrast agent to penetrate tissues in order to have enhancement, and monitor 
capillary integrity changes.  
Different methods have been used to improve the properties of MRI contrast agents based 
on small chelators. For instance, small chelators are being non-covalently bound to plasma 
proteins, such as albumin (MS-325), in order to greatly increase their relaxivity and blood retention 
time, however, these contrast agents can only be used in magnetic resonance angiography (MRA) 
[29, 30]. As it was mentioned previously, elimination or excretion time from the body is important 
for the contrast agent and needs to be optimized in order to have optimal imaging and reduced 
toxicity. Size of the contrast agent is therefore becoming important as molecules that are greater 
than ~ 7 nm or ~ 60 kDa in diameter can pass through the glomeruli. The circulation half-life of 
those molecules, compared to molecules with a diameter of less than 5 nm, can significantly 
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increase to over 78 minutes in mice, as the molecular weight is larger than 60 kDa [31-33]. 
Eventually, targeting specific molecules or biomarkers can dramatically increase the specificity 
and sensitivity of MRI contrast agents as powerful diagnostic and prognostic tools. Due to very 
low expression of biomarkers in the disease area, creating contrast agents with this capability will 
be beneficial. Moreover, high dose efficiency, low toxicity, optimal pharmacokinetics and 
thermodynamics and targeting capability and perfusion are indispensable for concreate molecular 
imaging. Understanding relaxivity as the most important criteria for designing an ideal contrast 
agent with the mentioned characteristics needs a thorough understanding of its theory to assist in 
development of MRI contrast agents [34]. In the next section, relaxivity and its theory and how it 
can assist the design of contrast agents will be discussed.  
 Strategies for the design of Gd3+-based MRI contrast agents 
In general, there are different approaches which will lead to increase in molecular relaxivity 
of contrast agents. First step can be optimization of the parameters that affect relaxivity and second, 
connecting multiple gadolinium complexes together. Linking multiple gadolinium complexes 
together for MR imaging have attracted great attention recently. The linking can occur either 
covalently (e.g. polymers, dendrimers) or non-covalently (e.g. liposomes). Many strategies have 
been used to optimize the relaxivity of these complexes and also designing them to target specific 
diseases.  
As a summary, most important factors affecting relaxivity are external field, the electronic 
properties of the gadolinium, water exchange, rotational diffusion, first and second coordination 
sphere hydration, and the ion to water proton distance. Each factor will be discussed in the next 
sections as well as the physical methods for the estimation of these parameters [6]. 
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Extracellular clinical MRI contrast agents like Magnevist ([Gd(DTPA)(H2O)]
2- are cheap to 
manufacture and have good safety profile. As it was mentioned earlier, doses as high as 0.3 
mmol/kg are given clinically for applications such as angiography and cerebral perfusion. After 
injection of the contrast agent at this dose, T1 becomes much shorter than T1 in any other tissue 
without contrast agent, and provides good contrast. One approach to increase the relaxivity is to 
increase the sensitivity of MRI for molecular targets instead of increasing the sensitivity of the 
contrast agent itself or making a better Magnevist.  
In order for a contrast agent to be effective in clinical exams with considerable and 
observable contrast, a relaxation rate change of at least ~ 0.5 s-1 is needed. For commercial contrast 
agents that are extracellular with a relaxivity of ~ 4 mM.s-1, ~125 µM of the agent is needed. If a 
targeted contrast agent is developed with the assumption of 1:1 binding stoichiometry, a minimum 
of 125 µM of the target needs to be present in order to observe the contrast. In order to assess the 
sensitivity, a study was conducted and concluded that the limit of detection of 
[Gd(HPDO3A)(H2O)] is around 30 µM in mouse skeletal muscle [19, 35].  
It can be concluded that the amount of potential biological targets detected by the contrast 
agent is limited. In order to have a reasonable and observable T1 change, relaxivity values and/or 
the number of Gd/molecule should be increased. Since molecular motion can affect relaxivity and 
the mobility will be dependent on molecular size, its rigidity, and possible tendency to bind other 
proteins, relaxivity must be optimized based on each molecule. As a matter of fact, no gadolinium 
complex exists which can be conjugated to a targeting molecule to necessarily create a targeted 
contrast agent with high relaxivity. Another important point is about the rotational dynamics of 
the final molecule which can be critical. With these parameters, there are several strategies to 
achieve an effective molecular targeted MRI contrast agent [36]. 
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The interaction between Gd3+ and water proton which affects its relaxation happens through 
a dipolar mechanism depending on 1/r6 which is the distance between the ion and the nucleus, 
therefore, it is crucial to have at least one exchangeable water in the inner coordination sphere of 
Gd3+ binding site. The number of water in the inner coordination sphere is represented by q and is 
called hydration number, however if this hydration number is bigger than one then the complex 
should be stable since the water can be displaced by ligands inside the inner coordination sphere 
[37].  
It is also very important for the complex to be stable and not reacting with any other 
molecules for in vivo applications since the gadolinium can be released because of these 
interactions. The rate in which the water is exchanging in and out of the first coordination sphere 
should be fast, therefore the solvent surrounding the contrast agent becomes important and the 
relaxation rate of bulk solvent should be increased.  In order for that to happen, Gd3+ should relax 
the water that has interaction with it, and the relaxed water should exchange fast enough with the 
bulk water. For complexes like [Gd(DTPA)(H2O)]
2- which has fast tumbling rate, the relaxation 
rate of the bound water is the rate limiting process. When rotational motion is slow, then water 
exchange rate becomes an important factor [37].  
The impact of both water exchange and rotational motion can be observed in an example 
where you compare the relaxivity of 0.1 mM MS-325 and MS-325-BMA in pH 7.4 phosphate 
buffer with saline (PBS) and 0.67 mM human serum albumin (HSA) solution at 37 ○C and 0.47 T. 
In this example, there are two contrast agents, one is one of the Gd-DTPA analogs called MS-325 
and the other one is its bis(N methyl)amido derivative along with their relaxivities at pH 7.4 
phosphate buffered saline (PBS) or in a PBS solution with human serum albumin (HSA) present. 
Gd3+ complexes with amido oxygen donor atoms present in their structure usually have slower 
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water exchange rates [6]. The complex of the bis (N-methyl) amide with Gd3+ which is the analog 
of DTPA, [Gd(DTPA-BMA)(H2O)], possesses a water exchange rate of about 10 times slower 
than [Gd(DTPA)(H2O)]2-along which has similar water exchange rates to their parent complexes. 
In PBS buffer, the relaxivity is similar since the relaxation of the bound water is the rate-limiting 
step [6, 37].  
This effect can determine how fast the molecules tumble in solutions and because of the 
similar size, their relaxivity values are similar. When there is serum albumin present in the solution, 
both of the Gd3+ complexes will bind to serum albumin and therefore as a result, their tumbling 
rate will be slower which will make the relaxation mechanism of the bound water more effective. 
In this example, it is evident that the water exchange rate is important and the slow water exchange 
in GdDTPA-BMA derivative complex affects its relaxivity. In some cases, increase in water 
exchange can improve relaxivity further and increase it, however, this will happen only if the 
process for relaxing the bound water is very efficient. 
For imaging of the majority of biological targets, multiple Gd3+ ions are needed to provide 
the required relaxation rate change. One option is linking multiple Gd3+ complexes to increase the 
effective correlation time for motion, however, it is important to understand and control the 
rotational flexibility which has a large impact on the relaxivity. Based on the way Gd3+ complexes 
are linked together, they can have different rotational motions and therefore, a different relaxivity 
value. Some complexes are linked in a linear oligomer way with anisotropic rotation, in this 
fashion, the rotation along the short axis of the molecule is fast and limits relaxivity. Usually, 
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dendrimers consist of Gd3+ complexes have higher relaxivity since the dendritic structure creates 
a more isotropic rotational dynamic which in this situation the effect of the larger molecular weight  
 
Figure 1.1. Different types of motions and linking strategies affecting relaxivity. 
 
and size on relaxivity is more effective (Fig 1.1 A). 
An example of a linear polymer is based on a modified dextran polymer with DO3A-
monoamide chelates with molecular weight of 52 kDa. The relaxivity of this molecule is about 
10.6 mM-1.s-1 (37○C, 0.47 T ) per Gd3+ [38]. Twenty-four of these Gd3+ chelates are linked together 
to create a polyamide dendrimer with the name of Gadomer-17. With similar conditions (40○C, 
0.47 tesla), Gadomer has a relaxivity of 16.5 mM-1.s-1 per gadolinium [36]. The Gd3+ chelates in 
the dendrimer can also have internal motion within the connectors in the dendrimer core.  
Another strategy to have the best effect of motion on relaxivity is to create a site for Gd3+ 
at the barycenter of a compound. For instance, Gadomelitol (also called P792 or Vistarem) which 
is a Gd-DOTA with large hydrophilic groups attached to each of the -carbons on the acetate 
branch follows this strategy. In this molecule, the Gd-H water vector rotates with the entire 
molecule, however, there is some level of flexibility within the hydrophilic arms, (Fig. 1.1 B). This 
A B C 
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limitation in rotation can cause a significantly high relaxivity which has r1 of 39.0 mM
-1s-1 (37○C, 
0.47 T) for a molecule with the size of just 6.4 kDa. It has been reported that this rotational effect 
can be tuned by changing the size of the hydrophilic arms [39-41].  
Another strategy for controlling rotational motion is called metal templated self-assembly 
approach [42, 43]. In this molecule, Gd3+ complexes are attached to rigid bidentate or tridentate 
ligands, and then a transition metal is used to connect the Gd3+ complexes in a compressed space. 
Another group has used this study with Gd3+ complexes with two water molecules [44]. In this 
structure, there are two complexes that are covalently linked to a bipyridyl ligand which coordinate 
Fe (II) in an octahedral structure leading to a high relaxivity per Gd3+ and per molecule. This 
specific compound has high Gd3+ content and low molecular weight which makes it more 
demanding as a contrast agent. The per Gd3+ relaxivity of the compound bipyridyl Gd3+ dimer is 
12.5 mM-1s-1 at 40 MHz, 37○C compared to 3.8 mM-1s-1 for [Gd(DTPA)(H2O)]. In conclusion, the 
high relaxivity can be attributed to two exchangeable water molecules and a large molecular 
weight. In the presence of Fe2+ and bipy ligands, the Gd3+ ions are part of the whole molecule with 
a longer correlation time which doubles the relaxivity to 26.5 mM-1s-1.  
These were just a few examples to demonstrate how relaxivity can be tuned in contrast 
agents of stable gadolinium complexes by changing the number of water molecules in Gd3+ 
coordination site, water exchange rate, and dynamics of the molecules related to their rotations. In 
some cases, these parameters can be changed by introducing a new environment such as buffer in 
the presence of serum albumin. Specifically, in this case, both water exchange rate and rotational 
motion contributed to an increase in relaxivity, and only one of them could not change relaxivity 
significantly by itself. Therefore, it would be very informative to know exactly what molecular 
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parameters can contribute to relaxivity in more details and how can these specific parameters be 
tuned. In order to answer these questions, we need to study the relaxivity theory more in details.  
 Relaxivity 
The deterioration of an MRI signal which is the decay of water relaxation is analyzed in 
terms of two separate processes: First, spin-lattice relaxation time (T1) and second, spin-spin 
relaxation time (T2). When a proton is placed in a magnetic field, the overall magnetization will 
be on the z axis. When an RF pulse is given, then the net magnetization will be oriented in different 
directions as long as the RF pulse is in place. Immediately after that RF pulse is ended, the protons 
will relax to their original position.  
Spin–lattice relaxation is the mechanism by which the z component of the magnetization 
vector comes into thermodynamic equilibrium with its surroundings (the "lattice") in nuclear 
magnetic resonance and magnetic resonance imaging. It is characterized by the spin–lattice 
relaxation time, a time constant known as T1. T1 characterizes the rate at which the 
longitudinal Mz component of the magnetization vector recovers exponentially towards its 
thermodynamic equilibrium, according to equation: 
Mz (t) = Mz, eq  - [ (Mz, eq –Mz (0)] e 
-t/T1         (1-2) 
Or, for the specific case that Mz (0) = 0 
Mz (t) = Mz, eq  (1-e 
-t/T1)           (1-3) 
It is thus the time it takes for the longitudinal magnetization to recover approximately 63% [1-
(1/e)] of its initial value after being flipped into the magnetic transverse plane by a 90° 
radiofrequency pulse. 
The spin–spin relaxation is the mechanism by which Mxy, the transverse component of 
the magnetization vector, exponentially decays towards its equilibrium value in NMR and MRI. It 
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is characterized by the spin–spin relaxation time, known as T2, a time constant characterizing the 
signal decay. It is named in contrast to T1, the spin–lattice relaxation time. It is the time it takes 
for the magnetic resonance signal to irreversibly decay to 37% (1/e) of its initial value after its 
generation by tipping the longitudinal magnetization towards the magnetic transverse plane. Hence 
the relation: 
Mxy (t) = Mxy (0) e 
-t/T2           (1-4) 
T2 relaxation generally proceeds more rapidly than T1 recovery. 
The MRI signal enhancement in tissues are determined by T1 and T2 relaxation time. MRI 
pulse sequences use different repetition time (TR) and echo time (TE) in order to observe the T1 
and T2 effect on signal enhancement. Based on TR and TE parameters, different pulse sequences 
can be applied such as T1-weighted MRI, T2 (or T2*)-weighted MRI, proton density-weighted, 
T1 map and T2 map.  Since T1 effect is being observed in T1-weighted MRI, it usually has a short 
TR and very short TE to minimize the T2 effect, For T2 (or T2*)-weighted MRI, TR is very long 
(usually more than 3 s) to minimize the T1 effect and TE is relatively long (at around 40 – 100 
ms). Proton density imaging has both T1 and T2 effect which has long TR (more than 3 s) and 
short TE. T1 and T2 maps are generally more sensitive than T1- and T2-wieghted sequences as 
they reflect the actual T1 and T2 values rather than intensities. To generate T2 map, one single TR 
is used and multiple TEs are applied. For T1 map inversion recovery, multiple inversion times (TI) 
are being used.  Using different TRs and TEs, MRI is able to show the differences of T1 or T2 (or 
T2*) of the tissue. As it was mentioned before, Gd3+-based MRI contrast agents are mainly T1 
agents because they can only shorten the T1 time of the water, however other contrast agents such 
as iron oxide nanoparticles are T2 agents because of their ability to shorten T2 time, therefore they 
are widely used in T2- or T2*-weighted MRI sequences. Generally, contrast agents have the ability 
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to shorten either T1 or T2 not both of them and these contrast agents cannot be used in both T1-
weighted and T2-weighted MR imaging. Moreover, clinical Gd3+-based MRI contrast agents have 
very low relaxivity and sensitivity which further limits their application in T1-weighted MRI. 
An MRI contrast agent with both high r1 and r2 has the capability to change the MRI signal 
in both T1- and T2-weighted images, and both T1 and T2 maps can be used for imaging with such 
contrast agent. In addition, T1 inversion recovery with short TE which uses inversion time to 
suppress the signal can be combined with such contrast agent. ProCA32.collagen1 has both high 
r1 and r2 values and enables both T1 and T2 imaging. The application of a T1-T2 contrast agent 
has not been widely reported in the literature since the majority of contrast agent are either T1 or 
T2 agents and their relaxivity specially for small-molecule clinical contrast agents are low.  
A gadolinium complex causes the relaxation of solvent water (bulk water) which is a 
phenomenon with multiple variables involved. When water molecule is close to Gd3+ or any other 
metal with similar properties, it will be relaxed and can be exchanged with water molecules in the 
solvent. Therefore, three types of water molecules will be involved. First, there is inner-sphere 
water. This type of water has directly coordinated Gd3+ in the binding site through its oxygen arms. 
Second, there is 2nd-sphere water. In this type of water molecule, they have hydrated the Gd3+ 
complex, and they spend specific time with the complex which is longer than the translational 
diffusion time of pure water. Third is outer-sphere water. Outer-sphere water can interact with the 
waters that are with Gd3+ and they are guided only by translational diffusion and a distance of 
closest approach [6].  
The water hydrogen has a T1 relaxation by Gd3+ which happens through dipolar mechanism. 
Generally, relaxation time will be affected by the number of water molecules, their distance to 
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Gd3+, rate of exchange with bulk solvent, as well as rotational correlation time, τc which all of 
them will be discussed in more details.  
Constant changes in magnetic field strength can cause spin transitions and relaxation. In 
order to quantify these changes, usually, a correlation time is defined as the time constant for 
characterizing these fluctuations and 1/τc is the average rate constant to quantify the changes in 
dipoles of magnetic field. The phenomena resulting in to fluctuation of magnetic dipoles are: 1. 
Electronic relaxation (1/T1e) at the Gd
3+ ion creates. 2. Rotational diffusion (1/τR) of the Gd
3+ 
complex. 3. Water exchange in and outside of the first (1/τm) or 2nd (1/ τm
´) coordination spheres 
for the hydrogen nucleus. The shortest time constant or the fastest rate has the maximum effect on 
the extent of relaxation. The lifetime of water in the second sphere and its corresponding 
correlation time is usually ~ 10’s of picoseconds, however, the water in the first coordination 
sphere has a much longer lifetime which is around 1 ns–10,000 ns, therefore, the correlation time 
is usually rotational diffusion or electronic relaxation [6].
 
Figure 1.2 Describing molecular parameters that are affecting inner- and 2nd-sphere relaxivity. 
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Fig. 1.2 is demonstrating these effects. The hydrogen nuclei have magnetic dipoles shown 
by the vectors. The water number that is shown by q are the waters in the inner-sphere which has 
Gd–H distance of r and a residency time of τm, and q´ waters in the second-sphere at a Gd–H 
distance of r´ and residency time τm´. Besides hydrogen, Gd
3+ also has magnetic dipole which is 
stronger and is shown by a large vector and quantified by spin S. The magnetic dipole can undergo 
relaxation which is defined by T1e and T2e. If the complex tumbles in a isotropical manner, the 
rotational motion resulting from this tumble is defined as rotational correlation time, τR.   
Water in the outer-sphere is defined by a parameter called translational diffusion correlation 
time τD and a distance of closest approach called a. Therefore, there are a total of 11 parameters 
that can contribute to relaxation at a magnetic field of B0. In addition, electronic relaxation also 
depends on magnetic field. It is important to mention that the simple measurement of relaxivity 
cannot represent the effect of all these parameters. Some of these parameters and their effect on 
relaxivity can be stimulated and some of these parameters can be determined independently. In 
conclusion, a more complete perception of the molecular basis of relaxivity evolved the contrast 
agent field and can result in improved agents with higher relaxivity [6].  
1.5.1 Inner-Sphere Relaxivity 
Relaxivity originating from the inner-sphere waters can be explained by equation (1-2). In 
this equation, there are two sites for exchange where T1m is the T1 of the water hydrogen in the 
inner-sphere and [H2O] is the water concentration in mM. In order to increase relaxivity, water 
number q can be increased or T1m or τm can be decreased.  
 
(1-5) [6] 
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1.5.2 Hydration number, q 
The safety of contrast agents used for human is the most important priority in developing 
them and they should be stable enough so that the complex that is holding the Gd3+ does not release 
it into the body, therefore due to safety concerns, the number of waters (q) that can be incorporated 
into the complex to increase the relaxivity of the contrast agent is limited. Theoretically, when 
there are more waters in Gd3+ coordination sites as ligands, the thermodynamic stability of the 
complex is compromised and the Gd3+ is likely to be released from the complex. Another 
disadvantage of increasing the water number is that other ligands such as endogenous phosphate 
or bicarbonate can replace and displace water and coordinate Gd3+ instead which results in reduced 
relaxivity. For instance, if an acetate group is removed from [Gd(DOTA)(H2O)]
- to produce 
[Gd(DO3A)(H2O)2], this will increase the hydration number but still results in a stable 
complex[45]. The water molecules can be displaced by anion binding as well. A group of 
compounds called hydroxypyridinone (HOPO) described in the literature have shown stability 
with q = 2 and are resistant to anion coordination [46-48]. 
1.5.3 Inner-Sphere water relaxation 
As it can be observed in eqn (1-5), both the relaxation time of the bound water (T1m), and 
the water residency time (τm) should be as short as possible to increase the relaxivity. At the 
beginning of development of MR contrast agents, T1m was larger than τm and therefore it was T1m 
that was limiting the relaxivity of these agents. The compounds shown in Figure 1.1 followed the 
same rule for their relaxivity in buffer. Dipolar relaxation originating from electron–nuclear spin 
coupling can be described by Eqns (1-6) and (1-7): 
 
(1-6) [6] 
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                 (1-7) [6] 
 
 
With respect to these equations, relaxation depends on the Gd–H distance, rGdH, Larmor frequency 
of the proton H (in rad/s), the electron Larmor frequency S (S = 658H), and correlation times 
τc1 and τc2. The 
2τc2
2 are referred to as dispersive terms since 2 τc2
2 1, the relaxation rate 
decreases and disperses with increase in frequency or magnetic field. Since the Larmor frequency 
of the electron is 658 times bigger than the proton, the first term in square brackets disperses at a 
lower magnetic field compared to the second term, however, if the correlation time is independent 
of magnetic field, then the relaxation rate relies on proton Larmor frequency. Usually, at low fields 
the rate decreases to almost 70% and then the rest will disperse at higher fields. For Gd3+ 
complexes, the correlation time depends on magnetic field and the NMRD behavior is more 
complicated. 
1.5.4 Gadolinium-water distance 
In equation (1-6), the term outside the square brackets are physical constants. First, it is the 
spin quantum number of Gd3+ which is S = 7/2, and Gd–H distance, which is shown by rGdH. Gd
3+ 
is a suitable metal as a relaxation agent since it has large spin number and slow electronic 
relaxation. Furthermore, Gd–H distance is important and if this distance is reduced, then it would 
result in increase in relaxivity. The distance varies based on literature, however it ranges between 
2.7 and 3.3 A° which is obtained indirectly. One of the direct determination methods of calculating 
the Gd–H ion–nuclear distance is to use neutron diffraction on single crystals or using isotopic 
exchange techniques. Electron–nuclear double resonance (ENDOR) spectroscopy is also possible 
to use for measurement of Gd-H distance directly. 1H ENDOR studies make the determination of 
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the hyperfine interactions between the Gd3+ and the water proton possible. One and two 
dimensional ENDOR studies have illustrated that Gd-H distance is about 3.1 A° for 8- and 9-
coordinate complexes of Gd3+ and it is independent of ligand type or total charge. It is nearly 
impossible to change this distance in order to have higher relaxivity values [49-51].  
1.5.5 Rotational diffusion 
Based on eqn (1-7), the correlation time can be most affected by the shortest correlation 
time which are either rotation, electronic relaxation, or chemical exchange times. At the magnetic 
field strength of 1.5 Tesla (64 MHz) which is the most commonly used magnetic field in clinical 
imaging, the most effective correlation time is rotational diffusion in most of the cases. For 
instance, in simple monomeric Gd3+ complexes, τR is in the range of 0.1 ns which have rotational 
rate constant in the range of few GHz leading to small relaxation. Slowing down rotation leads to 
higher relaxivity values at 1.5 tesla. 
In higher fields, if a molecule’s rotation is too slow, then based on 2τc2
2  1, the relaxivity 
decreases with increasing τR. Relaxivity can be simulated for three values of τR. For instance, r1 
can be simulated over a range of magnetic fields between 0-3 Tesla for correlation times of 0.1 ns 
(small molecule contrast agents, Gd-DTPA), 1 ns (intermediate motion), and 10 n (albumin bound 
contrast agents). It can be concluded that by increasing the rotational correlation time from 0.1 ns 
10 ns, the relaxivity will also increase, however, this effect is maximized at lower magnetic field 
strengths. It is worth mentioning that r1 cannot obtain the zero value since there is also an outer-
sphere parameter exists that contribute to relaxivity which has its own correlation time which is 
very short. 
Using various methods such as NMR relaxation, EPR, and fluorescence, rotational 
diffusion can be estimated. Furthermore, it can also be calculated from the Stokes–Einstein 
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equation as described in the literature. For larger molecules such as proteins, rotation may not be 
isotropic. Correlation time can be reduced with anisotropic rotation or internal motion within a 
molecule predicted by an isotropic model based on molecular weight. Anisotropy can be observed 
when relaxation is determined as a function of magnetic field. It has been reported that there are 
two types of motion in a complex molecule which the spectral density function can be simulated 
by two correlation times corresponding to these motions, one for the global motion (τg) of the 
molecule and another for the local motion (τ1) of the Gd–Hwater vector [6, 47, 48, 52]. 
 
 
(1-8) 
 
 
 
(1-9) 
 
 
Eqn (1-8) and (1-9) relates this parameter to dipolar relaxation of Gd3+ where C is a constant 
consists of terms from eqn (1-7). The degree of isotropic motion is described by the order 
parameter S2 (also shown by F to avoid confusion with the spin quantum number). At higher fields, 
Sτ  1 and the spectral density is given by the second term in parentheses in eqn (1-8). 
1.5.6 Electronic relaxation  
Electronic relaxation for Gd3+ is a sophisticated process which relies on magnetic field. At 
lower magnetic fields usually below 0.1 T, the electronic relaxation is short or fast and therefore 
can dominate the correlation time, see eqn (1-8). With increase in magnetic fields, the electronic 
relaxation decreases and therefore becomes slower than rotational motion, see eqn (1-11). As a 
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result, the correlation time of nuclear relaxation depends on magnetic field and changes as a 
function of field.     
 
 
  (1-10) 
 
 
(1-11) 
 
 
At lower magnetic fields, electronic relaxation is the dominant factor τc and as the relaxivity 
increases so as the magnetic field since electronic relaxation slows down and τc increases. In 
magnetic field strengths of about 0.7 T, relaxivity reaches its maximum and then starts to decrease 
since τcH becomes larger than 1, therefore, affecting eqn (1-8) and making it larger [47, 53]. 
1.5.7 Water exchange rate 
Water exchange is another important factor affecting the relaxivity. The water molecule 
coordinating the Gd3+ in the complex must be exchanging rapidly with the bulk water in the solvent 
so that it can transfer the relaxation effect to the solvent. The water exchange parameter can be 
explained through 17O NMR transverse relaxation rate measurements at different temperatures at 
high magnetic fields. There has been a significant body of data in the literature trying to address 
this effect. For instance, replacing an acetato oxygen donor with an amido oxygen donor will lead 
to a slower water exchange rate. In another case, for complexes experiencing dissociative water 
exchange, increase in the steric bulk can increase the water exchange rate. Replacing an acetato 
oxygen donor with the larger phosphonato oxygen donor can increase the exchange rate [54].  
The water residency time τm (kex = 1/τm) plays a direct role for relaxivity in the equation as 
well as through T1m. If water exchange value is short or very fast, then the τm can is the correlation 
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time that dominates T1m. In addition, if water exchange is very slow, relaxivity will be affected 
and decreased since the relaxation effect is not transferred to the bulk water sufficiently enough. 
The very fast water exchange can also have a negative impact on relaxivity since if the water is 
exchanging too fast then it does not have the ability to coordinate the Gd3+ and the time is not long 
enough for the water to be relaxed. The dependency of relaxivity on τm can be observed where 
inner-sphere relaxivity is simulated for a q = 1 in a 1.5 T system at different values of τR. The 
relaxivity can be affected with water exchange rate being too slow or too fast, however, this effect 
can observed if other important parameters such as τR are in their optimized conditions [55].  
1.5.8 2nd-sphere and outer-sphere relaxivity 
As it was mentioned before, 2nd-sphere and outer-sphere relaxivity can also contribute to 
relaxivity coming from the bulk water surrounding the Gd3+ complex. Using hard-sphere model of 
Hwang and Freed, the outer-sphere relaxivity can be simulated where relaxation is measured using 
the diffusion coefficient of water as well as distance of closest approach. The hydrogens of water 
that can be exchanged in the second coordination sphere of Gd3+ can also affect the relaxivity. 
These protons originate from water in the second coordination sphere or the sites being protonated 
on the molecule. As it was demonstrated, complexes even with q=0 can have high relaxivity. For 
instance in [Gd(DTPA)(H2O)]
2- approximately %50 of the effect originates from the inner-sphere 
water. In addition, according to outer-sphere prediction model, protein binding does not have any 
effect on relaxivity, however, the level and impact of 2nd-sphere on relaxivity is very difficult to 
predict. For complexes with q  0, all the previously mentioned parameters will affect the 
relaxivity as well as the number of hydrogens in the 2nd sphere that can be exchanged. Moreover, 
the hydrogen distance from Gd3+, and their lifetimes become important. When each of the single 
molecular parameters measured cannot contribute to the high relaxivity of a complex then the large 
25 
2nd-sphere effect is very well observed. Sometime by fitting NMRD data, additional parameters 
accounting for 2nd-sphere relaxivity can be modeled [56-58].  
1.5.9 Effect of field strength and temperature 
Relaxivity strongly depends on magnetic field strength. Moreover, since water exchange 
rate and rotational diffusion are affected by temperature, then as a result relaxivity will be affected 
by temperature as well. It is important to compare different relaxivity data at the same temperature 
and field strength. Usually the ideal temperature in which the data are compared is 37○C as it is 
the physiological temperature and all of the contrast agents are being applied in vivo at 37○C. 
Although most of the clinical MRI contrast agents function at 1.5 T (64 MHz), the clinical field is 
shifting towards higher magnetic fields as high as whole body 7.0 T (300 MHz) instruments. The 
reason is that the higher field strengths provide higher signal to noise ratio and increased resolution. 
At higher magnetic fields, the relaxivity is decreasing, therefore, clinical contrast agents should be 
less useful, however relaxation time of different tissues will increase with increase in magnetic 
field, therefore so less contrast agent with a fixed relaxivity is needed to produce the same level of 
contrast. Higher magnetic fields can reduce the acquisition time and the presence of a relaxation 
agent can make the acquisition time even shorter [59]. 
 
26 
 
Figure 1.3 A diagram demonstrating the parameters affecting relaxivity of a Gd3+-based MRI 
contrast agent complex [6]. 
In conclusion, there has been a tremendous effort to develop and design new MRI contrast 
agents with significant progress made. A more complete and thorough understanding of the 
parameters affecting relaxivity such as coordination chemistry and biophysics can result in 
improved contrast agents which will speed up the progress. among all of the parameters discussed, 
the most important one is the rotational motion since it depends on rotational dynamics. There are 
certain strategies being used to modulate the rotational dynamics in order to increase relaxivity. 
For instance, linking multiple gadolinium complexes is one of those approaches. Perception of 
how to modulate the water exchange rate at the Gd3+ coordination site and its complex can also 
benefit the current progress in the development contrast agents. At 1.5 T which is the most common 
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magnetic field for imaging with contrast agents, rotation, hydration, and water exchange rate are 
the key parameters.  
 Current advancements in improving the relaxvity of Gd3+-based MRI Agents  
Gadopentetate dimeglumine or Magnevist was the first gadolinium-based contrast agent 
(GBCA) which become available for clinical use worldwide in 1988. After that eight more 
gadolinium contrast agents based on chelates were introduced and approved in different countries 
across the world. Progress in the field of contrast media and the MRI instrument itself has increased 
the accuracy and application of contrast-enhanced-MRI (CE-MRI). Currently, CE-MRI as a 
diagnostic imaging tool covers approximately 30 million procedures annually. There is a close 
relationship between clinical diagnosis and the monitoring of specific therapies and research into 
new MRI contrast agents [60]. 
Significant progress has been made in improving the relaxivity of MRI contrast agents and 
there has been an ongoing effort. For instance, the relaxivity has been improved by covalently 
linking Gd3+-chelates to nano-carriers, such as dendrimers, liposomes, nnanoparticle emulsions 
viral capsids, and nanotubes. Moreover, non-covalent binding between Gd3+ chelators and 
proteins, such as MS-325, have shown significant increase of relaxivity [61-66]. However, there 
are limited number of publications which reported the use of proteins to function as ligands to bind 
Gd3+ to improve the imaging capabilities.  
Overall, there are two general approaches to use proteins Gd3+ ligands. First, Gd3+-chelates 
will be covalently or non-covalently conjugated to proteins. Second, Gd3+ binding pockets are 
directly designed inside the proteins or basically the protein itself functions as a chelator. The first 
approach has been used numerously to create new class of MRI contrast agents. In these studies, 
Gd3+ chelates were designed to non-covalently interact with proteins, and as a result they 
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significantly increased the relaxivity of Gd3+ chelates [29, 30]. Furthermore, in a study proteins 
such as albumin directly used to interact with DTPA-dianhydride to produce a DTPA-protein 
complex loaded with Gd3+ [67]. Albumin labeled with Gd3+ has been extensively used in many 
preclinical procedures such as assessment of tumor permeability and angiogenesis by CE-MRI of 
cancer tissue, and monitoring vasculature changes of tumors [68, 69]. In another study, a class of 
biodegradable contrast agents were designed by conjugating evenly distributed lysine residues on 
protein polymers to Gd3+ chelates. Then the polymer length and lysine distribution were optimized 
to produce an r1 of 14 mM
-1s-1 per Gd3+ and 46.1 mM-1s-1 per particle at 1.5 T and 37 ˚C. These 
contrast agents can be excreted rapidly in vivo [70]. As creating a Gd3+ binding pocket inside a 
protein is challenging, the second approach has not been used frequently. When a protein is 
designed to be used as chelator for Gd3+, several important parameters must be optimized for 
relaxivity which will be discussed later in this chapter.  
 Design of protein-based MRI contrast agent with improved relaxivity  
1.7.1 MRI contrast agents based on proteins   
One of the interesting approaches for the development of new MRI contrast agents is to 
use native or engineered proteins. Approximately one third of proteins have metal ions such as 
calcium, magnesium, zinc, copper, iron, and manganese in their structure and these proteins that 
exist naturally have Cu2+, Fe2+, Fe3+, Mn2+, and Mn3+ with spin quantum numbers ranging from 
1/2 to 1/5. Some native proteins, such as hemoglobin, and engineered proteins like BM3h have 
been used to monitor brain activities in human and animals [71-73]. In addition, studies have 
shown that metalloproteins can be engineered to trap different metals such as manganese or iron 
in ferritin with significantly high T2 property per particle (r2 = 5300 mM
-1s-1) which can be applied 
as T2 MRI agents [74-76]. Other proteins such as human protamine-1 expressed by live cells have 
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been used as chemical exchange saturation transfer (CEST) MRI contrast agent. This protein is 
based on a small arginine-rich protein, which functions through CEST mechanism [77]. In the next 
section our protein design for development of MRI contrast agent will be discussed.  
1.7.2 Choice of protein for designing Gd3+-based MRI contrast agents 
Instead of conjugating proteins with small Gd3+ chelators, a very different approach was 
chosen and used in which a Gd3+-binding pocket was designed and engineered into a protein 
scaffold to change it to a protein chelator [78-80]. The design of protein-based contrast agent 
(ProCA) was based on the discussions mentioned about the factors affecting relaxivity as well as 
several other considerations. Proteins are in the category of biocompatible materials which will be 
beneficial for in vivo applications. Other protein drugs such as insulin have been successfully used 
in humans against different diseases [81, 82]. Moreover, there are some proteins that their well-
folded structures and proper sizes allow god circulation and tissue penetration. For instance, a 
globular protein with molecular weight of 10–14 kDa has a size of 2–3 nm, therefore it can be 
excreted from kidney. Many computational and protein engineering strategies were applied to 
design Gd3+ binding sites in proteins with high coordination number and strong binding affinity. 
Some of these proteins have well-studied structural and dynamic profiles by high-resolution NMR 
which can be used for designing Gd3+ MRI contrast agents with improved metal binding and 
relaxation properties. Finally, when a protein-based contrast agent was developed with high 
relaxivity and metal-binding properties, its application can be extended to targeted contrast agents 
with the addition of different moieties to target various disease biomarkers by protein modification.  
 
 
 
30 
1.7.3 Design of MRI Contrast Agent based on -Parvalbumin  
Based on important parameters affecting relaxivity such as water number, rotational 
correlation time, water exchange rate, and etc as well as our strategy to design Gd3+ binding sites 
into a protein as an MRI contrast agent with high relaxivity, high dose efficiency and strong metal 
binding affinity, we have chosen -parvalbumin as a scaffold protein to host Gd3+-binding sites.  
Our lab had previously developed a protein contrast agent (ProCA32) [83] , which was designed 
and developed by creating one more negatively charged ligand S56D in the EF-hand motif 1 of rat 
or human α-parvalbumin to create Gd3+ binding affinity and selectivity. Parvalbumin protein was 
selected since it had strong calcium binding affinity (Kd = 8.35 ± 0.29 × 10−9 M; Fig. 1.4 a) and 
stability. Furthermore, F103W mutation was made to introduce luminescence resonance energy 
transfer (LRET) property to the protein to determine its metal binding affinity and water number 
by Tb3+ luminescence life time decay. The protein was further modified with PEGylation of 
ProCA32 by TMS(PEG)12 (named as ProCA32-P40) to increase blood retention time, liver 
preference, solubility, as well as stability of the designed protein [84]. 
There are some unique factors that make α-parvalbumin one of the best candidates for the 
design of a protein-based MRI contrast agent. Design of Gd3+ binding sites was based on our 
analysis of metal binding sites in different small chelators and metal proteins. It is important to 
mention that Gd3+, Tb3+ and Ln3+ have similar coordination to Ca2+. In addition, like Ca2+, they 
prefer oxygen as ligands. Other small chelators used in generating contrast agents such as DTPA 
have both oxygen and nitrogen atoms as ligands, however, proteins like α-parvalbumin use oxygen 
as a ligand most of the times [85]. In α-parvalbumin, oxygen ligands from the side chain oxygens 
of Glu and Asp are used at different stretches of the protein sequence to coordinate Gd3+. One 
position of metal geometry is left open to allow fast water exchange between solvent and metal 
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(Fig. 1.4 B). We have concluded that inserting a metal binding site without internal flexibility is 
crucial to achieve a high relaxivity contrast agent based on a protein. In the next section, different 
factors contributing to high relaxivity in ProCA32 will be discussed. 
 
Figure 1.4 Model structure of rat -parvalbumin (a) and ProCA32 (b) with several 
mutations 
 
1.7.4 Factors Contributing to High Relaxivity in ProCA32 
As it was mentioned before, there are different parameters such as correlation time and 
inner, second, and outer sphere water number that can affect the significantly high relaxivity in 
ProCAs compared to contrast agents based on small molecules. The first important parameter is 
the optimized Correlation Time which is one of factors contributing to the high relaxivity of 
ProCA32. As shown in previous equations, a protein contrast agent with τR of approximately 10 
ns has a near optimized relaxivity at the most common magnetic field of 1.5 T. High-resolution 
A B 
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NMR was used to study the dynamic properties of our designed protein contrast agent [86, 87]. 
Based on other proteins with the similar, the τc of a protein MRI contrast agent is approximately 
9.08 ns in the presence of metal and 9.20 nsec in the absence of metal. Furthermore, the dynamic 
NMR data demonstrate that the metal-binding pocket inside the protein contrast agent can rotate 
along with the scaffold protein as a rigid complex.  
The second parameter contributing to the high relaxivity value is the water number which 
is also optimized in the protein-based MRI contrast agent. As shown in previous equations, the 
relaxivity of a contrast agent directly corresponds to q. One can increase the relaxivity of a contrast 
agent by increasing the water molecules coordinating the Gd3+ at the same time. In a study to 
develop an enzyme responsive contrast agent named Egad, water access to Gd3+ (q = 0) was denied 
by addition of a galactopyranose moiety to a Gd-DO3A chelate, however, after galactosidase 
activation, galactopyranose sugar was cleaved from Gd3+, therefore exposing it to water molecules 
which subsequently increased water number from 0.7 to 1.2 [88] and the r1 increased from 0.90 
mM-1s-1 to 2.72 mM-1s-1 accordingly [89]. We have shown that ProCA32 has q=0.5 shared by the 
two binding sites of Gd3+ which can increase the relaxivity. Moreover, larger surface of proteins 
can also contribute to high relaxivity through second sphere relaxivity that could reach as high as 
3.3 and 8.8 mM-1s-1 at 20 and 60 MHz, respectively (τR = 10 ns, τm = 10 ns, q = 4, rGdH = 5 A°). 
According to all the parameters, it is highly likely that ProCA32 high relaxivity benefits from 
coordination water from the inner, second, and outer spheres of which cause the increase of 
relaxivity in ProCA32. 
 
 
 
33 
 
Table 1.2 The relaxivity of some of the research-based Gd3+ MRI contrast agents [67, 84, 87, 89-
106]. 
 
Category of Contrast Agent Contrast Agent r1 (mM-1s-1) r2 (mM-1s-1) B0 (T) 
Paramagnetic Nanoparticles Gd@C82(OH)22±2 61.1  4.7 
Nanodiamond Nanodiamond 58.82  1.5 
Trimetallic Nitride 
Metallofullerene CA 
Gd3N@C80[DiPEG(OH)x] 79  2.4 
Dendrimer Nanoclusters Dendrimer Nanoclusters 12.3   
Hydroxypyridonate Viral 
capsid conjugates 
Gd-TREN-bis-HOPO-
TAM-CO2H 
41.7  0.7 
Lipid Nanoparticles GdDOTA(GAC12)2 40  0.47 
Gold Nanoparticles Au@DTDTPA-Gdx 4.1  7.0 
Nanoassembled Capsules NACs 24  0.54 
Ca2+-Binding Proteins α-lactalbumin 4.2 5 3 
Nanoparticle emulsion Gd-perfluorocarbon 
nanoparticles 
34 50 1.5 
Nanoglobular MRI CAs G3 nanoglobular 10  3 
Porous Polymersomes porous polymersomes 7.2  1.5 
Liposome ACPL 12 11 1.5 
Collagen peptide conjugated 
with Gd-DTPA 
EP-3533 15.6 32.5 1.5 
Multimeric CAs  12.2  1.5 
Protein Carriers Albumin 11.5 12.4 0.25 
HOPO derivatives Gd-TREN-1,2-HOPO 10.5  0.47 
Cell-permeable CAs Gd3+-DTPA-Arg8 7.8  1.5 
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Small Chelators Gd-DTPA 5.4 8 1.5 
Dendrimers Gadomer-17 13  1.5 
1.7.5 Design of a Targeted Contrast Agent for Imaging of Biomarkers 
In order to image biomarkers with MRI, targeted contrast agents are needed to be 
developed with high specificity as well as sensitivity. Currently, many attempts have been made 
to design and develop targeted MR agents to obtain molecular imaging by MRI (Table 1.2). 
Different molecules such as antibody, peptide or small ligands, and small protein domains such as 
affibodies have been applied for targeting [61, 63, 107-117]. To have contrast agents with higher 
sensitivity, biomarker-targeting moieties are usually linked to these MRI contrast agents, such as 
nanoparticles. In a study, fibrin antibody was conjugated to emulsion nanoparticles and they were 
successfully used to image vulnerable plaques [62]. Furthermore, in a different study, arginine-
glycineaspartic acid (RGD) peptide was conjugated to emulsion nanoparticles for successful 
application in imaging integrin, which is expressed in high levels in many diseases such as cancer 
and atherosclerosis [114, 115, 118], however, nanoparticles have limited applications to imaging 
biomarkers on the blood vessel due to the large size and low tissue penetration. Many approaches 
have been used to solve the issues with macromolecules in terms of extravasation and diffusion 
barriers. Caravan and coworkers used conjugation approaches with targeting and labeling 
strategies to create antibody-tagged magnetic particles as well as peptides targeting collagen type 
I conjugated with multiple Gd-DTPAs named EP-3533 [109, 119, 120]. In these studies, a small 
collagen targeting peptide was conjugated with Gd3+-chelates and eventually was capable of  
targeting collagen type I in different diseases such as liver, lung and heart fibrosis [110, 121, 122]. 
In addition, small molecules such as peptoid-(Gd)8-dendron were synthesized and used for 
molecular imaging of vascular endothelial growth factor receptor 2 (VEGFR2) which is an 
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angiogenesis biomarker expressed in different tumors [113]. Although significant progress has 
been made in generating targeted MRI contrast agents, the development of these agents for 
molecular imaging by MRI is largely hampered by their low sensitivity compared to other agents 
in PET/SPECT. In addition, inadequate perfusion to diseased tissue, instability of the peptide-
based targeting moieties, and targeting specificity and selectivity are other major limitations of the 
current MRI agents.  
Figure 1.5 Top 5 final modeled structures predicted by I-TASSER for 
ProCA32.collagen1 
 
Fig. 1.6 demonstrates the modeled structures generated by I-TASSER for 
ProCA32.collagen1. C-score is a confidence score for estimating the quality of predicted models 
by I-TASSER [123]. It is calculated based on the significance of threading template alignments 
and the convergence parameters of the structure assembly simulations. C-score is typically in the 
range of -5 to 2], where a C-score of higher value signifies a model with a high confidence and 
vice-versa.  Therefore, model 1 with C score of -1.18 was chosen as our final model for 
ProCA32.collagen1.  
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Figure 1.6 The model structure and development of ProCA32.collagen1 
ProCA32 was generated from rat -parvalbumin by incorporating the S56D and F103W 
mutations, then ProCA32 was further developed to ProCA32.collagen1 by linking collagen type I 
targeting moiety at its C-terminal, then ProCA32.collagen was further modified with covalently 
linking PEG by PEGylation. The model structures were generated based on the structure of α-
parvalbumin (Protein Data Bank ID code 1RWY) and I-TASSER. 
 
Based on our previous design of ProCA32 discussed in section 1.7.3 [83], ProCA32 was 
chosen to design a protein-based MRI contrast agent with biomarker targeting capacity, therefore, 
a collagen type I peptide targeting moiety was designed based on previous studies [120] and linked 
to the C-terminal of ProCA32 through a flexible linker. We have named this protein contrast agent 
ProCA32.collagen1. The protein was further modified with PEGylation, a representation of this 
process can be seen in Fig. 1.6. Collagen type I is an important biomarker in different diseases 
such as liver fibrosis and metastasis. It is an important target for molecular imaging of liver fibrosis 
and metastasis since its accumulation is a characteristic of most types of chronic liver diseases 
(CLD), further details will be discussed in the next chapters.  In order to meet the requirements for 
MR imaging of different liver diseases, the targeting peptide was added to the C-terminal to avoid 
any alterations in the protein structure and its metal binding affinities which is very different from 
37 
other approaches. We have demonstrated that it is possible to increase relaxivity by addition of a 
targeting moiety to a protein MRI contrast agent without sacrificing relaxation and metal binding 
properties, such as affinity and metal specificity.  
 In vitro properties of MRI contrast agents 
1.8.1 Optimizing peptide targeting capability of MRI contrast agents 
The basis of biomaterial science and drug design is to have a  good understanding and 
knowledge of the key protein–protein interactions occurring in cell–matrix, macromolecular 
organization of the extracellular matrix (ECM), and pathogen-induced and degenerative diseases 
[124]. The recognition of adhesion moieties used in biomaterials usually occurs via methods that 
are based on techniques such as phage display [125] or by using trial and error strategies such as 
screening different sequences from ECM components [126, 127]. In drug design, however, a more 
efficient strategy is applied which provides structural information from complexes of the binding 
partners. Furthermore, computational and experimental procedures can be extremely beneficial for 
the identification of binding epitopes [128]. Similar methods can be used to the rational design of 
collagen-binding peptides that have relevance to biomaterial applications. Although substantial 
progress has been made in medicinal chemistry, chemical biology, and biochemistry, biomaterial 
scientists largely dependent on a few peptide motifs in biomimetic design, such as RGD peptides 
or enzyme-sensitive peptide sequences [129]. In order to investigate an ideal targeting moiety for 
collagen type I, more diverse and specific motifs are required, similar to the ECM [130]. The ECM 
is a hydrogel based on reversible supramolecular interactions and its most abundant protein is 
collagen. [131-135] 
Targeted Gd3+-based contrast agents can become great diagnostic tools combined with 
MRI to positively enhance images with the contrast they provide since MR has an order of 
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magnitude better spatial resolution than nuclear imaging modalities such as positron emission 
tomography (PET) and single photon emission computerised tomography (SPECT), however the 
first challenge facing these targeted MR agents has always been sensitivity [6]. Usually, Gd3+ in 
M levels are needed to be in the detectable range of MRI. One strategy can be generating a 
macromolecule which includes large numbers of metal complexes and targeting moiety (such as 
peptide or antibody). Different molecules such as polymers, dendrimers, liposomes and 
nanoparticles have been used successfully in animal models [63, 136-138], however nanoparticles 
have limitations for vascular targets as they have long half-life in blood leading to slow targeting 
capability as well as incomplete elimination from the body which usually leave Gd3+ behind. 
Another strategy is to use a chelate or multiple chelates of Gd3+ with a targeting moiety attached 
to them such as a peptide conjugated to one or more small molecule-chelates of Gd3+ such as Gd-
DTPA [139-142].  
Linking or conjugating short peptide fragments with affinity to biomarkers (peptide 
targeting) is a common approach used in molecular imaging because of its small size and advances 
in peptide synthesis [143], however application of peptides in targeting has some disadvantages 
such as their instability and degradation by enzymatic cleavage, having a short half-life in the 
body, and their undefined structure which could result in decreasing the binding specificity and 
affinity to the target biomarker. As discussed in previous section, we have used a protein chelate 
(ProCA32) to chelate two Gd3+ and conjugated a collagen type I targeting peptide to its C-terminal 
to produce ProCA32.collagen1 to overcome the mentioned challenges. Then, based on literature 
reviews and studying certain amino acid residues responsible for collagen binding, 
KKWHCYTYFPHHYCVYG sequence was chosen to be linked at the C-terminal via three glycine 
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linker so that the peptide can freely move for targeting. Using this approach, we have successfully 
imaged collagen type I with ProCA32.collagen1 in liver fibrosis and liver metastasis.  
1.8.2 Thermodynamic stability of MRI contrast agents  
Clinical contrast agents such as Gd-DTPA have long term toxic systemic effects (the LD50 
of Gd3+ is 0.2-0.3 mmol/kg and the LD50 of Na3Ca-DTPA is 5 mmol/kg) which is caused by free 
Gd3+ and the chelators. Since Gd3+ has an ionic radius (0.93 Å) very similar to Ca2+ (0.99), it is 
very likely that it can compete with Ca2+ in the biological systems and cause disruptions in the 
Ca2+ signaling pathways by interacting with calcium binding proteins such as calcium sensing 
receptor, and voltage-gated calcium channels. Therefore, it is crucial that contrast agents have 
enough stability in order to prevent Gd3+ from being released from their structure. Generally, the 
stability of contrast agents to Gd3+ is defined by thermodynamic, conditional, and kinetic stability. 
Since these contrast agents are used in medical diagnosis field, it is of great importance that Gd3+-
based chelators remain in the complex in vivo, and they need to have high metal binding stability 
and selectivity [144-147]. The chemical instability of the chelate can lead to exchanges with other 
metal ions (Zinc, copper, and calcium) which can, in turn, have biological consequences. 
Accumulation of Gd3+ in bones, interference with colorimetric serum determination of calcium 
and hence spurious hypocalcaemia, interaction with scintigraphic procedures, increased zincuria, 
interaction with metal-dependent biological systems such as metalloenzymes, are some these 
consequences, etc.  
Basically, two structurally distinct categories of gadolinium chelates are currently used: a) 
The ‘macrocyclic’ chelates such as Gd-DOTA, where Gd3+ is ‘caged’ in the pre-organized cavity 
of the ligand. (b) The ‘linear’ chelates such as Gd-DTPA or Gd-DTPA-BMA. The toxicity of 
gadolinium complexes actually depends on their ability to release free Gd3+ ions. Transmetallation 
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is a type of organometallic reaction that involves the transfer of ligands from one metal to another. 
Several cations such as Fe3+, Cu2+, Zn2+ or Ca2+ compete with the Gd3+ cation and a number of 
other anions such as PO4
3- , CO3
2- , OH- 
can compete with the ligand for the Gd3+. Thermodynamic stability can be described by eqn 1-12. 
 (1-12) 
 
where M is the endogenous bivalent cation which exchanges with Gd3+ in the chelate. Factors 
affecting the stability of contrast agents are their linear or cyclic structure and their overall charge 
of the molecule. The thermodynamic stability of contrast agents can be summarized as: 
Macrocyclic Ionic > Macrocyclic Non-ionic > Liner Di-ionic > Liner Non-ionic [148]. In addition, 
thermodynamic can be described by these following equations: 
  
   
(1-13)  
 
(1-14)  
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where KML is thermodynamic stability constant, [GdL] is the concentration of metal ligand 
complex and [Gd] and [L] are the concentrations of free Gd3+ and ligand in the solution. Clinical 
MRI contrast agents have thermodynamic stability constants ranging from 16.6-25.8 (log KML). 
Figure 1.7 Structure of some commonly used clinical contrast agents [149]. 
 
ProCA32.collagen1, with two Gd3+ binding sites, has a thermodynamic stability constant 
of 22.3, which is greater than Gd-DTPA-BMA (log KML= 16.6). The conditional stability constant 
determines the stability of the metal-chelator complex at physiological pH, which is the 
protonation of the chelator at pH 7.4 [150]. To investigate the metal binding affinity and selectivity 
of ProCA32.collagen1, we have used different fluorescence spectroscopic methods such as dye 
competition and Tb3+ energy transfer. ProCA32.collagen1 has a metal selectivity for Gd3+ over 
physiological metal ions log (KGd/KCa) = 14.4 and log (KGd/KZn) = 16.2. Furthermore, the Gd
3+ 
binding constant (log KGd) for ProCA32.collagen1 is comparable to DTPA and the metal 
selectivities of ProCA32.collagen1 for Gd3+ over Zn2+ and Ca2+ are much greater than other clinical 
contrast agents.  
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We also have investigated the stability of Gd3+ binding to ProCA32.collagen1 under the 
conditions of extracellular environment where there are other biological metal ions present and 
can compete with Gd3+ and subsequently affect the relaxivities of ProCA32.collagen1. The 
relaxivities (r1 and r2) of ProCA32.collagen1 were not significantly affected in the presence of Zn
2+ 
and Ca2+, more details will be discussed in Chapter 2 and 4. 
Table 1.3 Thermodynamic stability of some of clinical contrast agents compared to 
ProCA32.collagen1 and ProCA32-P40 [151]. 
Contrast Agent * Log 
(KTb) 
Log 
(KGd) 
Log 
(KCa) 
Log 
(KZn) 
Log(KGd) 
/ Log (KCa) 
Log(KGd) 
/ Log (KZn) 
Magnevist (DTPA) 22 22.46 10.75 18.6 12.24 4.13 
Eovist (EOB-
DTPA) 
N/A 23.6 11.82 18.78 12.22 5.18 
Dotarem (DOTA) N/A 24.7 17.23 21.05 7.46 3.65 
MultiHance 
(BOPTA) 
N/A 21.91 N/A 17.04 N/A 4.87 
ProHance (HP-
DO3A) 
N/A 23.8 14.83 19.37 10.07 4.37 
ProCA32-P40 21.08 22.44 9.55 8.77 13.1 14.3 
ProCA32.collagen1 22.80 22.30 8.70 6.12 14.4 16.2 
N/A, not available, * Values from NIST at pH 14   
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1.8.3 The kinetic stability and metal selectivity of MRI contrast agents 
Metalloproteins such as Ca2+-binding proteins are important in biological systems as they 
play a variety of roles in cell proliferation, migration, protein-protein interactions, protease 
activation, signal transduction, and immune-responses [152, 153]. These Ca2+- and Zn2+- binding 
proteins can potentially bind to free Gd3+ released from contrast agents in the body. Moreover, 
blood plasma and interstitial fluids in the body have multiple ions such as Ca2+ and Zn2+ and Fe3+ 
which can compete with Gd3+ in the contrast agent to release free Gd3+. There are also certain 
anions in the body that can compete with contrast agent itself such as phosphate (0.6 M) and 
bicarbonate (0.36 M) in the biological systems form which in turn further drives the disassociation 
of Gd3+ from the metal contrast agent complex. Kinetic stability properties determine the rate of 
this dissociation in a contrast agent in which an agent with high kinetic stability will release less 
Gd3+ per unit time [154]. In order to assess the kinetic stability, the dissociation rate of Gd3+ from 
the complex can be measured at pH=1, at which the dissociation rate of a contrast agent is 
significantly increased compared with physiological pH. As it was mentioned previously, linear 
Table 1.4 General data for all currently marketed Gd3+-based MRI contrast agents [1]. 
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contrast agents have higher dissociation rates or lower kinetic stability compared to cyclic contrast 
agents. As can be seen in Fig. 1.7, clinically approved contrast agents such as Gd-DTPA-BMA 
has the lowest kinetic stability, however Gd-DOTA has highest kinetic stability. It has been 
demonstrated that the dissociation rate of the Gd-chelator complex correlates with the Gd3+ 
retention in mouse 14 days after injection of these agents [35].  
1.8.4 Size is essential for contrast agent distribution and excretion 
Disease biomarkers have diverse locations based on the stage of the disease. For instance, 
Collagen type I is a biomarker expressed in higher levels in a variety of cancers such as liver and 
breast cancer as well as liver fibrosis and its progression to cirrhosis [155]. Collagen is also present 
in blood vessels and inside and on the surface of tumors, while other biomarkers such as HER-2 
is deeply expressed in a tumor outside of the blood vessel. Therefore, it is important to have an 
ideal half-life for targeting different biomarkers. Theoretically, longer circulation times might 
provide more time for Gd3+ release and toxicity, therefore, the contrast agent should have a 
moderate and optimized blood circulation time tailored towards the specific targeted biomarker. 
For molecular imaging of a liver metastasis and fibrosis, the contrast agent should have sufficient 
blood half-life to allow the contrast agent to penetrate deeply into the tumor and then quickly be 
excreted out of the body to reduce the toxicity. The half-time of ProCA32.collagen1 in mouse is 
about 9 hours depending on the surface modification [84] and exhibits enhancement in various 
organs but mainly in the liver. Since the collagen concentration increases (M levels) as fibrosis 
progresses and its extracellular location makes it readily accessible by the probe, therefore 
relatively longer half-life is needed. 
The half-life of clinical contrast agents that are based on small chelators are very different 
from other agents such as nanoparticles that have uptake by macrophages and have accumulations 
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in the liver and spleen. In a study regarding the distribution of gold nanoparticles with a diameter 
ranging from 10, 50, 100, and 250 nm, after 24 h, the 10 nm gold nanoparticles distributed in 
different organs such as blood, liver, kidney, spleen, heart, lung, and brain, however the majority 
of 50 nm gold nanoparticles distributed in blood, lung, liver, and spleen [156]. Usually, the agents 
that are larger than 50 nm mainly distribute in blood, liver, and spleen. In addition to tumor 
penetration and organ distribution, the size of the contrast agents can also affect renal excretion. 
For instance, a molecule with a size of larger than 7 nm in diameter (approximately 60 kDa) is not 
readily able to pass through the glomeruli, and the blood half-live of these molecules in mouse is 
longer than 80 min [31]. Lysozyme with a molecular weight of 15 kDa and diameter of 3.4 nm, 
has the blood half-life of 12 min. On the other hand, IgG has the molecular weight of 152 kDa has 
the blood half-life of 330 min. The toxicity of nanoparticles with a size larger than 15 nm has 
grown concern since the renal excretion is prevented for these large macromolecules due to the 
risk of accumulation in the human body [31]. 
1.8.5 Transmetallation studies of MRI contrast agents 
One of the important studies in MRI contrast agent field and their development is 
transmetallation of Gd3+ chelates by other physiological ions such as Fe3+, Cu2+, and Zn2+. 
Protocols based on relaxivity have been used to compare the transmetallation of the approved 
clinical contrast agents (2.5 mM) in the presence of 2.5 mM Zn2+ in the phosphate buffer. In these 
studies, the highest kinetic stability was achieved for Gd-DOTA [35]. In addition, further studies 
demonstrated the kinetic profile of Gd3+ dissociation from Gd3+-based MRI contrast agents in 
serum for the duration of 15 days using HPLC-ICP-MS. More unstable contrast agents such as 
nonionic linear ones like Gd-DTPA-BMA, demonstrated 10 times higher Gd3+ release than ionic 
linear contrast agents, such as Gd-DTPA. In contrast, macrocyclic contrast agents as the most 
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stable type of agents did not show any Gd3+ release such as Gd-DOTA. These studies demonstrate 
that cyclic contrast agents have good kinetic stability compared to linear contrast agents [157]. 
1.8.6 Toxicity studies of MRI contrast agents 
The major organs in the body which have Gd3+ deposits are usually bone, lung, and liver. 
The dissociation rate in which Gd3+ is released from the contrast agents has direct effect on its 
deposition in bones. Studies have reported Gd3+ retention in mice 14 days after injection of 
different Gd3+-based chelates with different dissociation rates. Results demonstrated that mice 
injected with Gd-DTPA-BMA or Gd-NP-DO3A had much higher Gd3+ deposition in the whole 
body, mainly in bone and liver, compared to mice injected with Gd-DOTA or Gd-HP-DO3A [35]. 
In another study, Gd3+ concentration in the bones of patients who had hip replacement was 
analyzed after injection of 0.1 mmol/kg Gd-HP-DO3A or Gd-DTPABMA. The analysis showed 
that Gd3+ retention was 1.77 and 0.447 μg per gram of bone for Gd-DTPA-BMA and Gd-HP-
DO3A, respectively as revealed by ICP-AES [158]. Furthermore, the use of these contrast agents 
in patients with kidney problems is reported to cause NSF. Biopsy results of patients with NSF 
have confirmed the presence of insoluble Gd3+-phosphate deposits in their skin [159, 160].  
The acute toxicity of ProCA32.collagen1 was studied with clinical chemistry tests and 
different components of plasma samples were measured such as liver enzymes (ALT, ALP, AST, 
LDH), urea nitrogen, bilirubin, and total protein content from CD1 mice 5-7 days post tail veil 
injection of 0.0013 mmol/kg of ProCA32.collagen1. The results showed negligible toxicity 
compared to control subjects (CD-1 mice).  
The serum stability experiment is another useful tool for monitoring unstable compounds 
in vitro. To test the stability of ProCA32.collagen1 in human serum, the protein was incubated in 
complex with an equal concentration of GdCl3 in human serum at 37 ˚C. The degradation of the 
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protein was monitored by both SDS-PAGE. The results showed that the protein remained intact 
for at least 48 hours in the absence of serum as well as in the presence of 70% human serum up to 
14 days of incubation. Long term Gd3+ retention and pharmacokinetics of ProCA32.collagen1 will 
be discussed in detail in the Chapter 4. 
 Molecular imaging by MRI using a biomarker-targeted contrast agent 
Monitoring different disease biomarkers in patients with invasive methods such as biopsy 
has so many disadvantages such as its invasiveness, high costs and sampling error, intra/inter-
observer variability, hospitalization in 1–5% of cases, mortality in 0.01–0.1% of cases, lack of 
accuracy due to substantial sampling error, cost associated morbidity, pain and bruising at the 
biopsy site, prolonged bleeding, infection of the biopsy site, and pneumothorax and hemothorax. 
For instance, there is a 33% error in diagnosis of liver cirrhosis which severely affect the patient 
outcomes [109, 161]. With its unique capacity to generate reproducible and non-invasive 
assessment of biological/disease processes of different organs at various time points, molecular 
imaging of disease biomarkers using MRI can be an important and ideal diagnostic tool to facilitate 
the understanding of the disease, monitoring disease progression and drug treatment and activity 
during preclinical and clinical application. Since MRI is cheaper compared to some other imaging 
modalities, its application for molecular imaging can dramatically lower the costs by reducing the 
number of animals required for a specific study. However, one of the major limitations of MRI to 
investigate specific disease biomarkers for diagnosis and drug treatment monitoring is the lack of 
sensitive contrast agents with high relaxivity, targeting capability, and tissue permeability.   
The majority of disease biomarkers have very low expression levels. Approximately, 
5×106 Gd3+ per cell are needed to acquire a good and sufficient contrast in MRI using current 
clinical contrast agents based on small chelators since they have low relaxivity of ~5 mM-1s-1[162]. 
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Studies have shown that endocytosis is a useful process for contrast agents in tissues since it helps 
them to accumulate in a local area, however recent studies showed otherwise and that the relaxation 
enhancement is suppressed when the local concentration of Gd3+ is higher than 1010 Gd3+ per cell 
[163-165]. The decrease in relaxivity can be attributed to insufficient water exchange across the 
plasma membrane. 
Targeted molecular imaging by MRI is now under development to increase sensitivity 
[109, 166]. The majority of these MRI contrast agents target biomarkers expressed on the surface 
of blood vessels and not so many have tried to target the biomarkers outside of the blood vessels. 
In order to improve the dose efficiency of MRI contrast agents, peptide fragments with high 
affinity to biomarkers are extensively applied for conjugation. For instance, two-component Gd3+-
based MRI contrast agents have been generated by binding of avidin-Gd3+ complexes to tumor 
cells which was labeled with a biotinlyated antibody [167, 168]. These contrast agents have the 
disadvantage of slow diffusion when targeting tumors in vivo. Moreover, antibodies demonstrate 
improper distribution and penetration in tumor blood vessel [80]. Peptides on the other hand have 
small size compared to the antibodies, therefore they have good tumor penetration [119, 169], 
however, these peptide-based MRI agents need further improvement in targeting capability and 
resistance to protease cleavage. Overall, the development of targeted MRI agents has long way to 
go despite the significant amounts of research. In conclusion, there is still unmet medical needs 
for the development of MRI contrast agents with higher relaxivity and improved targeting 
capability to image spatial distributions and patterns of biomarkers by MRI. 
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Magnetic resonance imaging (MRI) demonstrates several technical advantages such as 
deep tissue penetration, high spatial resolution, complete coverage of the entire liver, detailed 
structural and anatomical information, evaluation of organ morphology, and it is relatively 
inexpensive. Most importantly, MRI does not use ionizing radiation which makes it suitable for 
monitoring disease progression and treatment when repeated imaging is required for a long period 
of time [161]. More than 35% of MRI scans use MRI contrast agents, particularly paramagnetic 
gadolinium (Gd3+)-based contrast agents [83], which shorten T1 and increase MRI signal [7], 
however MRI lacks sensitive contrast agents. All clinically approved Gd3+-based contrast agents 
are based on small chelators with relaxivity (r1 and r2) ranging from 4–6 mM
−1·s−1. Their low 
relaxivities severely limit their sensitivity to be applied in detection of early stages of chronic 
diseases, their progression and treatment monitoring. In addition, they do not have the targeting 
capability for any disease biomarker. For instance, gadolinium–ethoxybenzyl– diethylenetriamine 
pentaacetic acid (Gd-EOB-DTPA) (Eovist, United States; Primovist, Europe; Bayer) and 
gadobenate dimeglumine (Gd-BOPTA) (Multihance; Bracco) are among the most popular and 
common clinical contrast agent which are T1-weighted liver contrast agents, and have 50% and 
5% hepatocyte uptake, respectively [8]. However, these contrast agents cannot detect early stages 
of many diseases where biomarkers expression play an important role in early diagnosis and 
progression. Therefore, development of targeted and sensitive MRI contrast agents with improved 
sensitivity, higher metal binding affinity and selectivity is needed to overcome MRI limitations 
and enable the earlier detection of different chronic diseases such as liver fibrosis, and monitor its 
progression as well as its treatment, which results in earlier diagnosis, treatment and subsequent 
reversion of the disease. 
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 Collagen type I: An appealing target for many chronic diseases 
Extracellular matrix (ECM) is a dynamic and complex environment characterized by 
biophysical, mechanical and biochemical properties specific for each tissue and able to regulate 
cell behavior. The ECM is composed of a large collection of biochemically and structurally diverse 
components. Biochemically, these components can be divided into proteins, proteoglycans, and 
glycoproteins, each of which has diverse sub-categories of components and varying physical and 
biochemical properties[170]. Collagen type I is the most abundant component of ECM. Collagen 
is abundant in humans accounting for one-third of total proteins. The fibrous, structural protein 
contains three polypeptide α-chains, displaying a polyproline-II conformation, a right-handed 
supercoil and a one-residue stagger between adjacent chains [171]. Each polypeptide chain has a 
repeating Gly–X–Y triplet, and the three polypeptide α-chains in the triple helix held together by 
inter-chain hydrogen bonds can be identical, but heterotrimeric triple helices are more prevalent 
than homotrimeric triple helices.  
Recent studies have highlighted the role of the ECM and shown the importance of 
deregulated ECM dynamics in molecular etiology of disease development. Excess ECM 
production or reduced ECM turnover, for example, are a salient feature in tissue fibrosis of many 
organs and collagen type I as the most abundant component of EMC plays an indispensable role 
in these processes [170].  
Collagen type I is an appealing target for molecular imaging of a variety of diseases such 
as liver fibrosis, liver metastasis, breast cancer, pancreatic cancer and aortic aneurysms. In organ 
fibrosis and different cancers, collagen accumulation as well as its concentration increases by the 
disease progression. In addition, collagen type I is an extracellular protein which makes it 
accessible for any agent.  
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Collagen targeted MR imaging contrast agent could act as an agent to image these diseases, 
and these agents may have higher efficacy for fibrosis and cancers assessment than the clinically 
available contrast agents. [30, 109]. Furthermore, MRI contrast agent providing a measure of 
collagen levels as well as its capability to bind cross-linked collagen would have utility in detection 
of early stages of diseases such as fibrosis, cirrhosis and drug treatment monitoring. Although 
other groups such as Caravan et al, conducted extensive research on developing contrast agents 
for detection of fibrosis, or pancreatic cancer, sensitivity and specificity is still a challenge in 
development of contrast agents for early detection [109, 110, 121, 122, 161, 172]. 
Using rational protein design, we have developed a protein-based MRI contrast agent 
ProCA32.collagen1 that targets collagen type I. ProCA32.collagen1 has high relaxivity values for 
r1 and r2 per Gd
3+ at both 1.5 and 7.0 T. In addition, ProCA32.collagen1 is able to detect both early 
and late stage (Ishak score of 3 and 5) of mouse liver fibrosis in multiple mouse models which has 
not been achieved by any clinical contrast agent such as Eovist and non-targeted contrast agent, 
ProCA32 previously developed by S. Xue. et al [83]. Moreover, ProCA32.collagen1 is able to 
detect small tumor lesions in uveal melanoma liver metastasis. 
 Motivation and challenges to be addressed  
Early diagnosis for many diseases has always been a challenge for scientists and clinicians. 
It can play an indispensable role in treatment efficiency and strategies. Development of MRI 
contrast agents is an evolving field, however clinical MRI contrast agents have faced major 
limitations in terms of application in early diagnosis for many chronic diseases due to lack of 
sufficient sensitivity and targeting capability. Our lab has been working on development of novel 
Gd3+ protein-based MRI contrast agents (ProCA) to overcome the challenges associated with 
current MRI contrast agents in clinics.  
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In order to apply our contrast agent in diagnosis of chronic diseases, there are several 
challenges the need to be addressed. First, can we develop a new MRI contrast agent with improved 
sensitivity to target a specific biomarker for early stage diagnosis of chronic diseases? Can we 
improve the safety of an MRI contrast agent by reducing its dose and toxicity? Third, can we 
develop a new MRI contrast agent capable of monitoring diseases progression and treatment? 
Forth, can we stage chronic diseases with the use of a noninvasive technique and absent of biopsy? 
Fifth, can we improve accuracy and specificity of chronic disease diagnostics by taking advantage 
of a T1-T2 dual mode contrast agent combined with imaging methodologies?  
 Overview of the dissertation 
 In this Ph.D. dissertation, in order to address these mentioned challenges and questions, I 
have developed a collagen type I targeted protein-based MRI contrast agent, ProCA32.collagen1 
with improved sensitivity and targeting capability compared to other previously developed contrast 
agents in our lab and clinically available contrast agents.  
Chapter 2 details experimental methods and protocols that we used for the dissertation. 
Chapter 3 describes our rationales for design of a novel collagen type I targeted protein 
contrast agent (ProCA32.collagean1) and its expression, purification and characterization. 
Chapter 4 describes the biophysical properties of ProCA32.collagen1 such as its metal 
binding affinities, relaxivities, pharmacokinetic, transmetallation, collagen type I affinity, serum 
stability and toxicity studies.  
Chapter 5 details the successful application of ProCA32.collagen1 in early detection of 
liver fibrosis in TAA/alcohol induced mouse liver fibrosis using both r1 and r2 property. Moreover, 
ProCA32.collagen1 ability to map liver cirrhosis heterogeneity in DEN- and TAA/alcohol-induced 
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mouse models is elaborated as well as its capability in revealing vascular structural changes, 
intrahepatic angiogenesis and portal hypertension.  
Chapter 6 reports the successful application of ProCA32.collagen1 for early detection of 
human uveal melanoma tumors metastasis to mouse liver. In addition, ProCA32.collagen1 
capability in distinguishing different uveal melanoma growth patterns (Nodular vs Infiltrative) in 
liver is described. 
Chapter 7 reports the studies of hepatocellular carcinoma (HCC) tumor detection in liver 
in DEN-induced mouse model using ProCA32.collagen1. ProCA32.collagen1 is able to 
distinguish cirrhotic regions in liver from HCC tumors. 
Chapter 8 describes our attempt in extending the application of ProCA32.collagen1 in 
imaging collagen in mouse model of thoracic and abdominal aortic aneurysm (TAA/AAA) with 
subcutaneous infusion of angiotensin II (AngII) from implanted osmotic pump.  
Chapter 9 provides our studies in application of ProCA32.collagen1 in early detection of 
Nonalcoholic steatohepatitis (NASH) in Nonalcoholic fatty liver disease (NAFLD) in mouse 
models on a NASH diet. 
Chapter 10 describes and summarizes the major findings of this dissertation and future 
direction.  
In Appendix, my studies on a different topic involving Connexin43 (Cx43) gap junction 
regulation by Ca2+/Calmodulin will be discussed. We have identified several Calmodulin binding 
sites in Cx43, and fluorescence spectroscopy was used to study the interaction between Cx43 and 
calmodulin in the presence of Ca2+.  
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2 MATERIALS AND EXPERIMENTAL METHODS 
 Molecular cloning, expression, purification and Lysine PEGylation. 
In the contrast agent design, collagen type I-targeting peptide 
(KKWHCYTYFPHHYCVYG) for type I human collagen) was linked to the C-terminal of 
ProCA32 by a flexible linker (GGG). The protein contrast agent was named ProCA32.collagen 
and then it was purified according to Henzl’s and Xue et al procedure with some modifications 
[83, 173]. First, ProCA32.collagen was expressed in Escherichia coli BL21 (DE3) cell strain, and 
then it was induced by 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) when the optical 
density at 595 nm (OD595) reached 0.6. After induction, the culture temperature was reduced from 
37 °C to 28 °C for expression overnight. The bacterial pellets were re-suspended and sonicated in 
10 mM Tris.HCl buffer for 12 times at pH 7.2 with 1 μL of benzonuclease (Novagen). The 
supernatant of the cell lysate was incubated at 85 °C for 20 min, cooled to 4 °C in an ice-water 
bath, and centrifuged (41,100 × g, 20 min, 4 °C). Impurities including DNA, were then precipitated 
by addition of 3% (wt/vol) streptomycin sulfate and placed at 4 °C overnight. On the next day, the 
precipitate DNA was removed by centrifuge and the supernatant was dialyzed at least in 4 changes 
of buffer in 4 °C for 24 h against 10 mM Tris.HCl at pH 8.0 then the protein mixture was further 
purified using a HiTrap Q column (GE Healthcare) by fast protein liquid chromatography (FPLC) 
. After removing unbound proteins with 3 column volumes of 10 mM Tris at pH 8.0, the column 
was eluted with a 0–1 M NaCl gradient in 10 mM Tris·HCl at pH 8.0. Purified ProCA32.collagen 
was confirmed by SDS-PAGE and UV spectrum. Gd3+ was loaded to ProCA32.collagen at a 2 : 1 
ratio. Other metals in ProCA32.collagen such as Ca2+ was removed by chelex-100 and the metal 
content in ProCA32.collagen was analyzed by ICP-OES. The protein was PEGylated by the 
following steps: First, it was dialyzed three times against 10 mM Hepes at pH 7.0–7.2. Second, 
55 
ProCA32.collagen was mixed with Methoxy Succinimidyl Carboxymethyl Ester (M-SCM-2000) 
reagent with molecular weight of 2 kDa (JenKem Technology), with a molar ratio of 1:5, and then 
incubated at room temperature for 4 h or 4 °C overnight. Third, unreacted free M-SCM-2000 was 
quenched by adding 100 mM Tris·HCl with a final concentration of 10 mM. Fourth, PEGylated 
ProCA32.collagen was further purified using HiTrap Q column and then concentrated about 4 
times using concentrator with 3kDa membrane to remove the unreacted free PEG (MW 2 kDa). 
After removing unbound fractions with 3 bed volumes of 10 mM HEPES at pH 8.0, the proteins 
bound to the column were eluted with a 0–1 M NaCl gradient in 10 mM HEPES at pH 8.0. 
PEGylated products were analyzed by SDS/PAGE with protein staining by Coomassie Brilliant 
Blue and PEG staining by I2.  
 Liver fibrosis and metastasis animal models 
2.2.1 Thioacetamide (TAA)/alcohol induced fibrosis  
Balb/c mice (6 - 7-week-old male) were I.P. injected with 100 mg/kg TAA and gradually 
increased to 200 mg/kg TAA in two weeks. 10% alcohol was also fed to mice along with the TAA 
treatment. For rPKM2 experiment, 5 mg/kg of rPKM2 was mixed with TAA for injection starting 
at two and a half weeks, and lasted for total of seven weeks. TAA mixed with buffer or rPKM1 
was the control.  
For the PKM2 antibody experiment, TAA was continuously treated for twelve weeks. After 
that, TAA and alcohol was stopped and 4mg/kg of PKM2 antibody was I.P. injected every other 
day for ten doses. Buffer and rabbit IgG were the control.  
The body weights were recorded every week or every four days. At the end of the 
experiments, animals were sacrificed. Livers, other organs, and blood samples were collected. 
Liver weights were measured and liver pictures were taken. Tissue sections were prepared and 
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analyzed by IF, IHC, or H&E stains using commercially available antibodies as indicated. Serum 
samples were prepared from collected blood samples. The serum samples were analyzed by the 
service of Comparative Clinical Pathology.  
Liver fibrosis was induced with Balb/C mice by administration of TAA and 10% ethanol 
in drinking water for 12 weeks. At the end of cirrhosis induction, the animals were treated via 
buffer. After the treatments, animal body weights, liver weights, and out-surface of livers were 
examined. All animal experiments in this study complied with the Association for Research in 
Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research 
and complied with an approved animal protocol from the Institutional Animal Care and Use 
Committee at Georgia State University and the University of Georgia. 
2.2.2 DEN induced Cirrhosis and HCC 
For all of our studies, we employed female and male mice with C57BL/6 genetic 
background. Experiments involving animals were conducted in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals and were approved by the Georgia State University 
IACUC. Animals were housed in a pathogen-free animal facility under a 12 h light/dark cycle and 
fed a standard rodent chow and water ad libitum. In order to induce liver tumor development, 14-
day-old mice were treated with a single dose of DEN (Sigma–Aldrich # N0756) given dissolved 
in saline at a dose of 25 mg/kg body weight by i.p. injection on day 12. Mice in one randomly pre-
assigned group were killed 10 months after DEN administration for histological and biochemical 
analyses. Mice were randomly distributed in various groups having equal males and females.  
Immediately after euthanizing, livers were removed, weighed and the numbers of visible 
tumors on the liver surface were counted macroscopically. The largest lobes were fixed in formalin 
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and embedded in paraffin. Sections were stained with hematoxylin and eosin and examined 
microscopically.  
2.2.3 Uveal melanoma liver metastasis model 
All animal procedures performed in this study complied with the Association for Research 
in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision 
Research and complied with an approved animal protocol from Institutional Animal Care and Use 
Committee at Georgia State University and University of Georgia. To generate hepatic melanoma 
implantation model, C57BL/6 female mice, 7–10 wk old, were anesthetized with i.p. ketamine 
hydrochloride, 90 mg/kg, and xylazine, 10 mg/kg. After anesthesia, a small horizontal abdominal 
incision (1 cm) was made in the left upper quadrant such that the left lobe of the liver will be 
exposed. A total of 5 × 106 of mouse B16LS9 melanoma cells were drawn into a Hamilton syringe 
with a 29-gauge needle creating a 5-μL slurry that were injected into the parenchyma of the 
exposed liver under an operating microscope. Gentle pressure was applied to the hepatic injection 
site for 1 min with a cotton-tipped applicator after tumor cell injection. The left lobe of the liver 
was repositioned into the peritoneal cavity, and the abdominal wall was then closed with 5.0 
sutures. To generate the uveal metastasis model, aliquots of 5 × 105 cells of B16LS9/2.5 μL were 
inoculated into the choroid of the right murine eye of 7- to 10- week-old PEDF-null C57BL/6 
female mice (8), using a transscleral technique that allows the inoculated cells to remain in the eye. 
The mice were anesthetized and a tunnel was prepared from the limbus within the sclera to the 
choroid with a 30 1/2-gauge needle under the guidance of a dissection microscope. The tip of a 
10-μL glass syringe with a blunt metal needle (Hamilton) was introduced into the choroid through 
the needle track, and no cells were inoculated until the needle tip was inside the eye. A 2.5-μL 
suspension of cells was inoculated. No tumor cell efflux from the eye occurred, and the 
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subconjunctival space remained free of tumor cells. The inoculated eyes were enucleated after 1 
wk, fixed in 10% (vol/vol) formalin, and routinely processed for light-microscopic examination. 
Serially adjacent 5-μm-thick sections were stained with hematoxylin and eosin (H&E) and 
evaluated for the presence and location of melanoma. Hepatic tissue was collected at 3 wk after 
MRI. 
Human uveal melanoma 92.1 cells were inoculated into the supra choroid space of the right 
eye using a transcorneal technique. For each inoculation, a million cells were delivered in a volume 
of 2.5 uL. The mice were anesthetized with intraperitoneal injection of ketamine and xylazine 
mixture. A tunnel was prepared from the limbus within the cornea, sclera and ciliary body to the 
choroid with a 301/2-gauge needle   under a surgical microscope. The tip of a 10 uL glass syringe 
with a 31-gauge /45-degree point metal needle (Hamilton, Reno, NV) was used to introduce cell 
suspension into the supra choroid space through the needle track. The right eye was enucleated at 
2 weeks after tumor cell inoculation [174, 175].   
 Metal binding affinity measurements of ProCA32.collagen1  
In order to investigate the Gd3+ binding affinity of PEGylated ProCA32.collagen, a buffer 
system is used in which Tb3+ binding affinity can be measured since Gd3+ is spectroscopically 
silent. Then the Gd3+ binding affinity was calculated using a competition assay [83]. Determining 
Tb3+ binding affinity of ProCA32.collagen1 was based on the Tb3+ luminescence resonance energy 
transfer (LRET) experiment in which 30 μM ProCA32.collagen1 was prepared in 5 mM DTPA, 
50 mM HEPES, and 150 mM NaCl at pH 7.2. The ratio of Tb-DTPA concentration ([Tb-DTPA]) 
and free DTPA concentration ([DTPA]free) were controlled by titration of TbCl3 in the system. The 
protein-Tb3+ LRET emission spectra were collected between 520 and 580 nm using an excitation 
wavelength of 280 nm. The free Tb3+ concentrations ([Tb]free) in each titration point were 
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calculated by eqn (2-1). The dissociation constant between Tb3+ and ProCA32.collagen1 
(KdTb,ProCA) is calculated by the Hill equation (2-2). 
 
                                                      (2-1) 
 
                                                               (2-2) 
 [Tb3+]free is the free Tb
3+ concentration calculated from the buffer system, KdTb, DTPA is 
the dissociation constant of Tb3+and DTPA, the dissociation constants of Tb3+ to DTPA were 
obtained from National Institute of Standards and Technology Standard Reference Database [75]. 
[Tb-DTPA] is the concentration of Tb-DTPA complex that is formed during titrations, [DTPA]free 
is the free DTPA in the buffer, f is the fractional change of the LRET signal at each titration point 
and n is the hill number, Kd
Tb, ProCA 
is the dissociation constant between Tb3+and 
ProCA32.collagen1.  
After achieving the binding constant of Tb3+ for ProCA32.collagen1, a competition assay 
was performed to measure the binding affinity of ProCA32.collagen1 for Gd3+. The Tb3+ 
fluorescence spectra were recorded by tryptophan excitation at 280 nm and emission from 500 to 
650 nm. 10 μM of ProCA32.collagen1 was used and 20 μM of Tb3+were incubated with different 
concentrations of GdCl3 from 0 to 1000 μM at room temperature overnight. The Tb
3+-FRET 
changes were measured by the emission at 545 nm. The apparent dissociation constants (Kdapp) 
were calculated by fitting the plot of LRET peak intensities over different concentrations of Gd3+ 
(eqn (2-3)) and the dissociation constants of Gd3+ to ProCA32.collagen1 (KdGd,ProCA) were 
calculated by eqn (2-4). 
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 (2-3) 
 
                                                           (2-4) 
 
where f is the fractional change of the LRET signal, [Tb]T is the total Tb
3+ concentration, 
[Gd]T is the total Gd
3+ concentration in each titration point, and KdGd,ProCA is the dissociation 
constant between Gd3+ and ProCA32.collagen1 determined by eqn (2-2). 
The Kdapp for ProCA32.collagen1 was calculated first and then this value was used to 
calculate the actual dissociation constant using the equation 4. 
For determining the calcium binding affinity of ProCA32.collagen1, a calcium equilibrium 
buffer system was used where, 10 μM of ProCA32.collagen1 was added to the calcium–EGTA 
buffer system containing 50 mM HEPES, 150 mM NaCl, and 5 mM EGTA at pH 7.2. The system 
was titrated with different concentrations of CaCl2 to alter the concentration ratio between the Ca-
EGTA ([Ca-EGTA]) and free EGTA ([EGTA]free). The tryptophan (Trp) fluorescence changes 
were monitored under the emission spectra between 300 and 390 nm as excited at 280 nm. The 
free calcium concentration at each titration point was calculated by eqn (2-5) 
 
                      (2-5) 
Furthermore, free calcium concentrations in the buffer were tightly monitored and 
calculated using equation derived from Tsein’s equation [176] with some modifications and the 
Kd of EGTA-Ca
2+ =1.51×10-7 M was obtained from NIST. The Kd of Ca
2+ to ProCA32.collagen1 
(KdCa,ProCA) was determined by eqn (2-6). 
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                                 (2-6) 
 
where f is the fractional change of Trp fluorescence intensity, [Ca]free is the free Ca
2+ 
concentration in each titration point determined by eqn 5. The same data points were fitted using 
Adair equation [173] which will result in two separate association constants Ka for each binding 
site.  
The Zinc binding affinity of ProCA32.collagen1 was determined using a similar assay by 
competition titration using Fluozin1 dye [79, 177]. The fluorescence of 2 µM Fluozin-1 was 
excited at 495 nm and the emission spectra were collected between 500 and 600 nm in the presence 
of 2 µM Zn2+ and different concentrations of ProCA32.collagen1. The apparent dissociation 
constant (Kdapp) was calculated by eqn 2-7.  
 
          (2-7) 
 
where f is the fractional change of the fluorescence intensity of Fluozin-1, [Zn]T is the total 
Zn2+ concentration, and [ProCA]T is the total concentration of protein contrast agent at each 
titration point. The dissociation constants between ProCAs and Zn2+ (KdZn,ProCA) were then 
calculated by eqn (2-8). 
 
                                            (2-8) 
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where Kdapp is determined by eqn (2-7), KdZn,Fluozin is the Zn
2+ affinity to Fluozin-1 and 
[Fluozin]T is the total Fluozin-1 concentration.  
 Histology analysis 
2.4.1 Immunohistochemistry and Hematoxylin and Eosin analysis 
For immunohistochemistry, paraffin-embedded liver sections were cut (4 μm) and mounted 
on slides (ProbeOn; Fisher Scientific). The sections were dried, deparaffinized, and hydrated with 
xylene and graded ethanol. Formalin-fixed samples were then stained with Sirius Red according 
to standard procedures. Sirius Red stained slides were analyzed by a pathologist, at Emory 
University School of Medicine, to score the amount of liver disease based on Ishak scoring system 
[178, 179] . Furthermore, CPA which is % area stained with Sirius Red, was calculated from the 
histology images using ImageScope. 
For H&E Staining, livers were fixed in 10% (vol/vol) formalin. Then they were dehydrated 
in increasing concentrations of alcohol, cleared in xylene, and embedded in paraffin. Serial 5-μm 
sections were prepared, stained with H&E, and processed for light-microscopic examination.  
2.4.2 Immunofluorescence staining 
Immunofluorescence staining was performed on fibrotic tissues collected from the mice 
liver post injection of ProCA32-P40 and ProCA32.collagen1 for 48 hours. Tissues were 
immediately frozen in liquid nitrogen after dissection and stored in -80C. After that the tissues 
were embedded in optimal cutting temperature (OCT) cryostat sectioning medium and cut with a 
thickness of 5 μm. ProCA32-P40 and ProCA32.collagen1 were stained by home-made rabbit 
antibody against ProCA32 and Alex Fluo 555-conjugated secondary antibody (red) against the 
rabbit antibody. The nuclei of the cells were stained by DAPI (blue). 
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 Mouse MRI imaging  
All mice were imaged on a 7-T Agilent MRI scanner at the University of Georgia. Animals 
were anesthetized using isoflurane and their respiration rate was monitored with a small animal 
physiological monitoring system. Anesthesia was adjusted to maintain a respiration rate of 65 ± 5 
breaths per minute. T1 map (inversion recovery) and T2 map MRI images were collected before 
and after intravenous (I.V.) administration of 5 mmol/L of ProCA32.collagen1 or ProCA32-P40. 
T1 map images were acquired with inversion recovery times of 10, 222, 435, 648, 861, 1074, 1287, 
and 1500 ms. Other acquisition parameters include: repetition time of TR = 5000 ms, Effective 
TE=32.67 ms, field of view FOV = 35×35 mm, matrix = 256×256, slice thickness = 1.0 mm, and 
12 image slices with no gap. T2 map images were collected before and after the contrast agent I.V. 
injection of 5 mM ProCA32-P40 or ProCA32.collagen1 with different time points using the 
MSME sequence with the following parameters: TR = 2000 ms, different echo times, TE (8, 16, 
24, 32, 40, 48, 56, 64, 72, 80, 88, 96 ms), matrix = 256×256, FOV = 35×35 mm, and slice thickness 
= 1 mm and 12 image slices with no gap. The final T2 and R2 map images were generated by 
using a ImageJ plugin MRI T2 calculator, and the T1 and R1 map images were generated with 
MATLAB. After MRI experiment, animals were sacrificed and different organs including liver 
were collected for biodistribution, and histology experiments.  
T1-wieghted MRI images were recorded with TR of 500 ms and TE of 15 ms with matrix 
resolution of 256×256, FOV = 35×35 mm, and slice thickness = 1 mm and 12 image slices with 
no gap. T2-weighted images were recorded with TR=2000 ms and TE of 8 ms with matrix 
resolution of 256×256, FOV = 35×35 mm, and slice thickness = 1 mm and 12 image slices with 
no gap. Heavy T2-weighted images were recorded with longer TE times in order to completely 
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remover the T1 effect. The TE used is 4000 ms and TE=10 ms. Other parameters remained the 
same.  
 Statistical analysis  
Statistical analysis of signal to noise ratio (SNR) was performed using two-tailed Student’s 
t test. The statistical analysis of contrast-to-noise ratio (CNR) of T1- and T2-weighted imaging 
were analyzed by one-way ANOVA. Statistical analysis was performed in GraphPad Prism 5 
(GraphPad Software). Longitudinal relaxation rate (R1) maps and their associated histograms were 
generated from the images using a custom written MATLAB (Mathworks, Natick, MA) program 
for voxel wise fitting of the inversion recovery signal intensities as a function of inversion recovery 
time. The mouse group sizes were set to support statistically valid data and to minimize the use of 
the animal. Mice were randomly assigned to groups for the experiments. The animal studies were 
not blinded, because the same investigators performed the grouping, experiments, and analysis, 
rendering blinding of these studies unfeasible. An experienced pathologist was blinded to the 
groups of H&E and Sirius red staining to evaluate the staging of fibrosis as well as organ toxicity 
of contrast agents.   
In addition, the change in liver longitudinal relaxation rate ∆R1 which is defined as R1post-
R1pre as well as Increase Rates of Liver R1 values (%) defined as  
    
                                           (2-9) 
 
Was calculated. Receiver Operating Characteristic (ROC) analysis used to demonstrate our 
developed contrast agent ability in staging liver fibrosis  
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 Determination of r1 and r2 relaxivity values 
The ability of a contrast agent to change a relaxation rate is represented quantitatively as 
relaxivity, r1 or r2, where the subscript refers to either the longitudinal (1/T1) or the transverse rate 
(1/T
2
). Relaxivity is simply the change in relaxation rate after the introduction of the contrast agent 
(Δ(1/T)
1
) normalized to the concentration of contrast agent or metal ion (M): 
 
                                                                                (2-10) 
 
The relaxation rates of contrast agents (r1 and r2) were determined using different 
concentrations of GdCl3 and protein (2:1) at 37 °C with 1.4 T Bruker Minispec using saturation 
recovery and CPMG sequence, respectively. Using the equation below the relaxation rate for both 
T1 and T2 were measured. The slope of the curve will be longitudinal (r1) and transverse (r2) 
relaxivities. Furthermore, the T1 and T2 of Gd-DTPA and ProCA32.collagen1 were also measured 
by using a 7 T Agilent scanner using saturation recovery and spin echo sequence. r1 and r2 were 
calculated by eqn 10. 
 
                                          (2-11) 
 
 Enzyme-linked immunosorbent assay (ELISA) assay 
Collagen type I solution from rat tail (Sigma-Aldrich) was coated in 96-well plates at 4 °C 
overnight. After being blocked with 5% bovine serum albumin (BSA), a series of different 
concentrations of ProCA32.collagen1 was incubated with the collagen type I solution. After 
incubation at 4 °C overnight, the unbounded ProCA32.collagen1 was washed away with 1× TBST. 
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The homemade polyclone rabbit-anti-ProCA32 antibody was applied with 1: 1000 dilution as the 
primary antibody against protein contrast agent. A stabilized goat-anti-rabbit HRP-conjugated 
antibody (Pierce) was used as the secondary antibody. After a robust wash with 1× TBST, the 
remaining secondary antibody in the 96 well plate was visualized by using 1-Step™ Ultra TMB-
ELISA Substrate Solution (Thermo Fisher Scientific). The absorbance intensity was detected by 
the FLUOstar OPTIMA plate reader at an absorbance wavelength of 450 nm. 
 Pharmacokinetics, distribution and toxicity studies  
All the animals were injected with 5 mM of Gd-DTPA, ProCA32-P40, and 
ProCA32.collagen1. Different organ tissue samples from the mice were collected after euthanasia. 
The collected tissues (~ 0.2 g) were digested with 70% (wt/vol) ICP-grade HNO3 at 40 °C 
overnight. The HNO3 solution containing the digested tissues were collected the next day, filtered, 
and diluted with 2% (wt/vol) HNO3 to 8 mL. Then each sample containing different organ was 
analyzed by ICP-OES to measure the Gd3+ concentration at wavelength of 342.246 nm. YCl3 at 2 
ppm was used as internal reference and different Gd3+ standard solutions with different 
concentrations ranging from 5 ppb to 1000 ppb were made. 
For pharmacokinetics studies, the blood concentration-time profiles after intravenous 
injection of ProCA32.collagen1, ProCA32-P40, and Eovist in mice were analyzed using two-
compartmental analysis using WinNonlin ™ 5.0.1 software (Pharsight Corp., Palo Alto, CA). 
Mean blood concentration values from 3-6 mice at each sampling time point were used for the 
mice pharmacokinetic analysis. The area under the blood concentration-time curve (AUC) was 
calculated using the log-linear trapezoidal rule. The elimination half-life (t1/2) was calculated by 
the equation t1/2 = 0.693/K, where K was estimated from the terminal slope of the blood Gd
3+ 
concentration versus time curve. The systemic clearance (CL) was determined from dose/AUC, 
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with AUC (area under the curve to infinity) by linear interpolation and extrapolation to infinity y 
from Clast x t1/2β/0.693 (where Clast was concentration at each last sampling point). The volume of 
distribution at steady-state (Vss) was determined by the equation Vss = CL × (AUMC/AUC), 
where AUMC is the area under the first moment curve. The mean residence time (MRT) was 
calculated from AUMC/AUC. 
For clinical chemistry test studies of ProCA32.collagen1, mice with an average body 
weight of 30 g were I. V. injected with 0.0012 mmol/kg of ProCA32.collagen1. The bloods of the 
mice were collected five days post injection using heparin-coated capillary. Then the serum of 
blood was obtained by centrifuge at 3000 rpm at 4 ˚C for 10 min. Approximately 300 μL of mice 
serum were collected for clinical chemistry tests conducted in IDEXX Laboratories. The clinical 
chemistry tests assessed the liver, kidney, and heart functions based on the levels of different liver 
enzyme, proteins, glucose and ions in the serum. 
 Serum stability and transmetallation of ProCA32.collagen1 
About 300 μM of ProCA32.collagen1 complexed with Gd3 was mixed with human serum 
with 1:1 ratio, and then incubated at 37 ˚C for different time points. SDS-PAGE gel was used to 
to detect the presence of Gd3+-ProCA32.collagen1 after incubating in the serum for each time 
point. The protein separated by SDS-PAGE is stained by Coomassie brilliant blue or Ponceau S 
solution to monitor its stability. Transmetallation of ProCA32.collagen1 and clinical MRI contrast 
agents were evaluated by measuring the relaxivity changes in the presence of Zn2+ and phosphate 
over time. The relaxivity of ProCA32.collagen1 was monitored with 55 or 110 μM 
ProCA32.collagen1, 100 μM Gd3+, 100 μM Zn2+, and 1.2 mM PO43−. 
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 Measurement of water coordination number in ProCA32.collagen1 
The number of water ligands coordinated to ProCA32.collagen1 complexed with Gd3+ 
complex was determined by measuring Tb3+ luminescence decay in H2O or D2O using the 
previously published methods with some modifications [180]. Tb3+ was excited at 265 nm with a 
Xenon Flash lamp and the Tb3+ emission was collected at 545 nm at a series of time points in both 
H2O and D2O solutions. Luminescence decay lifetime of Tb
3+ or Tb3+ complex with different 
chelators and ProCA32.collagen1 in H2O and D2O solution were determined by fitting 
monoexponential decay equation. A standard curve of water number (q) over ΔKobs (the difference 
of the decay constant between H2O and D2O) was plotted using Tb- NTA (q=5), Tb-EDTA (q=3), 
Tb-DTPA (q=1) and Tb3+ in aqueous solution (q=9). The water number of ProCA32.collagen1 
was calculated based on the standard curve. 
3 DESIGN, EXPRESSION AND PURIFICATION OF PROCA32.COLLAGEN1 
 Introduction  
As it was mentioned in Chapter 1, currently used MRI contrast agents are not sensitive 
enough for patient’s needs in diagnosis and treatment monitoring, therefore development of new 
and more sensitive MRI contrast agents with targeting capability is urgently required. To design 
contrast agents based on proteins with improved in vivo and in vitro applications, there are several 
important criteria that need to be taken into consideration. First, protein- based MRI contrast agent 
should be stable and resistant to factors such as protease cleavage to prevent degradation in the 
body. Furthermore, protein-Gd3+ complex should be stable with protein binding strongly to Gd3+ 
to avoid competition with other physiological cations such as Ca2+ and Zn2+ and inions. Since free 
Gd3+ is toxic with LD50 of 0.2 mmol/kg [144], Gd3+ must bind to protein contrast agent to avoid 
free Gd3+ being released before excreted out. Second, the contrast agent should have high 
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sensitivity and therefore higher relaxivity to increase the dose efficiency. If relaxivity is higher, 
then the total injection dosage of Gd3+ will be decreased to reduce to the toxicity caused by free 
Gd3+ release. High relaxivity of contrast agent also improve the sensitivity of MRI for imaging 
biomarkers. Third, protein contrast agent should have a proper size to optimize organ/tissue 
distribution and blood retention time. It is recommended for contrast agents to have fast 
accumulation in the organ/tissue and fast excretion to reduce the toxicity. Fourth, immunogenicity 
of protein-based MRI contrast agent must be decreased, therefore, PEGlytion is one of the factors 
to reduce this effect. Fifth, protein contrast agent should have targeting capability, therefore, 
targeting moieties should be grafted inside or conjugated to improve the imaging specificity and 
enable quantitative biomarker imaging.  
Previous members in our lab have designed two Gd3+ binding sites into a scaffold protein 
called rat -parvalbumin and were able to increase relaxivity by tuning τc and secondary 
coordination shell contributors as well as improving metal binding affinities [83]. However, 
targeting specific biomarkers to image in different diseases was still a challenge and needed further 
investigation [78]. Design of ProCA32.collagen1 
 Design of ProCA32.collagen1 with collagen type I targeting capability  
In order to design a protein contrast agent with targeting capability, collagen targeted 
protein MRI contrast agent, ProCA32.collagen1 was designed by covalently linking a collagen 
type I targeting peptide (KKWHCYTYFPHHYCVYG) moiety consisting natural amino acids to 
the C-terminal of protein contrast agent ProCA32 (with two Gd3+ binding sites). A flexible hinge 
was used to optimize the targeting capacity of the peptide [83] (Fig. 1.6). The collagen type I 
targeting peptide was chosen in way that residues in the peptide are contributing both to the binding 
and relaxivity by tuning correlation time. Cysteine residues can form a cyclic peptide to interact 
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with collagen I and Lysine residues are improving in vivo MR imaging through PEGylation.  
Lysine PEGylation of the whole contrast agent can improve protein solubility, blood retention time 
and reduce immunogenicity [84]. The designed ProCA32.collagen1 was bacterial expressed, 
purified, and modified and confirmed to form a 1:2 Gd-ProCA32.collagen1 complex using ICP-
OES (Methods) [83] [177].  
 Results 
3.3.1 Expression and purification of ProCA32.collagen1 
Fusion of a collagen-targeting peptide to ProCA32 can generate collagen-targeted MRI 
contrast agent, ProCA32.collagen1 since ProCA32 has multiple Gd3+ binding sites and our protein-
based MRI contrast agent will be able to quantitatively evaluate the collagen expression in 
different diseases such as uveal melanoma tumor in the liver and liver fibrosis. Therefore, this 
protein was expressed and purified. The transformation was carried out using B21 (DE3) plyss cell 
line. Then, small scale (250 mL of LB medium) and Large scale (1000 mL): 1 L of LB medium 
was used for expression. The temperature was 37°C for small scale and then the medium was 
transferred to large scale (1 L). After optical density of bacteria reached 0.6, 500 μL of IPTG was 
added to induce the expression of the protein and then the temperature was decreased to 25°C for 
overnight expression. Cell pellets are collected by centrifugation, and then HEPES (10 mM) buffer 
with pH=7.4 was added into the cell pellets. For cell pellets coming from 1 L of LB medium, 10 
mL of PBS buffer was used plus 100 μL of PMSF and 1 μL of benzonulease (for DNA cleavage). 
Sonication was performed for 12 times until a homogenous solution was reached. The solution 
was centrifuged at 17000 rpm speed for 10 min and the supernatant was collected, and then boiled 
for 10 min. Again the solution was centrifuged for 6000 rpm for 10 min and supernatant was 
collected. 3% streptomyosin was added into the mixture and incubated at 4°C overnight to 
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precipitate the DNA and remove it from the protein. Centrifugation was carried out for another 10 
min and the supernatant was collected (6000 rpm). The solution was then heated to 80-85°C for 
10 min and then centrifuged down at 6000 rpm and supernatant was obtained. In the next step, the 
protein was dialyzed overnight in 10 mM HEPES buffer at pH=8.0. to be negatively charged (500 
uL of PMSF was added). Then before injection of supernatant to FPLC for further purification, 
EGTA is added to the final concentration of 20 mM to remove any extra calcium and then the 
supernatant is filtered and injected to FPLC.  
For purification using FPLC, an ion exchange column was used. A resin is chosen so that 
the protein binds to resin by a charge interaction. In the final step of FPLC, the concentration of 
salt in the buffer is increased in order to elute the protein out of the column. Figure 3.1 
demonstrates the SDS-page results for expression and purification of ProCA32 with collagen 
targeting moiety. 
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Figure 3.1 Modeled structure of ProCA32.collagen1 and its expression and purification.  
A. Model structure of ProCA32.collagen1 based I-TASSER. B. Expression of ProCA32.collagen1 
in BL21 (DE3) plys (BI: Before Induction, AI: After Indcution). C. Different steps of 
ProCA32.collagen1 purification.  
 
The results in Fig. 3.1 demonstrates that the protein has been successfully purified using 
our established purification protocol and furthermore, boiling the sample helps the purification and 
A B 
C 
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elimination of unwanted proteins. As can be seen in Fig. 3B, after boiling, most of the undesired 
proteins were removed from our target protein. Figure 3.2 illustrates the FPLC spectra of the 
purified protein. As it can be seen in the figure, four major peaks can be observed. The first peak 
corresponds to undesired proteins and maybe some of our target proteins at very low amount. 
However, both peak 2 and 3 in the FPLC spectra belongs to our ProCA32.collagen1 with a slight 
difference. The second peak is the Holo form of our protein-based contrast agent (Ca2+-bound) and 
the third peak is the Apo form of our protein (Ca2+-free). Since our contrast agent binding sites are 
supposed to be occupied with Gd3+, the Ca2+-free form is desired for future experiments in order 
to avoid any effects on Gd3+ binding affinity of ProCA32.collagen1.  
 
Figure 3.2 Diagram of ProCA32.collagen1 purification using FPLC. 
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The majority of Peak 1 include unwanted proteins, and peak 2 is the Ca2+-bound form of 
ProCA32.collagen1 and peak 3 include the Ca2+ free form which is the desired form and peak 4 
has DNA.  
In the last peak, DNA will elute out as peak number four. At the end, all fractions for peak 3 
were collected and combined, and a SDS-page gel electrophoresis was run to make sure the protein is 
completely pure. Then the concentration of the protein was measured using UV-Vis instrument. Figure 
3.3 shows the UV-Vis spectrum of pure ProCA32.collagen1. A small shoulder right before 280 nm 
wavelength can be observed which is another indication for the presence of our protein. 
 
Figure 3.3 UV-Vis spectrum of ProCA32.collagen1 after FPLC purification 
A. shows the Apo form of ProCA32.collagen1 after concentration of peak 3 and B. demonstrates 
the Holo form of ProCA32.collagen1 after concentration of peak 2 (No.1 and 2 correspond to 
different concentrations of the protein).  
A B 
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Two different batches of the protein were purified with different concentrations. To further 
confirm the purity of the protein, a sample was sent to mass spectrometry facility in order to obtain 
the electro spray ionization (ESI) spectrum.  
3.3.2 Lysine PEGylation of ProCA32.collagen1 
To optimize the protein solubility, blood circulation time, and avoid possible enzymatic 
degradation and reduction of immunogenicity; Poly ethylene glycol (PEG) conjugation with 
protein has been often used in pharmaceutical and biotechnical applications. The desired protein 
can be modified using several PEG conjugation strategies such as amino group modification, thiol 
group modification. For this purpose, ProCA32.collagen1 has been PEGylated with NHS-Ester on 
lysine residues. 
The contrast agent was modified using Methyl-POEn-NHS ester, PEG-40 with molecular 
weight of 2 kDa and 40 repeating units of ethylene glycol. At first, ProCA32.collagen1 and PEG-
40 were mixed with 1:5 ratios in 10 mM HEPES buffer (pH 7.2) and allowed to shake at room 
temperature for about 2 hours or at 4 °C overnight. Then, 100 mM Tris/HCL was added to the 
reaction mixture to stop the reaction by quenching the unreacted free PEG-NHS ester. The mixture 
was then concentrated about 4 times using concentrator with 3-6kDa membrane to remove the 
unreacted free PEG (MW 2 kDa). PEGylated protein was identified by Iodine staining and SDS-
PAGE. Iodine can stain the free PEGylated protein along with free PEG in the solution while 
Coomassie brilliant blue can stain the protein that is already conjugated with PEG. Figure 3.4 
shows the SDS-page results with Coomassie brilliant blue stain (left) and iodine stain (right) before 
and after PEGylation. As it can be seen most of the protein has been PEGylated.  
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PEGylation on Cysteine resides is also possible, however, due to possible role of cysteine 
in binding to collagen type I, Lysine PEGylation was chosen, further details will be discussed in 
the next chapter.  
 
 
Figure 3.4 SDS-page results for Lysine PEGylation of ProCA32.collagen1. 
Left (Coomassie blue stain) and right (BaCl2/I stain) gels show ProCA32.collagen1 before and 
after Lys PEGylation. Multiple bands after PEGylation is showing that multiple Lys residues in 
the protein are PEGylated.  
Figure 3.5 demonstrates the structure of the contrast agent after PEGylation with PEG. As it 
can be seen in the figure, multiple sites have been PEGylated since there are multiple Lys residues in 
both the protein and targeting peptide. 
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Figure 3.5 Structure of ProCA32.collagen1 after PEGylation 
 
 
 Discussion 
3.4.1 Optimization of ProCA32.collagen1 purification 
In order to improve the yield of ProCA32.collagen1, several modifications were made in 
the original purification protocol of parvalbumin to remove DNA contamination more efficiently 
and simplify the purification procedure. To remove DNA, additional step before FPLC for DNA 
precipitation was added. We added 3 % streptomycin sulfate and incubated at 4○C overnight. After 
centrifugation at 13000 rpm for 10 min, the supernatant was heated at 85○C for 5 min. After 
centrifugation, the supernatant was dialyzed against 10 mM Tris/HCl at pH 8.0 before injecting 
into FPLC column. Moreover, the buffer pH was increased from 7.5 to 8.0. Since the Q column is 
anion exchange column, increasing the pH of buffer improves the binding of ProCA32.collagen1 
to the column. It was observed that our protein can be eluted out from Q column at 200 mM NaCl, 
therefore, the percentage of buffer B (containing 1 mM NaCl) during elution was decreased from 
70% to 25%. In addition, the flow rate of FPLC was decreased from 5 mL/min to 2 ml=L/min to 
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improve the binding of ProCA32.collagen1 to Q column. Nine column volumes are usually used 
to let buffer B slowly increase from 0% to 25%. The very slow increase of salt gradient further 
helps the separation between ProCA32.collagen1 and DNA. After FPLC purification step, the 
remaining DNA can be further eliminated by concentrating protein using through 3-6 kDa 
membrane. 
The FPLC purification curve is shown in Fig. 3.2. The UV absorbance at 280 nm from 
FPLC detector shows four peaks during the elution with buffer B. Each peak was collected and 
then measured by UV spectroscopy, SDS PAGE and agarose gel. The third fraction (peak 3) 
showed a single band at 14.3 kDa, which is consistent with the molecular weight of 
ProCA32.collagen1. UV spectrum of this fraction (Fig. 3.3A) is the same as parvalbumin (PV) in 
the old purification techniques. The first and second peaks have the Holo form of 
ProCA32.collagen1 and the last peak contains protein with a molecular weight of 30 kDa. DNA 
and UV absorbance data demonstrated that peak 1 and peak 4 has a lot of DNA/RNA since they 
showed high absorbance at 260 nm. The final yield of ProCA32.collagen1 is about 50-70 mg per 
liter bacteria expression in LB medium. 
 Summary  
To design novel protein-based MRI contrast agent with collagen type I targeting ability 
(ProCA32.collagen1), PV was selected as the scaffold protein based on the criteria discussed for 
an ideal contrast agent. This developed protein is well folded, highly stable and soluble, tolerant 
to mutations, have a rigid structure and strong metal binding sites for Gd3+. There is also no 
reported interaction between this protein and PV. We have chosen a collagen type I targeting 
peptide to create a targeting capacity and improve its relaxivity by altering PEGylation locations. 
We have constructed vectors for the bacteria expression. We have also optimized the bacterial 
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expression and tag-less purification procedures of ProCA32.collagen1 by selecting expression 
strains and removal of DNA contaminations. After purifying ProCA32.collagen1, different 
biophysical properties of the contrast agent such as metal binding affinity and selectivity, 
relaxivity, metal coordination ligands, and serum stability were examined. ProCA32.collagen1 
was also PEGylated for in vivo studies, such as MR imaging, biodistribution, pharmacokinetics 
and toxicity. 
4 STUDIES OF BIOPHYSICAL PROPERTIES OF PROCA32.COLLAGEN1 
 Introduction 
Safety is one of the most important criteria in development of contrast agents, therefore, 
the contrast agent must have superior biophysical properties such as high Gd3+ stability, high metal 
selectivity as well as relaxivity. As it was mentioned before, long term toxicity of the contrast 
agent usually originates from the free Gd3+ release in the body because of the competition of other 
physiological cations and onions, such as Zn2+, Mg2+ and PO43-. The ionic radius of Gd3+ is 0.93 
Å, which is similar to the ionic radius of Ca2+. Therefore, Gd3+ has the ability to bind to the 
physiological Ca2+ and occupy binding sites in Ca2+ binding proteins. It is very likely that this 
interaction can disrupt and affect the dynamic function of calcium binding proteins. Moreover, 
Gd3+ accumulation could cause NSF (Nephrogenic systemic fibrosis) in long terms, which is a 
lethal disease in patients with the impaired kidney function [181, 182]. A safe MRI contrast agent 
with high metal stability and Gd3+ selectivity is urgently required to reduce the toxicity caused by 
MRI contrast agent injection. Traditional techniques such as pH titration were applied to measure 
the meal binding affinities for the small-chelator based clinical contrast agents [183]. Small 
chelators, such as DTPA, has a Gd3+ binding affinity of 1.8 × 10-21 M. In proteins however, since 
there are multiple protonations of residues, traditional methods such as pH titration cannot be 
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applied to measure the dissociation constant (Kd) between ProCA32.collagen1 and Gd3+ or other 
metals. FERT methods that are based on Tb3+ or Eu3+ can be applied to determine protein-metal 
binding affinity measurement but one of the major limitations of these methods is the lack of 
sensitivity which they can only determine a Kd of around 1 μM or above. Due to this limitation, 
the metal binding affinity for Tb3+ reported for our previous contrast agents such as ProCA1 was 
around 10-7 M. With several other methods being developed such as the Ca45 flow dialysis, 
equilibrium dialysis, florescence dye titration and NMR for determination of metal binding 
affinities for calcium binding proteins [72, 184], the Gd3+ binding affinity of EF-hand binding 
proteins is still not accurately reported. The Ca2+ binding affinity of all EF-hand proteins for 
instance PV can reach to 10-9 M. Therefore, a more accurate method is required to measure Gd3+ 
binding affinity in the range between 10-22 and 10-18 M for our contrast agent, ProCA32.collagen1. 
Relaxivity is another key parameter for MRI contrast agents as discussed thoroughly in 
Chapter 1. The MRI signals are generated based on the different relaxation properties of protons. 
However, such differences are very small among organs in vivo. The contrast and sensitivity of 
MRI can be improved by administrating the contrast agents. MRI contrast agent works as 
“catalyst” to catalyze the relaxation properties of each water molecule. By differential distribution 
in vivo, MRI contrast agents make the relaxation properties different in each organ. The relaxivity 
of clinical MRI contrast agent is around 5 mM-1s-1. The theoretical maximum relaxivity, however, 
is about 100 mM-1s-1, therefore, there is a strong need to develop MRI contrast with high relaxivity. 
Since ProCA32.collagen1 is a targeted contrast agent, therefore, it needs to have proper 
binding affinity to collagen type I, in order to generate the targeting effect.  
In this chapter, we first report a sensitive technique previously developed by our lab to 
measure metal binding affinities (Tb3+, Gd3+, Ca2+, and Zn2+) and selectivity of 
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ProCA32.collagen1. We then report our studies on determining relaxivity and water number of 
ProCA32.collagen1 designed in Chapter 1 and 2. In addition, using ELISA method, we report the 
collagen type I binding affinity of ProCA32.collagen1. At the end, we will report the detailed 
pharmacokinetic studies of ProCA32.collagen1 required for in vivo studies.  
 
 
Contrast-enhanced magnetic resonance imaging is evolving rapidly with different clinical 
applications in imaging various diseases, therefore several important characteristics of MRI 
contrast agents such as their biodistribution, safety profile and pharmacokinetics have been well 
studied over the past few years. Based on their distribution, clinical MRI contrast agents can be 
categorized into three classes. First class is non-specific MRI contrast agents or Extracellular Fluid 
Agents (ECF), second class is liver specific MRI contrast agents, and third class is blood pool MRI 
contrast agents. Some clinical contrast agents such as Magnevist, Omniscan, ProHance, Optimark, 
and Dotarem are part of the non-specific MRI contrast agents. Due to their small size and low 
molecular weight and no interaction with biomarkers in the body, there are mainly distributed in 
blood vessels and extracellular-extravesicular spaces with very short blood half-life which is less 
than 5 min in mouse and less than 30 min in humans. The organ that these contrast agents are 
mainly accumulated is kidney which is their way of excretion from the body. Therefore, they can 
be used for kidney imaging. 
  In addition, this type of MRI contrast agents can accumulate in lesions and disease tissues 
with blood vessel damage, therefore, they can be used for cancer, and stroke imaging.  Second 
class which are liver specific MRI contrast agents such as MultiHance and Eovist are also small 
chelator-based contrast agents, however, the major difference between these and non-specific MRI 
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contrast agents is that they are covalently incorporated with one hydrophobic moiety, which 
facilitates liver accumulation of these contrast agents. Clinical studies demonstrated that, 10% 
MultiHance and 50% of Eviost is excreted from the liver [185]. Mn-DPDP is another liver specific 
MRI contrast agent with similar structure as vitamin A which has uptake by liver cells. The 
accumulation of Mn-DPD in liver increases the MRI signal significantly, however, there are some 
stability concerns associated with DPDP in the liver which can cause Mn2+ release [21]. A blood 
pool MRI contrast agent, MS-325 is a new FDA approved drug which can reversibly binds to 
serum albumin. The binding of MS-325 to albumin can increase its relaxivity as well as its blood 
half-life which increases its circulation time. Due to its unique blood distribution properties, MS-
325 has been approved for imaging blood vessel abnormalities [21]. In addition to clinical MRI 
contrast agents, nano-sized MRI contrast agents, such as dendrimers liposome, nanotubes, and 
emulsions have been developed with dramatically different pharmacokinetic and distribution 
properties. The pharmacokinetics, distribution and excretion of these contras agents are largely 
affected by the size, charge and targeting moieties of the contrast agents. One of the disadvantages 
of these contrast agents is that with a size larger than 7 nm, they cannot be eliminated from renal 
filtration, and therefore their blood retention time are much longer. Liver and spleen are the major 
sites of accumulation of these agents due to the phagocytosis of immune-cells. Nanoparticles with 
molecular weight larger than 30 kDa is accumulated in the tumor tissue due to EPR effects [31, 
78]. 
4.1.1 Gadolinium deposition  
These approved compounds were all designed to be completely excreted after injection. 
The pharmacokinetic studies in humans noted that recovery of gadolinium decreased in patients 
with severe renal insufficiency. From studies on NSF patients it is clear that some gadolinium is 
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retained. Several reports show Gd to be present in skin biopsies of NSF patients [186-191]. 
Recently Kay et al. [192] described a case report of a female patient who died with NSF. 
Gadolinium was found in all tissues surveyed and there were very high levels of Gd reported in 
the kidney and the heart. Swaminathan et al. [186] also noted high concentrations of Gd in the 
heart and vessels on postmortem analysis of NSF subjects. It is not yet established whether Gd is 
also retained in patients with renal impairment but who do not develop NSF. It is still not 
established what the form of Gd is in these patients. For instance, is the Gd3+ still part of the 
contrast agent? Is it present as some insoluble inorganic deposit like the carbonate or phosphate 
salt, since these are very insoluble. Or is the Gd removed from the chelate but bonded to the 
calcium binding site of a calcium binding protein since it is known that gadolinium can replaced 
calcium in proteins. If the Gd is released from the contrast agent, what is the mechanism for 
release? Frenzel et al. [157] recently reported the serum stability of approved contrast agents and 
found that about 20% of Gd was released from gadoversetamide and gadodiamide after 15 days in 
human serum at pH 7.4, 37 °C compared to <2% release for the linear ionic chelates, while the 
macrocyclic chelates showed no detectable Gd release. Gd release in serum was increased when 
phosphate concentration was increased [157]. This would suggest that in renally insufficient 
patients where the plasma half-life increases to days, there would be significant Gd release from 
gadodiamide and gadoversetamide. Factors influencing Gd release are the presence of metals that 
have high affinity for the Gd-binding ligand like Zn2+, Cu2+, or Fe3+ and/or the presence of 
ligands with high affinity for Gd such as phosphate and carbonate. Another potential mechanism 
for Gd release would be low pH in a lysosome if the contrast agent is taken up intracellularly, e.g. 
in the renal proximal tubules. It is well established that the rate of Gd release increases with 
decreasing pH.  
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Gibby and coworkers compared Gd levels in the bone of patients that were scheduled for 
hip transplant following a contrast enhanced MRI [21, 158]. Bone was taken about 4 days after Gd 
administration. Patients received either gadodiamide (N=9) or gadoteridol (N=10) at the standard 
0.1 mmol/kg dose. They found 4-fold higher levels of Gd in the bone of subjects who received 
gadodiamide (1.77±0.704 μg Gd/g bone) than for those who received gadoteridol (0.477±0.271 μg 
Gd/g bone). Assuming a similar distribution to all bone and depending on the fractional weight of 
bone in the individual, this would equate to about 1 – 2% of the injected dose of gadodiamide 
being present in the bone after 4 days. This study did not identify whether the Gd was still 
associated as the contrast agent. However, since both gadodiamide and gadoteridol have similar 
clearance rates, the excess Gd remaining after gadodiamide injection is presumed to be dissociated 
Gd. It is unknown how fast the Gd will clear from the bone. In animal studies (see below), bone 
levels of Gd decreased with time after contrast agents were injected. For “free” Gd, which localizes 
mainly to liver and bone, elimination of Gd was on the order of 1–3% per day in rodents. 
On the one hand it is straightforward to detect and quantify Gd in biopsy or autopsy 
samples. Since Gd is not an essential element and is not ubiquitous in the environment, there is no 
background signal to contend with. Elemental analysis techniques like inductively coupled plasma 
(ICP) with mass spectrometry (MS) or optical detection are sensitive means to quantify Gd. 
However, this is a destructive technique that reports only on the elemental composition and not on 
form of the Gd, i.e. whether it is still present as contrast agent. Scanning electron microscopy 
(SEM) with x-ray spectroscopy is also used. This can detect Gd and can also indicate the 
distribution of other heavy elements that are spatially localized with the Gd. However, SEM cannot 
indicate in what form the Gd exists in tissue. There is also potential bias in the SEM technique 
because this technique is sensitive to heavy atoms. For instance, a microcrystalline deposit of 
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gadolinium phosphate, with its high local concentration of Gd and P atoms, would be much more 
visible than a diffuse distribution of Gd still present as contrast agent or Gd bound to calcium-
binding proteins. There remains a need for additional biophysical studies to determine the 
speciation of Gd in skin and other organs. 
Although the ECF agents generally behave very similarly, there are some differences 
among their physical properties. The diamide complexes gadodiamide and gadoversetamide have 
considerably lower thermodynamic stability (log K~17 vs log K >21 for other Gd complexes) 
[193]. The linear complexes tend to be more reactive to metal substitution (transmetallation) or 
decomplexation. The incidence of NSF seems to reflect these physical chemistry findings. Most 
cases have been reported with gadodiamide, the least stable and least inert compound. Other cases 
have been reported with gadopentetate and gadoversetamide, while no non-confounding cases 
have yet been reported with the other contrast agents. In terms of market share, gadopentate > 
gadodiamide > gadoteridol > other agents. 
4.1.2 Gadolinium deposition in animals in approved contrast agents  
There have been concerns about Gd deposition in tissue since Gd-based contrast agents 
were first reported. A fundamental product criterion was full elimination of the Gd. In rodent 
studies the bone and the liver are target organs for Gd deposition. Tweedle and colleagues 
published a series of studies comparing Gd retention in rats and mice after injection of Gd-DTPA, 
GdHP-DO3A, Gd-DOTA, and Gd-DTPA-BMA as well as some other compounds, including “free 
Gd” administered as GdCl3 or gadolinium acetate [35, 194]. When “free Gd” is administered i.v. 
most of the dose is deposited in the liver and the bone of rodents. Very little is excreted and 
clearance has been reported to be on the order of 1 to 3% per day. When contrast agents are 
administered, the biodistributions of Gd-DTPA, GdHP-DO3A, Gd-DOTA, and Gd-DTPA-BMA 
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are very similar for the first 24 hrs. At 7 and 14 days the data begins to separate. The organs with 
remaining Gd are kidney, liver, and bone. In a direct comparison of 4 compounds the order of 
tissue retention was Gd-DTPA-BMA > Gd-DTPA ~ Gd-DOTA ~ GdHPDO3A [28]. There was 
no statistical analysis performed in that study but it is apparent from the values and standard 
deviations reported that there is significantly more Gd remaining in the whole body, liver, or femur 
of mice or rats treated with Gd-DTPA-BMA compared to the other agents. This difference was 
interpreted as being due to greater Gd release from the chelate. This hypothesis is supported by a 
double label study by Kosokat and Urich who used [153Gd] and [14C] labeled Gd-DTPA in rats 
and found a 153Gd:14C ratio of 6:1 in liver and 9:1 in bone. Tweedle et al. [28] also noted that 
formulated Omniscan which is a mixture of gadodiamide with 5% sodium caldiamide (Na[Ca-
DTPA-BMA]) showed less whole body retention than gadodiamide injected alone. Animal studies 
with MS-325, Gd-EOB-DTPA, and Gd-BOPTA all showed very low values of Gd in bone at 7 or 
14 days post injection similar to those reported for Gd-DTPA [195-200]. 
In renally impaired patients the exposure to Gd is increased; the longer plasma half-life 
results in a large AUC. Since the terminal plasma half-life in rats is 15–20 min compared to about 
90 minutes in healthy humans for ECF agents, one way to mimic the increased Gd exposure in 
renally compromised subjects is to administer high doses of agent daily to rats. Sieber and 
colleagues recently reported a series of studies taking this approach. They administered formulated 
Omniscan, Optimark, Magnevist, Multihance, Gadovist, or Dotarem at 2.5 mmol/kg daily (except 
weekends) for four weeks to rats [198-200]. This daily dose is 25 times the standard 0.1 mmol/kg 
dose and resulted in a cumulative dose of 50 mmol/kg. They examined Gd levels in the skin, liver 
and femur at the end of the study. In all three organs the order of Gd deposition was the same with 
Omniscan > Optimark > Magnevist > Multihance ~ Gadovist ~ Dotarem in terms of how much 
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Gd was deposited. Although there were differences among the contrast agents, Sieber et al. [198-
200] only reported statistical analysis to show the amount of Gd deposited after Omniscan injection 
was significantly higher compared to the other contrast media. No other comparisons were made. 
Interestingly the relative concentrations of Gd in the skin, liver, and femur differed. For instance, 
there was about 8 times more Gd in the skin following Omniscan compared to Magnevist, but 
about 3 times more in the femur or 2 times more in the liver. Interestingly liver levels were similar 
for the linear Magnevist complex and the macrocycles Dotarem and Gadovist, although there were 
clear differences in the skin or the bone (Magnevist higher). 
In this same repeat dose model, Sieber et al. [198] also investigated the influence of excess 
ligand. Formulated Omniscan contains gadodiamide and 5% excess ligand as the calcium complex 
(caldiamide) while Optimark contains gadoversetamide and 10% excess ligands. They repeatedly 
gave either the gadolinium complex (gadodiamide or gadoversetamide), gadolinium complex + 
5% excess ligand, or gadolinium complex + 10% excess ligand for 20 days to rats. The Gd 
concentration in the skin was significantly higher after treatment of the gadolinium complex alone 
compared with 5% excess ligand. By increasing the excess of ligand from 5% to 10%, the Gd 
concentrations in the skin were further reduced by a factor of three. The addition of 5% excess 
ligand in both contrast agents reduced Gd levels significantly in the femur and the liver, but 
additional excess ligand had no further benefit in these organs. 
Approved gadolinium-based contrast agents have 3 categories of biodistribution 
extracellular with renal elimination, extracellular with mixed renal and hepatobiliary elimination, 
and intravascular with renal elimination. After intravenous injection the distribute in the blood and 
the extracellular space and transiently through the excretory organs. Preclinical animal studies and 
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the available clinical literature indicate that all these compounds are excreted intact Elimination 
tends to be rapid and for the most part, complete. 
In renally insufficient patients the plasma elimination half-life increases substantially from 
hours to days depending on renal function. In patients with impaired renal function who then 
developed NSF, administration of the ECF agents gadodiamide, gadoversetamide, and 
gadopentetate dimeglumine have been shown to result in Gd deposition in the skin and internal 
organs. It is unknown whether Gd deposition results in non-NSF subjects as well and if so, whether 
such deposition correlates with impaired renal function. In one study of hip replacement recipients, 
at 4 days post Gd administration, patients that received gadodiamide had 4-fold higher Gd levels 
in bone than those who received gadoteridol which suggests that there may be Gd deposition in 
non-NSF subjects. In the cases of Gd deposition in NSF patients, it is likely that the Gd is no longer 
associated with its chelator, but this has still not been definitively shown. The speciation of Gd in 
human tissue remains an open question – is the Gd still bound to the chelate and if not, what is it 
bonded to? Is the form of Gd the same in skin deposits compared to internal organs? From the 
limited Gd distribution data available in NSF subjects, there appears to be differences in 
distribution compared to the preclinical rodent studies. For instance, high myocardial uptake of 
Gd in post-mortem analysis is not consistent with the rodent studies. Besides the speciation of Gd, 
the trafficking of Gd in NSF subjects is another open question, i.e. if dechelation occurs, then 
where does it occur and how is the Gd transported to other organs? 
Finally, the route of administration is critical to understanding the biodistribution and 
potential Gd deposition of these GBCA. Despite this low incidence of NSF, GBCA have proven 
to be very safe especially when administered intravenously at approved dosages. The package 
insert should always be consulted for up to date safety information. Alternate routes of 
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administration (e.g. subcutaneous, intrathecal, etc), formulation (e.g. in a liposome or other 
nanoparticle), or cell labeling will likely alter the biodistribution and may impact Gd tissue 
deposition and/or toxicity. Such studies should be undertaken with caution. 
 Results 
4.2.1 Metal binding affinity of ProCA32.collagen1 
With a previously developed metal-buffer system in our lab, we were able to apply this 
system to measure metal binding affinities of ProCA32.collagen1. This metal-buffer system can 
control the free metal concentration in the solution, therefore, an accurate measurement of Kd can 
be achieved successfully for ProCA32.collagen1 and metal ions such as Ca2+, Zn2+, Gd3+ and Tb3+.  
4.2.1.1 Measurement of ProCA32.collagen1 binding affinity to Tb3+ 
Since Gd3+ is a spectroscopically silent element, we first determined the binding affinity of 
ProCA32.cllagen1 to Tb3+ and then used a competition assay to measure the affinity to Gd3+. To 
determine the accurate affinity of ProCA32.collagenl to Tb3+, Tb3+-DTPA buffer system 
previously developed was used. This system has 5 mM DTPA, 30 μM ProCA32.collagen1, 0.06 
μM Rhod-5N, 5 mM HEPES, and 100 mM NaCl at pH 7.2 to mimic the physiological conditions. 
The Kd of DTPA to Tb3+ is 9.55 × 10-22 M. Tb-DTPA can generate a buffer ranging from 10-24 
and 10-18 M of free Tb3+. There is Rhod-5N present in the buffer system, which is a low-affinity-
metal indicator with fluorescence properties which can increase the fluorescence signal when free 
[Tb3+] is higher than 10-6 M. The Rhod-5N was introduced into the system as an internal standard 
and it is important to make sure that DTPA is not saturated by Tb3+. Fig. 4.1 shows Tb-
ProCA32.collagen1 LERT signal changes after Tb3+ titration. In a similar experiment performed 
in parallel, 5 mM DTPA without ProCA32.collagen1 was titrated with Tb3+ to monitor its 
background signal and Rhod-5N at each titration point. As it can be seen in Fig. 4.1 A, Tb3+-
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ProCA32.collagen1 LERT signal occurs in the Tb-DTPA buffer system, which demonstrates that 
ProCA32.collagen1 can bind to Tb3+ in concentrations between 10-23 and 10-19 M. Using Hill 
equation described in Chapter 2 (equation 2-2), we can calculate the Kd (Fig. 4.1 B). 
ProCA32.collagen1 has a Kd of 6.14 × 10-22 M to Tb3+. 
 
Figure 4.1 Resonance energy transfer process between Tb3+ and Trp in 
ProCA32.collagen1 
 
 
 
Figure 4.2 Determination of Tb3+ binding affinity of ProCA32.collagen1.  
Determination of Tb3+ binding affinity of ProCA32.collagen1 using Tb-DTPA chelator buffer 
system in which Free [Tb3+] was kept in a range between 10−23 and 10−17 M using a tightly 
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controlled concentration ratio between Tb3+-DTPA and free DTPA. The interaction between Tb3+ 
and ProCA32.colagen1 was quantified by fluorescence intensity increase due to luminescence 
resonance energy transfer between Trp in ProCA32.colagen1 and Tb3+. 
 
 It is worth mentioning that, PEGylated and non-PEGylated protein had similar binding 
affinities which shows that PEGylation did not affect the binding affinity, Moreover, 
ProCA32.collagen1 had similar Tb3+ binding affinity to non-targeted contrast agent, ProCA32-
P40 which is an indication that addition of targeting moiety of collagen type I to the contrast agent 
did not change the affinity to Tb3+ (Table 4.1). As it is shown in Fig. 4.2 A, Terbium fluorescence 
spectrum changes after adding Tb3+ into 5 mM DTPA with 30 μM ProCA32.collagen1 in 50 mM 
HEPES with 100 mM NaCl at pH 7.2. Rhodamin 5N fluorescence changes also after adding Tb3+ 
into 5 mM DTPA with 0.06 Rhodamin 5N in 50 mM HEPES with 100 mM NaCl. In addition, 
fluorescence intensity does not change during Tb3+ titration in Rhodamin 5N and DTPA.  
4.2.1.2 Measurement of ProCA32.collagen1 binding affinity to Gd3+ 
After measuring Tb3+ binding affinity, Gd3+ binding affinity to ProCA32.collagen1 was 
measured using competition assay.  In this experiment, 10 μM of Tb3+ and 5 μM 
ProCA32.collagen1 were incubated with different concentrations of Gd3+ at room temperature 
overnight in a similar buffer as the Tb3+ binding experiment. The next day, Tb-FRET fluorescence 
signal was measured at excitation 280 nm and emission at 545 nm. As shown in Fig. 4.3 A, Gd3+ 
can compete Tb3+ out of ProCA32.collagen1 with a decrease of FRET upon the gradual addition 
of Gd3+ with an apparent Kd (Kapp) of 6.4 × 10-6 M. Using the apparent Kd and FRET signal 
decrease, we then calculated Kd between Gd3+ and ProCA32.collagen1 using equation (2-3 and 2-
4). As shown from Table 4.1, the Gd3+ binding affinity of ProCA32.collagen1 is 1.96 × 10-22 M 
which was similar to ProCA32-P40. This result shows that ProCA32.collagen1 has very similar 
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Gd3+ stability and affinity compared to most clinical MRI contrast agents, such as Gd-DTPA, 
Multihance, Eovist and Dotarem. and much better Gd-stability than Ominiscan and Optimark (Tale 
4.2).  
 
 
Figure 4.3 Determination of Gd3+ binding affinity of ProCA32.collagen1.  
Gd3+ binding affinity was calculated using competition assay. Different concentrations of Gd3+ 
were incubated with Tb3+- loaded ProCA32.colagen1. The fluorescence intensity decreases due to 
luminescence resonance energy transfer between Trp in ProCA32.colagen1 and bounded Tb3+ 
was quantified when Gd3+ competed Tb3+ out of the metal binding pocket. 
4.2.1.3 Measurement of ProCA32.collagen1 binding affinity to Ca2+ 
Development of metal-chelator buffer system can control the free metal concentration in 
solution which can then help us successfully measure the accurate Kd between ProCA32.collagen1 
and metal ions such as Ca2+ and Zn2+. As a contrast agent, it is extremely important that is has 
selectivity to Gd3+ and cannot be competed out by physiological ions such as Ca2+ and Zn2+ in the 
body.  
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Since ProCA32.collagen1 is based on α-parvalbumin, which is a calcium-binding protein, 
it has been reported that is has strong Kd around 10-9 M to Ca2+ [201] which is even stronger than 
EGTA, therefore we predicted that ProCA32.collagen1 should have similar Ca2+ binding affinity. 
This strong Kd cannot be accurately measured by regular fluorescent titration methods because of 
limitation in free metal background in solution as well as the sensitivity of these methods. 
Theoretically, in order to have an accurate method for Kd measurement, one needs to use protein 
and metal concentration close to the Kd. Development of metal-chelator buffer system can 
overcome these limitations and keep the free Ca2+ concentration between 10-13 M to 10-8 M, and 
then Trp fluorescence change in ProCA32.collagen1 which is close to the binding site can be used 
to monitor the Ca2+ binding affinity at very low concentrations of free Ca2+. Fig. 4.4 demonstrates 
the experimental procedure of Ca2+-EGTA buffer system. This buffer system has 5 mM EGTA, 
100 mM KCl, 50 mM HEPES at pH 7.2. ProCA32.collagen1 was added into this system to a final 
concentration of 5 μM before the experiments. As it is observed, the system has 1000-times higher 
concentrations of EGTA compared to ProCA32.collagen1. This is to make sure that the majority 
of ProCA32.collagen1 can stay in the apo form or Ca2+ free form. Different concentration of Ca2+ 
was titrated into the system. The free Ca2+ concentration can be calculated based on Equation (2-
5). Ca2+ binding to ProCA32.collagen1 can cause the fluorescent intensity changes and 
conformational change in the protein since Trp signal is being monitored. Based on this 
fluorescence signal change in each titration point, the fraction of the Ca2+ bound to 
ProCA32.collagen1 can be derived (Fig. 4.4 B). Then the data can be fit using the titration points 
(Fig. 4.4 A) and Hill Equation (Equation (2-6)). 
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Figure 4.4 Determination of Ca2+ binding affinity of ProCA32.collagen1. 
Determined Ca2+ affinity to ProCA32.collagen1 using the Ca2+-EGTA buffer system. Free [Ca2+] 
was kept in a range between 10−10 and 10−4 M by the tightly controlled concentration of Ca2+ and 
EGTA. The interaction between Ca2+ and ProCA32.colagen1 was monitored by the Trp 
fluorescence intensity increase by increasing Ca2+ concentration. 
It is important to point out that upon addition of Ca2+ to ProCA32.collagen1, not only the 
fluorescence signal increases but also Trp peak shifts to lower wavelengths which is an indication 
of conformational change in ProCA32.collagen1 upon Ca2+ binding. Fig. 4.5 illustrates how free 
Ca2+ concentration can be calculated based on total concentration of Ca2+ in the Ca2+-EGTA buffer 
system. Generally, the total Ca2+ of the buffer system comes from three sources (1) basal Ca2+ in 
the buffer, even after dialysis with Chelex-100 bag to remove excess Ca2+; (2) Ca2+ which has 
bound to ProCA32.collagen1 and introduced to the system upon addition of ProCA32.collagen1 
before titration; (3) Known Ca2+ concentration titrated in to the system. The total basal Ca2+ 
concentration, [Ca2+ ]basal can be measured by Fura-2 dye, which is around 10
-7-10-6 M after chelex-
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95 
100 treatment. According to Equation (2-5), [Ca2+]basal is responsible for 10
-12 - 10-11 M of free 
Ca2+ when total EGTA concentration is 5 mM. Concentration of ProCA32.collagen1 added in this 
experiment is 5 μM. If Kd of ProCA32.collagen1 to Ca2+ is 10-9 M, then we can generate 10 μM 
of total Ca2+ into the system, which further contribute 7.37 × 10-10 M of free Ca2+ in the system. 
The total Ca2+ concentration in each titration point is tightly controlled, and the exact total Ca2+ 
concentration titrated into the system is known. For instance, if we titrated 100 μM of total Ca2+ 
in the system, it generates 7.51 × 10-9 M free Ca2+ in the system according to Equation (2-5). 
 
Figure 4.5 Schematic demonstration of free Ca2+ calculation in Ca-EGTA buffer system 
 
After all the calculations, the Kd of ProCA32.collagen1 was 4.93 × 10-8 M which is similar 
to ProCA32-P40. In addition, each individual association constant (Ka) of ProCA32.collagen1 to 
Ca2+ can also be calculated using Adair equation. It has been hypothesized that binding affinity is 
not a fixed term, but dependent on ligand saturation. Having demonstrated that hemoglobin 
contained four Hemes (and therefore binding sites for oxygen), Adair equation works from the 
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assumption that fully saturated hemoglobin is formed in stages, with intermediate forms with one, 
two, or three bound oxygen molecules. The resulting fractional occupancy can be expressed as: 
 
             (4-1) 
 
Or, for any protein with n ligand binding sites:                                       
                                (4-2) 
 
After using equation 4-2, the data were fit and each individual Ka was calculated. Average 
Ka1=3.45×10
 7M, Average Ka2=1.13×10
 7 M. 
 
Figure 4.6 Determination of Ca2+ binding affinity of ProCA32.collagen1 using Adair 
equation. 
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4.2.1.4 Measurement of ProCA32.collagen1 binding affinity to Zn2+ 
Another physiological metal ion which can compete with Gd3+ in contrast agents is Zn2+ 
causing transmetallation in contrast agents. The binding affinity of ProCA32.collagen1 to Zn2+ 
was determined using Fluozin-1 competition methods [79]. In this experiment, Zn2+ and Fluozin-
1 were incubated together in 50 mM HEPES, 100 mM NaCl, pH 7.2. After that ProCA32.collagen1 
was titrated into the solution. The fluorescence signal of Fluozin-1 was monitored in each titration 
point. Due to competition of ProCA32.collagen1, Zn2+ will be removed from Fluozin-1 during 
titration which causes the fluorescence signal of Fluozin-1 to decrease until it reaches a plateau 
(Fig. 4.7 A). After fitting the titration points with 1:1 binding equation (2-8), Zn2+ binding affinity 
of ProCA32.collagen1 was calculated to be 1.33×10-6 M (Table 4.1).  
 
 
Figure 4.7 Determination of Zn2+ binding affinity of ProCA32.collagen1.  
Zn2+ binding affinity was determined using Fluozin-1 competition assay in which 
ProCA32.collagen1 is competing with Fluozin-1 for Zn2+. 
A B 
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4.2.2 Relaxivity measurements of ProCA32.collagen1 
Relaxivity of ProCA32.collagen1 as the most important property of a contrast agent was 
measured in the buffer containing 50 mM HEPES, 100 mM NaCl, pH 7.2 at 37 ̊ C. Since relaxivity 
depends on the field strength, and MRI instruments are evolving fast to higher magnetic fields for 
higher resolution, ProCA32.collagen1 relaxiviy was measured at both 1.4 T which is the most 
widely used clinical magnetic field and 7.0 T which is higher field strengths. We incubated 
different concentrations of Gd3+ with different concentrations of ProCA32.collagen1 in order to 
plot a curve for relaxivity. Four points were used plus zero point without any Gd3+. These four 
points are: 80 µM ProCA32.collagen1:160 µM Gd3+,  40 µM ProCA32.collagen1:80 µM Gd3+, 20 
µM ProCA32.collagen1:40 µM Gd3+, and  10 µM ProCA32.collagen1:20 µM Gd3+. We then plot 
the curve with Gd3+ concentration in the x axis in mM and relaxation rate in the y axis in s-1. Bruker 
bench top 1.4 T relaxometer was used to measure T1 and T2 in ms. 
We calculated the per Gd3+ relaxivity of ProCA32.collagen1. The final relaxivity was 
calculated with 1:2 ratio between Gd3+ and ProCA32.collagen1 at 37 ˚C 1.4 T. Fig. 4.8 shows the 
r1 and r2 measurements of PEGylated and non-PEGylated ProCA32.collagen1 at 1.4 T and 7.0 T. 
Table 4.1 Summary of metal binding affinities of ProCA32.collagen1 and clinical contrast 
agents 
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Since ProCA32.collagen1 has two Gd3+ binding sites, 1:2 ratio was chosen to make sure that all 
sites have been occupied with Gd3+. Interestingly, the per Gd3+ r1 and r2 of non-PEGylated 
ProCA32.collagen1 is 30 ± 0.3 and 42 ± 0.3 mM-1s-1, respectively and these values for PEGylated 
ProCA32.collagen1 were 34 ± 0.12 mM-1s-1 and 50 ± 0.16 mM-1s-1 for r1 and r2, respectively. It is 
important to point out that relaxivity of ProCA32.collagen1 increased after PEGylation.  
Moreover, these values are larger than ProCA32-P40 which is an advantage for this targeted 
contrast agent. Relaxivity values were also calculated for ProCA32.collagen1 at 7.0 T field 
strength. The results (Fig. 4.8 C) show a significant increase in r2 (108 ± 1.2 mM
-1s-1) value and a 
slight decrease of r1 (21.3 ± 0.5 mM
-1s-1). As Table 4.2 demonstrates, these values for 
ProCA32.collagen1 are significantly higher than clinical contrast agents and even higher than 
ProCA32-P40.   
 
 
Figure 4.8 Relaxation rate of ProCA32.collagen1 at different magnetic fields.  
(A) Relaxation rate of non-PEGylated ProCA32.collagen1 at 1.4 T, 37 ○C. Changes in r1 and r2 
relaxation rates were plotted over various concentrations of [Gd3+]. (B) Relaxation rate of 
PEGylated ProCA32collagen at 1.4 T, 37 ○C. (C) Relaxivity values (r1 and r2) of PEGylated 
ProCA32.collagen1 at 7.0 T, 37 ○C. 
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Table 4.2 Summary of r1 and r2 relaxivity of ProCA32.collagen1 and clinical contrast 
agents 
 
4.2.3 Serum stability of ProCA32.collagen1 
Since ProCA32.collagen1 will be applied for in vivo studies with good metal stability and 
relaxivity, it needs to have good serum stability as well. Therefore, it is extremely important that 
PEGylated ProCA32.collagen1 will not be cleaved by the enzyme in the serum and maintain intact 
structure before secreting out of the body. In order to assess the stability of ProCA32.collagen1 
with PEGylation, the contrast agent was incubated in the 50% serum and then detected by SDS-
PAGE. As Fig. 4.9 shows, ProCA32.collagen1 is very stable in the serum for at least 13 days. 
After a couple of days, the native proteins in the serum start to degrade, however, 
ProCA32.collagen1 was still present in the blood serum. All of these data further confirm that 
ProCA32.collagen1 is as stable as ProCA32-P40 and can be a suitable contrast agent for in vivo 
studies.   
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Figure 4.9 ProCA32.collagen1 stability in human serum.  
ProCA32.collagen1 is stable after incubation in serum at 37 °C for up to 12 days as raveled by 
Coomassie Brilliant Blue Ponceau S solution staining. 
4.2.4 Transmetallation studies of ProCA32.collagen1 
Metal stability and selectivity is one of the important criteria for designing contrast agents 
and they are extremely needed for the development of contrast agents. Other physiological ions 
such as Zn2+ can compete with Gd3+ and force them out of the binding pocket of contrast agents. 
After measurement of the binding affinities of ProCA32.collagen1 to different metal ions such as 
Zn2+, Ca2+ and Gd3+, the results demonstrated higher selectivity of ProCA32.collagen1 compared 
to clinical contrast agents (Table 4.1). These results led us to assess the transmetallation property 
of ProCA32.collagen1 since it was going to be applied in vivo. 
Zn2+ and PO43- are the major competitors of Gd3+ in physiological conditions. To study the 
transmetallation of ProCA32.collagen1, relaxation rate changes of the contrast agent was measured 
over time in the presence of Zn2+ and PO43-. As reported in the literature, different clinical contrast 
agents had different transmetallation rates in this solution. (Fig. 4.10). The linear contrast agents 
with no charge such as Omniscan experienced the highest transmetallation effect, however, 
macrocyclic non-charged MRI contrast agents such as ProHance, had no transmetallation in the 
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presence of Zn2+ and PO4
3- for at least 4 days based on the study [202]. For other clinical contrast 
agents, although the number of negative charge and ligand type are very similar, different ionic 
linear MRI contrast agents has different transmetallation rate. 
We used the similar procedure to assess the transmetallation properties of 
ProCA32.collagen1 in the presence of Zn2+ and PO4
3-. Due to the higher relaxivity, 25 times lower 
Gd3+ concentration, and 25-50 times lower chelator concentration was used in this study. To better 
compare the transmetallation properties of ProCA32.collagen1 with clinical MRI contrast agent, 
this experiment was applied using 25 times lower concentrations of Zn2+ and PO4
3-. As shown in 
Fig. 4.10, the relaxation rate of ProCA32.collagen1 is not changed in the presence of Zn2+ and 
PO4
3- for about 4 days, demonstrating that ProCA32.collagen1 is very selective to Gd3+ at these 
conditions. 
 
Figure 4.10 Stability of ProCA32.collagen1 and clinical contrast agents.  
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The relaxation rates change of clinical contrast agents (♦ Eovist; ● Magnevist; □ 
MultiHance; △ Ominiscan; ■ ProHance; ○ Dotarem; and ProCA32.collagen1 (◊, loaded with 
Gd3+ to at approximately 1:1 ratio) in phosphate buffer in the presence of ZnCl2 at different time 
points up to 4 days. 
Transmetallation of ProCA32.collagen1 and clinical MRI contrast agents were evaluated 
by measuring the relaxivity changes in the presence of Zn2+ and phosphate over time. The 
relaxivity of ProCA32.collagen1 was monitored with 55 or 110 μM ProCA32.collagen1, 100 μM 
Gd3+, 100 μM Zn2+, and 1.2 mM PO4
3−. In this experiment, when Zn2+ is competing Gd3+ out of 
the structure of contrast agents, Gd3+ will form a precipitate with PO4
3− in the buffer which is an 
indication of instability of the contrast agent.  
4.2.5 Water number determination of ProCA32.collagen1 
Water number was one the factors discussed in Chapter 1 affecting the relaxivity of contrast 
agents. The number of water molecular interacting with Gd3+ at the same time is important. 
Furthermore, determination of water number can illustrate the special arrangement of the Gd3+ 
binding ligands. Tb3+ luminescence life time experiment was performed in order to test that the 
relaxivity and metal binding affinity of ProCA32.collagen1 can be tuned by changing water 
number [173, 176]. Generally, the fluorescence decay of the Tb3+ is caused by the radiative decay 
(Г) and non-radiative decay (K). Non-radiative decay has many factors, such as molecular 
collation, quenching, energy transfer. H2O molecule is one of the major factors which creates the 
non-radiative decay of the Tb3+ fluorescence, however, D2O cannot generate non-radiative decay 
of Tb3+ fluorescence. As a result, the difference of the decay rates of Tb3+ in the presence of H2O 
and D2O (ΔKobs) represents the number of water molecules interacting with Tb
3+-
ProCA32.collagen1. 
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In order to measure the exact number of water number of ProCA32.collagen1, different 
organic chelators (NTA, EDTA, DTPA) and Tb3+ in aqueous solution were used to create a 
standard curve. The water number for NTA, EDTA, DTPA and Tb3+ and aqueous solution have 
been reported in the literature. X-ray diffraction was used to determine the water numbers of these 
chelators [173, 176]. To create a standard curve, Tb-DTPA, Tb-EDTA, Tb-NTA and free Tb3+ are 
prepared in H2O and D2O solution. Then Tb
3+ fluorescence was excited at 280 nm and the 
fluorescence decays were monitored at 545 nm. The fluorescence decay was fitted by single 
exponential decay Equation. The decay rate (Kobs) and life time (τ) of Tb
3+ in H2O and D2O were 
then calculated. After that the standard curve was plotted on the reported water number of these 
chelators and difference of Kobs in H2O and D2O (ΔKobs) (Fig. 4.11). Water number of 
ProCA32.collagen1 was calculated and q=0.5 which is the same as ProCA32-P40. 
 
 
Figure 4.11 The luminescence decay of Tb3+ in H2O (blue) or D2O (white) in solution of 
ProCA32.collagen1. (A) Tb3+ and ProCA32.collagen1 were mixed with 1 to 2 ratios. (B) Water 
number of Magnevist, Eovist, ProCA32-P40, ProCA32.collagen1. 
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4.2.6 Collagen type I binding affinity of ProCA32.collagen1  
Since ProCA32.collagen1 is a collagen type I targeted MRI contrast agent, its binding 
affinity to this biomarker needs to be measured. Collagen type I is the most abundant component 
of extracellular matrix (ECM), therefore it is more accessible to contrast agents than other 
biomarkers that are expressed on the membrane. Indirect ELISA (enzyme-linked immunosorbent 
assay) was used to determine the binding affinity of ProCA32.collagen1 to collagen type I. ELISA 
(enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and 
quantifying substances such as peptides, proteins, antibodies and hormones. Other names, such as 
enzyme immunoassay (EIA), are also used to describe the same technology. In an ELISA, an 
antigen must be immobilized on a solid surface and then complexed with an antibody that is linked 
to an enzyme. Detection is accomplished by assessing the conjugated enzyme activity via 
incubation with a substrate to produce a measurable product. The most crucial element of the 
detection strategy is a highly specific antibody-antigen interaction. Figure 4.12 shows the basic 
principles of ELISA.  
In our experiment, collagen type I solution from rat tail with stock concentration of 4 
mg/mL was coated in ELISA plate mixed with coating buffer (0.2 M sodium 
carbonate/bicarbonate, pH 9.4) overnight at 4°C. Approximately 30 µL of collagen type I was 
mixed with 80 µL of coating buffer. Coating buffer is used to activate the plate. It is important to 
pay attention to the capacity of the plate and how much protein is coated. In the next step, the plate 
is washed with 100 µL of 1×TBST (10×TBS +Tween 20) three times, each time for about 5-10 
minutes under constant shaking at room temperature. Next, the blocking buffer (%5 of Bovine 
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Serum Albumin in 1×TBST) is prepared and 100 µL is added to the plate with constant shaking at 
room temperature for about 1.5-2 hours.  
 
Figure 4.12 Basic principles of ELISA. 
 
Different concentrations of ProCA32.collagen1 starting from 0 nM up to 164000 nM were 
added to the plate in the blocking buffer and incubated for either 2 hours at room temperature or 
4°C overnight. Then the plate is washed again with 100 µL of 1×TBST (10×TBS +Tween 20) 
three times, each time for about 5-10 minutes under constant shaking at room temperature. Primary 
antibody (rabbit anti mouse) was added with 1:1000 dilution to the blocking buffer and then 100 
µL was added to the plate with constant shaking at room temperature for 1.5-2 hours.  
The plate was washed again with the same procedure, and the secondary antibody (goat 
anti rabbit) was added with 1:2000 dilution in the blocking buffer with shaking at room 
temperature for about 45 minutes. Then the plate was washed again and 1-Step Ultra TMB-ELISA 
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solution (100 µL) was added. It is important that each well in the plate has the same exposure time 
to the ELISA substrate solution for better results. In the last step, a stop solution (2M sulfuric acid) 
is added to stop the reaction. Then the absorbance in each well is read by plate reader.  
 
Figure 4.13 The dissociation constant of Lysine and Cysteine PEGylated 
ProCA32.collagen1 to collagen type I using indirect ELISA. ProCA32-P40 without any targeting 
moiety did not show any specific binding.  
After measuring the absorbance of multiple concentration points, the data were fit with one 
to one binding equation and a dissociation constant of 1.4 ± 0.2 µM was calculated (Fig 4.13 A). 
It is important to point out that residue PEGylation affect the binding affinity of the contrast agent 
significantly as Cysteine residues reported to play a crucial role in the binding [120]. Cysteine 
PEGylated ProCA32.collagen1 showed much lower binding affinity to collagen type I (Kd=71.8 
± 2 µM) due to prevention of forming a cyclic peptide in the targeting moiety to bind to collagen 
I (Fig 4.13 B). 
 
 
 
A B 
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4.2.7 Pharmacokinetic studies of ProCA32.collagen1 
In addition to metal affinity and relaxivity properties of ProCA32.collagen1, detailed 
pharmacokinetic characteristic of ProCA32.collagen1 was also studied.  There is an excellent 
correlation between relaxivity, Gd3+ binding affinity and selectivity, and in vivo pharmacokinetics 
required for detection of different stages of liver fibrosis and metastasis as well disease 
heterogeneity. In order to obtain pharmacokinetic parameters, ProCA32.collagen1 (0.016 
mmol/kg) was intravenously injected into mice (n=3-6) and blood was collected from saphenous 
vein at different time points before and after injection up to 7 days. After collection, serum of each 
sample was obtained and the Gd3+ concentration was measured using ICP-OES at a wavelength of 
342 nm (Gd). Then the data were fit using two-compartment distribution model and 
pharmacokinetic parameters such as terminal half-lives (blood/plasma), volumes of distribution, 
and total clearance were calculated.  
The blood concentration-time profiles after intravenous injection of ProCA32.collagen1 in 
mice were analyzed using two-compartmental analysis using WinNonlin ™ 5.0.1 software 
(Pharsight Corp., Palo Alto, CA). Mean blood concentration values from 3-6 mice at each 
sampling time point were used for the mice pharmacokinetic analysis. The area under the blood 
concentration-time curve (AUC) was calculated using the log-linear trapezoidal rule. The 
elimination half-life (t1/2) was calculated by the equation t1/2 = 0.693/K, where K was estimated 
from the terminal slope of the blood Gd3+ concentration versus time curve. The systemic clearance 
(CL) was determined from dose/AUC, with AUC (area under the curve to infinity) by linear 
interpolation and extrapolation to infinity y from Clast x t1/2β/0.693 (where Clast was concentration 
at each last sampling point). The volume of distribution at steady-state (Vss) was determined by 
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the equation Vss = CL × (AUMC/AUC), where AUMC is the area under the first moment curve. 
The mean residence time (MRT) was calculated from AUMC/AUC. 
ProCA32.collagen1 has the terminal elimination half-life of 9.93 h. In addition, volume of 
distribution (Vc) and volume of distribution at steady state (Vdss) were 1.53 and 1.77 L/kg, 
respectively. Total body clearance (CL) for ProCA32.collagen1 was 0.36 mL/min/kg. Table 4.3 
summarizes the pharmacokinetic parameters of ProCA32.collagen1 compared to ProCA32-P40 
and Eovist. 
The pharmacokinetic characteristics of ProCA32.collagen1 in the mouse showed a 
relatively high volume of distribution and vascular confinement of the contrast agent, which is 
superior than clinical contrast agents like Magnevist, where the agent is largely distributed to the 
extravascular extracellular space (outside the central nervous system) after intravenous 
administration. Blood ProCA32.collagen1 concentrations dropped to a significantly lower level by 
2 days (Fig. 4.14) after its administration and mean residence time (MRT) for ProCA32.collagen1 
was 14.51 h. ProCA32.collagen1 had an increased elimination half-life compared to Eovist and 
ProCA32-P40.  
The systemic clearance of ProCA32.collagen1 was about 3 times higher than ProCA32-
P40 which is a non-targeted contrast agent. The difference could be attributed to a potentially 
higher renal glomerular filtration rate or higher hepatic clearance of the agent. Biodistribution in 
mouse showed accumulation of ProCA32.collagen1 in the liver and spleen, consistent with 
reticuloendothelial system (RES) clearance of macromolecular contrast agents. The volume of 
distribution at steady state (Vss) was two times higher than that of ProCA32-P40 which is an 
indication of contrast agent distribution in tissues.   
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Figure 4.14 Pharmacokinetics of ProCA32.collagen1. 
Gd3+ concentration in serum collected after injection of ProCA32.collagen1 (n = 3-6) at different 
time points measured by ICP-OES at 342 nm up to 7 days, however the data up to 72 h are shown. 
After injection, the Gd3+ concertation in serum decreased until it was below the detection limit of 
ICP-OES. The concentration of Gd3+ in serum samples were fit with exponential model in order 
to extrapolate the necessary PK parameters. 
 
As Table 4.3 demonstrates, ProCA32.collagen1 has improved pharmacokinetic properties 
compared to non-targeted contrast agent, ProCA32-P40. ProCA32.collagen1 has slightly longer 
elimination half-life compared to ProCA32-P40 which is due to its targeting capability. However, 
its show much faster clearance rate with increased exposure time which is important for a targeted 
contrast agent.  
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Table 4.3 Summary of PK parameters for ProCA32.collagen1 and ProCA32-P40. 
 
 
4.2.8 Safety studies of ProCA32.collagen1 
Due to safety issues related to Gd3+ toxicity of MRI contrast agents, ProCA32.collagen1 
distribution in different mouse organs was studied. The Gd3+ concentration in each organ was 
measured using ICP-OES in order to assess the possible Gd3+ deposition in organs. Furthermore, 
clinical chemistry tests were performed after injection of high concentration of ProCA32.collagen1 
and different enzymes and analytes reflecting the functions of liver and kidney were measured to 
investigate the toxicity of ProCA32.collagen1.  
At the end, tissues of mice injected with ProCA32.collage1 were collected and H&E 
staining was performed on each tissue and assessed by a pathologist blinded to our studies and the 
results were then compared with control mice.   
4.2.8.1 Distribution of ProCA32.collagen1 in different organs 
As Fig. 4.15 demonstrates, each mouse organ was collected and Gd3+ concentration was 
measured 14 days after 0.025 mmol/kg injection of ProCA32.collagen1. For this procedure, 
approximately, 0.2 g of each tissue was sectioned and digested in 1 mL of ICP-grade concentrated 
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nitric acid overnight at room temperature until a clear solution was achieved then the solution was 
diluted with %2 nitric acid to 6-8 mL and then the Gd3+ concentration was measured.  
As the results show, our contrast agent has very negligible accumulation in bone, skin and 
brain, however Eovist which is a clinical contrast agent showed high depositions of Gd3+ in bone, 
skin and brain as well as other organs.  
 
Figure 4.15 Biodistribution analysis of ProCA32.collagen1. 
Long term organ toxicity demonstrates the biodistribution of ProCA32.collagen1 and Eovist 14 
days after injection in mice in different organs using ICP-OES. As it can be seen, different organs 
such as brain, skin and bone have high accumulations of Gd3+ which is an indication of free Gd3+ 
being released. 
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4.2.8.2 Clinical chemistry tests 
Clinical chemistry tests performed by an independent company. For this purpose, serum 
samples after injection of 0.025 mmol/kg ProCA32.collagen1 was collected and shipped. The mice 
clinical chemistry profiles were collected by analyzing mice serum samples 5 days after injection 
of saline (gray, n = 5), or 0.023 mmol/kg ProCA32.collagen1 (black). Data are expressed as mean 
± SD. Different tests performed for clinical chemistry profile studies. 
Alanine Transaminase (ALT) test is used by the body to metabolize protein. If the liver is 
damaged or not functioning properly, ALT is released into the blood. This causes ALT levels to 
increase. A high result on this test can be a sign of liver damage. 
Aspartate Aminotransferase (AST) Test: Aspartate aminotransferase (AST) is an enzyme 
found in several parts of the body, including the heart, liver, and muscles. Since AST levels aren’t 
specific for liver damage, it’s usually measured together with ALT to check for liver problems. 
When the liver is damaged, AST is released into the bloodstream. A high result on an AST test 
might indicate a problem with the liver or muscles. 
Alkaline Phosphatase (ALP) Test: Alkaline phosphatase (ALP) is an enzyme found in your 
bones, bile ducts, and liver. An ALP test is typically ordered in combination with several other 
tests. High levels of ALP may indicate liver damage, blockage of the bile ducts, or a bone disease. 
Creatine Kinase (CK) Test: Measurement of serum creatine kinase (CK) activity is 
essential in the evaluation of suspected neuromuscular disease.  In skeletal muscle CK plays a 
major role in energy generation, buffering cellular ATP and ADP concentrations by catalyzing the 
reversible exchange of high-energy phosphate bonds between phosphocreatine and ADP, 
regenerating ATP from ADP produced during muscle contraction. A diagnosis of liver disease 
should not be made with elevations of AST and ALT alone in the absence of concurrent 
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measurement of serum CK activity. If serum CK activity is not measured, misdiagnosis of a liver 
disease may be made when the actual problem is a myopathy. 
Total Proteins test:  Albumin is the main protein made by liver. It performs many important 
bodily functions. For example, albumin: Stops fluid from leaking out of your blood vessels 
Nourishes the tissues, Transports hormones, vitamins, and other substances throughout the body 
An albumin test measures how well the liver is making this particular protein. A low result 
on this test indicates that the liver isn’t functioning properly. Globulin is a set of sixty proteins 
including the antibodies or gamma globulins and protein-carbohydrate compounds known as 
glycoprotein. There are four basic groups of globulin proteins known as the alpha-1, alpha-2, beta 
and gamma proteins.  
These are used to help transport proteins through the lipoproteins and assisting the blood 
in clotting. They also act as plasma cells which indicate whether there is an antibody deficiency in 
the blood stream. The liver produces much of the alpha and beta globulins used for this purpose.  
The level of these proteins is measured against the levels of albumin, the other major type 
of protein in the bloodstream.  Albumin and globulin are two types of protein in body. The total 
protein test measures the total amount albumin and globulin in your body. 
Bilirubin and Creatinine Test: Bilirubin attached by the liver to the glucose-derived acid, 
glucuronic acid, is called direct, or conjugated, bilirubin. Bilirubin not attached to glucuronic acid 
is called indirect, or unconjugated, bilirubin. All the bilirubin in the blood together is called total 
bilirubin. Bilirubin is a waste product ordinarily processed by the liver. The breakdown of red 
blood cells creates this waste product. It passes through the liver before being excreted through 
stool. A damaged liver can’t properly process bilirubin. This leads to an abnormally high level of 
bilirubin in the blood. A high result on the bilirubin test indicates that the liver isn’t functioning 
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properly. If bilirubin is not being attached to the glucose-derived acid (conjugated) in the liver or 
is not being adequately removed from the blood, it can mean that there is damage to your liver. 
Testing for bilirubin in the blood is a good way of testing for liver damage. 
Creatinine Test: Creatinine is a chemical waste molecule that is generated from muscle 
metabolism. Creatinine is produced from creatine, a molecule of major importance for energy 
production in muscles. Creatinine is transported through the bloodstream to the kidneys. The 
kidneys filter out most of the creatinine and dispose of it in the urine. The kidneys maintain the 
blood creatinine in a normal range. Creatinine has been found to be a fairly reliable indicator of 
kidney function. Elevated creatinine level signifies impaired kidney function or kidney disease. 
As Fig 4.16 shows, liver and kidney function tests appeared to be normal after injection of 
ProCA32.collagen1 and the results were the same as control mice, therefore, ProCA32.collagen1 
did not cause any toxicity after injection.   
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Figure 4.16 Toxicity studies of ProCA32.collagen1. 
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(A, B, C, D, E) Clinical chemistry tests after injection of 0.023 mmol/kg, ProCA32.collagen1. The 
mice clinical chemistry profiles were collected by analyzing mice serum samples 5 days after 
injection of saline (gray, n = 5), or 0.025 mmol/kg ProCA32.collagen1 (black). Data are expressed 
as mean ± SD. 
4.2.8.3 Tissue toxicity of ProCA32.collagen1 
The 0.0013 mmol/kg ProCA32.collagen1 or saline (control) was i.v. injected in CD-1 mice. 
H&E staining was used to evaluate the toxicity of the ProCA32.collagen1 to these tissues after 
injection. An experienced pathologist was blinded to the groups of H&E staining to evaluate the 
organ toxicity of ProCA32.collagen1. ProCA32.collagen1 shows no toxicity in all kinds of mice 
tissues and organs studied, including liver, kidney, muscle, spleen, brain, and heart. The images 
are representative of three independent experiments. As results show in Fig. 4.17, all the tissues in 
all viral organs appeared to be normal after injection of ProCA32.collagen1 which shows that the 
contrast agent does not cause any tissue damage due to Gd3+ deposition.  
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Figure 4.17 Tissue toxicity studies of ProCA32.collagen1. 
The 0.0013 mmol/kg ProCA32.collagen1 or saline (control) was i.v. injected in CD-1 mice. H&E 
staining was used to evaluate the toxicity of the ProCA32.collagen1 to these tissues after injection. 
An experienced pathologist was blinded to the groups of H&E staining to evaluate the organ 
toxicity of ProCA32.collagen1. ProCA32.collagen1 shows no toxicity in all kinds of mice tissues 
and organs studied, including liver, kidney, muscle, spleen, brain, and heart. The images are 
representative of three independent experiments.  
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 Discussion  
4.3.1 Design of ProCA32.collagen1 with collagen targeting capability and dual high relaxivity 
Collagen targeted protein MRI contrast agent, ProCA32.collagen1 was designed by 
covalently linking a collagen type I targeting peptide moiety consisting of natural amino acids to 
the C-terminal of protein contrast agent ProCA32 (with two Gd3+ binding sites). An intra-disulfide 
bond formed by two cysteine residues to stabilize conformation required for collagen I binding. In 
the modeled structure, Lysine residues are positioned to bind collagen type I while its PEGylation 
also increase relaxivity by tuning correlation time. A flexible linker was used to maximize 
targeting capacity and relaxivity yet maintaining metal binding capability [83]. PEGylation of the 
contrast agent can improve protein solubility, blood retention time and reduce immunogenicity 
[84]. The designed ProCA32.collagen1 was bacterial expressed, purified, and modified and 
confirmed to form a 1:2 Gd-ProCA32.collagen1 complex using ICP-OES (Methods) [83] [177].  
We determined collagen I binding affinity of PEGylated ProCA32.collagen1 using enzyme 
linked immunosorbent assay (ELISA). The contrast agent exhibits high affinity to collagen type I 
with dissociation constant of Kd=1.42  0.2 M (fitted by 1:1 binding model) [135, 203]. On the 
other hand, PEGylated ProCA32 without addition of a collagen targeting moiety did not show any 
specific binding to collagen I.  
 The determined relaxivity of r1 and r2 of PEGylated ProCA32.collagen1 were 34 ± 0.12 
mM-1s-1 and 50 ± 0.16 mM-1s-1 per Gd3+, respectively at 37 °C and 1.4 T or 68  0.25 mM-1s-1 and 
100  0.32 mM-1s-1 per particle, respectively. Interestingly, at high magnetic fields of 7.0 T, 37 °C, 
PEGylated ProCA32.collagen1 exhibits the highest r1 (21.3 ± 0.5 mM
-1s-1 per Gd3+ or 42.6 ± 1 
mM-1s-1 per participle) and r2 (108.5 ± 1.2 mM
-1s-1 per Gd3+ or 217 ± 2.4 mM-1s-1, per particle) 
compared to reported contrast agents (Table 4.2).  ProCA32.collagen1’s r1 and r2 relaxivity values 
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are 5-10 and 12-17 times greater than those of clinical contrast agents at 1.4 and 7.0 T, respectively. 
Therefore, this targeted contrast agent can be applied to both low and high magnetic field strengths 
with both T1 and T2 weighted molecular imaging.  Such large value of r1 and r2 are likely due to 
secondary shell water contribution since water number q in the first coordination shell determined 
by luminescence resonance energy transfer (LRET) using Tb3+ luminescence life time decay is 
0.5.  
4.3.2 High Gd3+ binding affinity and metal selectivity, and low toxicity of ProCA32.collagen1  
To address one of the major causes of nephrogenic systemic fibrosis (NSF) associated with 
free Gd3+ toxicity, we next examined metal binding affinity and selectivity of ProCA32.collagen1. 
We determined the dissociation constant (Kd) of ProCA32.collagen1 to Tb
3+ to be 6.14 ± 0.2 × 10-
22 M using Tb3+-DTPA buffer system and Tb3+ luminescence resonance energy transfer (Tb3+-
LRET) between Tb3+ and Trp adjacent to the metal binding sites. Addition of Gd3+ results in 
decrease of the LRET signal between Tb3+ and Trp due to competition of metal binding sites. The 
Gd3+ binding affinity of ProCA32.collagen1 is 2.0 ± 0.25 × 10-22 M which is comparable to the 
approved clinical contrast agents (Table 4.1). Since competition of physiological metal ions such 
as Zn2+, Mg2+ and Ca2+ [6, 11] is considered to be one of the most important risk factors for Gd3+ 
release in vivo, we then determined metal binding constants for these metal ions [83, 176].  Table 
4.1 shows that ProCA32.collagen1 exhibits 1014-1016-fold increases in metal selectivity (kinetic 
stability) for Gd3+ over Ca2+ and Zn2+ compared with all approved agents including macrocyclic 
“safe” agents Dotaram and ProHance. To the best of our knowledge, like ProCA32-P40, 
ProCA32.collagen1 has the greatest metal selectivity among all other approved Gd3+-based 
contrast agents.  
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4.3.3 Additional improved safety properties of ProCA32.collagen1 
ProCA32.collagen1 has several additional improved safety properties. Transmetallation 
studies demonstrate the relaxation rates of clinical contrast agents (Eovist; Magnevist; Ominiscan; 
ProHance) gradually decrease upon incubation with 2.5 mM Zn2+ in 30 mM PO43- [83].   In 
contrast, the relaxation rates of ProCA32.collagen1 remain unchanged suggesting that 
ProCA32.collagen1 has strong capability against transmetallation, similar to approved “safe” 
contrast agents Dotarem and ProHance.  Further, ProCA32.collagen1 remains intact without 
cleavage upon incubation with human serum at 37C for 13 days.  Recent brain deposition has 
underlined the importance of metal safety [204, 205]. Importantly, ProCA32.collagen1 does not 
have brain deposit possibly due to lack of penetration to blood barrier.  Moreover, 
ProCA32.collagen1 did not show any acute toxicity as clinical chemistry test values are within 
the normal range demonstrating the normal function of organs specially kidney and liver. No 
tissue and organ toxicity was observed. More importantly, the projected required injection dosage 
of ProC32.collagen1 in human for significant MRI enhancement in liver is ~ 20-230-fold lower 
than clinical contrast agents such as MultiHance (Table 4.2).  
Our developed ProCA32.collagen1 represents a major leap in addressing concerns about 
metal toxicity and Gd3+ deposition associated with current contrast agents in several aspects. 
Administration of contrast agents helps with visualization of diseases at MRI. Specifically, 
majority of clinical Gd3+-based MRI contrast agents cause T1 shortening and signal enhancement 
on T1 map images, however most of these agents have been linked to the occurrence of 
nephrogenic systemic fibrosis (NSF) in renal impaired patients due to release and accumulation of 
Gd3+ from the agent because of transmetallation [157, 206] . Furthermore, they are all based on 
small-molecule chelates and have very low relaxivity (both r1 and r2) and sensitivity without 
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targeting capability, therefore, they are only able to detect moderate and advanced stage of 
diseases. The clinical contrast agents also use a high clinical injection dosage due to their low 
sensitivity with a short imaging window without the capability of enhancing the entire organ such 
as Eovist. ProCA32.collagen1 with high r1 and r2 relaxivity has very low injection dosage (Table 
4.1) of 0.0013 mmol.kg-1 projected in humans which is 20-200-fold lower than clinical contrast 
agents. In addition, its high selectivity towards Gd3+ makes it a safer agent.   
 Summary  
In summary in this chapter, some of the most important properties of a contrast agent was 
reported. ProCA32.collagen1 has very strong binding affinity to collagen type I and superior r1 
and r2 relaxivity. The contrast agent has very high binding affinity and selectivity towards Gd
3+ 
and is very resistant to transmetallation. ProCA32.collagen1 is also very stable in the human serum 
up to 13 days without any degradation. It is worth mentioning that PEGylation not only increases 
the stability and solubility of the contrast agent but also increase its relaxivity and sensitivity for 
in vivo applications which will be discussed in the coming chapters. ProCA32.collagen1 did not 
show any tissue and long-term organ toxicity based on low and negligible Gd3+ accumulations.  
5 APPLICATION OF PROCA32.COLLAGEN1 IN IMAGING OF LIVER FIBROSIS 
 Introduction 
5.1.1 Organ fibrosis 
Fibrosis is a common feature in many different pathologies. It is characterized by the 
accumulation of extracellular matrix (ECM) components and is associated with up to 45% of 
deaths in industrialized countries [207]. In general, fibrosis mechanisms include exacerbated 
injury-related responses that are dysregulated versions of conventional tissue repair processes 
[208]. Core elements in disease progression can be acute, recurrent or persistent epithelial and 
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endothelial injuries that can both initiate and sustain fibrosis [209]. These pathogenic pathways 
furthermore involve changes in numerous inflammatory, endothelial and mesenchymal cells, 
resulting in increased production of fibronectin, osteopontin, hyaluronan, proteoglycans, laminins 
and a variety of collagen subtypes [210]. The abnormal ECM deposition which is typical of fibrosis 
leads to a disruption and distortion of the tissue architecture and function [211]. These fundamental 
fibrotic processes are shared across a variety of tissues and organs, including connective tissue, 
gastrointestinal tract, liver, kidney, lung and heart (Fig. 5.1). While the mechanisms of fibrogenesis 
are similar, the regenerative capacity and the ability to reverse advanced fibrosis vary 
tremendously. Resolution of fibrosis is for example possible in the liver when the underlying cause 
is removed; this is for instance the case in complete suppression of hepatitis B virus replication 
and curative treatment of hepatitis C [212].  
The desmoplastic reaction and increased ECM production in tumors is remarkably similar 
to organ fibrosis [213]. Cancer-associated fibroblasts (CAF) are one of the most crucial 
components of the tumor microenvironment and have been implicated in angiogenesis, 
immunosuppression and metastasis [214, 215]. Fibrotic stroma affects disease progression in 
various tumors, e.g. breast cancer, in colon/colorectal cancer and in pancreatic tumors, as well as 
in head and neck cancer [216, 217]. In contrast to fibrosis as a common endpoint for all of the 
above organs and tissues, the etiologies causing fibrosis are highly diverse, encompassing an array 
of different triggers such as acute injury, chronic inflammation, autoimmune reactions and genetic 
alterations. In some cases, the exact etiology may even remain unknown. While a detailed 
description of these triggers and their disease-initiating mechanisms is beyond the scope of this 
review, several prototypic examples can be provided, to exemplify the high prevalence and far-
reaching consequences of fibrotic processes in human diseases. Among the most obvious 
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etiologies for induction of fibrosis are exposure to ionizing irradiation and mechanical obstruction, 
resulting from e.g. myocardial infarction, surgical intervention, gall- and kidney-stones. 
Frequently accountable chronic illnesses with fibrotic elements include psoriasis, Crohn's disease, 
pneumoconiosis subtypes, steatohepatitis, viral hepatitis and glomerulosclerosis. Also, many 
autoimmune disorders, such as rheumatoid arthritis, systemic lupus erythematosus, Sjörgen's 
syndrome, progressive systemic sclerosis, Hashimoto's thyroiditis and ankylosing spondylitis are 
associated with fibrosis. 
Underlying genetic predispositions that make individuals susceptible to fibrosis are 
neurofibromatosis, cystic fibrosis, alpha 1-antitrypsin deficiency, tyrosinosis, Wilson's disease and 
hemochromatosis, as well as hypertrophic and restrictive cardiomyopathy. There are multiple 
fibrosis related diseases, in which the exact triggers are unknown, such as sarcoidosis, idiopathic 
pulmonary fibrosis, retroperitoneal fibrosis, acute interstitial pneumonitis and dilated 
cardiomyopathy.  
Accurate diagnosis and staging of fibrosis is essential for proper prognosis and progression 
monitoring. The presence and the severity of fibrosis actually are the best predictors for disease 
progression in chronic kidney disorders and in fatty liver disease [218]. Traditionally, needle-based 
biopsies have been the gold standard for fibrosis diagnosis and staging. Biopsies, however, are 
faced with multiple limitations, including their invasive nature, procedure-associated risks, limited 
representativeness for the entire organ, and inter- and intra-observer sampling variability [219]. 
In the recent years, increasing numbers of studies have focused on the development of non-
invasive imaging techniques for fibrosis diagnosis, staging and treatment monitoring. Non-
invasive imaging techniques such as X-ray imaging, computed tomography (CT), ultrasound (US), 
magnetic resonance imaging (MRI), photoacoustic imaging (PAI), optical imaging (OI), positron 
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emission tomography (PET) and single-photon emission computed tomography (SPECT) have all 
been employed for this purpose [220-223]. Biopsies and liquid biomarkers to assess fibrosis 
An accurate determination of fibrosis stage is crucial for the prognosis, for determining 
surveillance strategies and for selecting a suitable therapeutic approach. Traditionally, needle-
based biopsies are considered the gold standard and they often are the only available means for 
specific fibrosis assessment and exact disease differentiation. In the case of systemic lupus 
erythematosus (SLE), for instance, a renal biopsy is crucial to diagnose the specific form of lupus 
[224]. In general, multiple stainings can be employed for visual inspection, such as hematoxylin 
and eosin staining or more specifically trichrome or Sirius Red staining (marking collagenous 
fibers) or immunohistochemistry specific for certain types of collagens or other ECM components 
[225]. 
 
 
Figure 5.1 Pathological characteristics of fibrosis in different tissues. 
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To achieve optimal accuracy in the diagnosis of fibrosis, the biopsy bias has to be 
minimized, starting with the excised sample, which should have specific properties. An adequate 
kidney biopsy is 10 mm in length and at least 1.2 mm in width, and it should contain 10–15 
glomeruli [226]. A liver biopsy is considered adequate if it has a length of at least 20 mm and 
contains at least 11 portal tracts (some experts even prefer 16 portal tracts) [227]. However, such 
“optimal” liver biopsies only represent 1/50,000 of the total liver volume. For the diagnosis of 
arthritic diseases, a biopsy sample of the synovial fluid is considered equally informative as a 
sample of the synovial tissue. The diagnosis of connective tissue disease is commonly performed 
on the basis hematological tests (complete blood count, erythrocyte sedimentation rate), 
biochemical analysis (C-reactive protein, hepatic function, renal function) and immunologic 
investigations (autoantibodies, rheumatoid factors, antinuclear antibodies, antibodies to DNA, 
antiphospholipid antibodies) [228]. 
In case of tumors, a biopsy is the standard diagnostic procedure to determine the nature 
and stage of the tumor, as well as its malignant potential. Although the essential role of 
desmoplastic processes for tumor growth and metastasis has been recognized [229], they are not 
considered in routine pathological assessments. Many studies have suggested that especially in 
invasive colorectal cancer [230-232] and in pancreatic ductal adenocarcinoma [233-235], the 
desmoplastic reaction is a key hallmark determining therapeutic outcome. Thus far, however, 
histopathological information on e.g. myxoid stroma as an indicator for epithelial-to-mesenchymal 
transition [230], has not yet managed to become broadly accepted and implemented for disease 
differentiation, prognosis assessment and treatment selection [236]. 
While needle-based biopsies inevitably play an important role in the diagnosis and staging 
of fibrotic diseases, they suffer from several drawbacks, including invasiveness with the risk of 
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life-threatening complications, sampling errors, and intra- and inter-observer variability [237, 
238]. Moreover, repeated biopsy procedures are difficult and impractical, due to the increased risk 
of complications [121]. Nevertheless, because of the lack of reliable tools and technologies to 
obtain information noninvasively, up to 4 biopsies are still routinely taken in large phase III trials, 
e.g. in patients suffering from non-alcoholic steatohepatitis (NASH) [239]. 
In tumors, biopsy-based diagnosis is particularly complicated, because of intrinsic 
heterogeneity in the primary tumor, as well as heterogeneity between the primary tumor and 
metastases [240]. In such situations, also the accessibility of the pathological site(s) and the risk 
of spreading/seeding cancer cells play an important role [241]. In light of these limitations, liquid 
biopsies are increasingly emerging in the field of cancer diagnosis as a refined and non-invasive 
alternative (and/or as an add-on) to needle-based biopsies [242]. A liquid biopsy, in the form of a 
blood sample, can provide information on the genetic profile of cancerous lesions (and the 
heterogeneity therein) by means of analyzing circulating tumor cells or circulating cell-free tumor 
DNA [243, 244]. 
Because of their high applicability, reproducibility and widespread availability, liquid-
based biopsies not only hold great promise for cancer diagnosis, but also for the assessment of 
classical fibrotic diseases. For the assessment of liver fibrosis, for instance, several serum 
biomarkers are available that are composite scores of not strictly liver-specific parameters as well 
as some that have been associated with fibrosis stage, but both types have been mainly proposed 
for patients with chronic hepatitis C [245]. The most commonly used tests include the FibroTest® 
(which combines alpha-2 macrolobulin, haptoglobin, apolipoprotein, bilirubin, gamma glutamyl 
transferase, age and gender into an algorithm), the aspartate-to-platelet ratio index (APRI) and the 
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Enhanced Liver Fibrosis score (ELF; which includes amino-terminal propeptide of procollagen 
type III (PIIINP), TIMP metallopeptidase inhibitor 1 and hyaluronic acid) [246, 247]. 
Shortcomings of liquid-based biomarkers are that they may not be organ-specific (enough), 
that they may be limited to the indication of impaired organ function or inflammatory state, and in 
particular that they may not specifically reflect fibrosis or discriminate between different stages of 
fibrosis [248, 249]. The abovementioned new biomarkers may help to provide more fibrosis-
specific information, since they mostly assess molecules of the ECM. These novel markers now 
require validation in large cohorts of patients and in long-term studies [249]. In the future, such 
liquid biopsy techniques may be used in combination with other modalities, such as imaging, to 
improve the accuracy of fibrosis diagnosis and staging. 
5.1.2 Non-invasive imaging of fibrosis 
In the last decade, non-invasive imaging techniques have received a lot of attention for the 
assessment of fibrosis. Such set-ups and strategies typically include anatomical, functional and/or 
molecular imaging approaches that allow for the examination of the affected organ (or even the 
whole body) in a readily repeatable manner. In the case of fibrosis, this makes non-invasive 
imaging not only attractive for initial diagnosis, but also for staging and progression monitoring. 
Several imaging protocols have been evaluated for this purpose over the years, ranging from the 
basic assessment of anatomical/morphological changes, via the quantification of differences in 
functional properties, to the identification of molecular adaptations and disease-specific changes. 
Importantly, non-invasive imaging can also be employed for treatment monitoring, thereby 
potentially facilitating the clinical translation of novel anti-fibrotic therapies. In the following 
sections, using selected examples from the literature, we will provide an overview of the 
noninvasive imaging techniques that are commonly used in the context of fibrosis, and we will 
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discuss their (pre-) clinical application in systemic autoimmune diseases, in parenchymal organs, 
such as liver, kidney, lung and heart, and in desmoplastic tumors [249]. 
5.1.3 Liver fibrosis  
The global burden of liver disease is already enormous [250-252] and an exponential 
increase is predicted for the next couple of decades [253]. A recent meta-analysis showed that 
fibrosis (in a stage-dependent manner) closely correlates with liver-related mortality, as well as 
with overall mortality [254, 255]. Consequently, the degree of liver fibrosis is of great importance 
for proper diagnosis, prognosis assessment and therapeutic intervention in chronic liver disease. 
Up to now, the histologically determined stage of fibrosis is the strongest independent risk factor 
for predicting liver-associated complications and the need for liver transplantation, as well as for 
liver-related and overall mortality [256]. Non-invasive assessment of liver fibrosis has thus far 
only been established for chronic hepatitis B and C virus infections, via the combination of two 
concordant tests, i.e. serum biomarkers plus transient elastography [245]. To distinguish between 
benign fatty liver disease and progressive non-alcoholic steatohepatitis, invasive biopsies are still 
required [257]. This biopsy procedure comes with multiple drawbacks, including the associated 
risks, sampling errors and intra and inter-observer variability. The latter is especially obvious, 
when semi-quantitative scoring systems are applied, which include grading (steatosis, ballooning, 
portal inflammation) and staging (fibrosis) [245, 247, 257]. 
In terms of anatomical imaging, standard gray-scale US is routinely used in the clinic for 
the assessment of liver disease. It provides baseline information on liver morphology and texture 
[247]. As an example, Choong and colleagues used gray-scale US to show that the liver surface 
progressed from being smooth to extremely nodular as the severity of the disease increased. The 
authors also reported coarsened echotexture and blunting of liver edges in patients with liver 
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fibrosis. However, this type of anatomical US imaging is limited to the detection of advanced stage 
fibrosis and does not provide sufficient accuracy for ruling out early-stage liver fibrosis [258]. 
Besides US, non-contrast enhanced CT has also been shown to be able to depict liver surface 
nodularity, and it does so with high accuracy and high intra- and inter-observer independency 
(upon assistance of an automated computer algorithm). So far, this technique has only been tested 
retrospectively for the differentiation of cirrhotic from non-cirrhotic livers, and further evaluations 
are needed to assess its reproducibility, as well as its (prospective) performance in intermediate-
stage liver fibrosis [259]. 
Functional imaging of liver fibrosis has encompassed a variety of elastography modalities, 
which assess liver stiffness and which have had a massive impact on the non-invasive diagnosis 
of liver fibrosis. These elastography methods include transient elastography (TE), acoustic 
radiation force impulse imaging (ARFI), shear wave elastography (SWE) and MR elastography 
(MRE) [260]. FibroScan® was the first TE device which was approved for the rapid and user 
friendly quantification of fibrosis at the bedside [261]. The FibroScan® system consists of an US 
transducer combined with a vibrator that enables the direct relation of shear wave propagation to 
tissue stiffness [262, 263]. Initial inaccuracies and even application failures of TE devices in obese 
patients were partially overcome with an adapted XL probe that allows for deeper tissue 
penetration [264]. As opposed to TE, both ARFI and SWE use focused US pulses to estimate shear 
wave velocities in the liver which are related to tissue stiffness. ARFI is based on the elasticity 
information from the axis of the pushing beam that creates a 2D stiffness map, whereas SWE 
depends on the shear waves propagating sideways from the axis of the US beam [265, 266]. In 
liver SWE scans, fibrotic liver tissue is characterized by a higher stiffness as compared to healthy 
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liver tissue [267]. The elastic modulus of the depicted fibrotic liver is - with an average of 28 kPa 
- almost 5 times higher than the one measured in a healthy liver. 
In comparison to the above-mentioned US elastography techniques, in which transient 
elastography in obese patients is compromised, MRE has been shown to have superior diagnostic 
performance not only for the detection of advanced fibrosis, but also for differentiating the 
individual progression states from simple steatosis to steatohepatitis [248, 268, 269]. In a recent 
prospective trial, MRE was found to be more accurate in identifying liver fibrosis (stage 1 or 
higher) than TE in patients with non-alcoholic fatty liver disease [270]. In this context, Chen and 
co-workers investigated the precision of MRE for discriminating patients with simple steatosis, 
steatohepatitis and hepatic fibrosis. A clear difference in hepatic stiffness manifested in all three 
conditions, and the highest stiffness was observed in patients with hepatic fibrosis followed by 
steatohepatitis and simple steatosis [271]. These results indicate that the use of MRE allows for 
separating patients with simple steatosis from the ones with steatohepatitis, which would allow for 
earlier and more specific therapeutic interventions. The MRE procedure can be incorporated into 
a routine liver MRI protocol with only a few minutes added to the total scan time [272, 273]. The 
postprocessing procedure is simple, but the hardware and software additions to the MRI are 
expensive and might impede clinical translation and implementation [274]. Recently, the 
feasibility of a cost-effective and portable photoacoustic imaging system (PAI) and US dual 
modality imaging setup has been evaluated in a preclinical CCl4- induced murine fibrosis model 
and it turned out to be an interesting addition to the currently available elastography techniques 
[214]. This alternative set-up relies on hemoglobin as a chromophore that absorbs light and the 
combination with US for proper selection of the liver region to be evaluated [275]. The PAI signal 
is increased in fibrotic livers due to the more heterogeneous tissue structure caused by ECM 
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deposition and angiogenesis. Analogously, PAI - in the form of a multispectral optoacoustic 
tomography set-up (MSOT) - has recently also gained interest for application in several other 
fibrosis-related diseases, including Crohn's disease [276, 277]. 
 Moreover, a number of tools and technologies have been proposed for molecular imaging 
of liver fibrosis. These include MRI and nuclear imaging techniques that are used in combination 
with targeted contrast agents. The liver-specific contrast agent gadolinium ethoxybenzyl 
dimeglumine (Gd-EOB-DTPA), also known as Primovist® in Europe or Eovist® in the USA, is a 
MRI contrast agent that was originally developed for the detection of liver metastasis and 
hepatocellular carcinoma (HCC) [278, 279]. After intravenous injection Gd-EOB-DTPA 
progressively distributes into the hepatocytes via the organic anion transporter polypeptides 
OATP1B1 and OATP1B3 and excretes into the bile ducts via the multi drug resistance protein 2 
(MRP2) [280]. The uptake and excretion of Gd-EOB-DTPA by the hepatocytes is also impaired 
in liver fibrosis, which enables the detection of severe fibrosis and cirrhosis in patients [281]. 
Molecular MRI has also shown promise in case of imaging of ECM components, such as 
elastin and collagen. Evidence for the use of ECM-targeted MR contrast media has been obtained 
in several liver fibrosis animal models. Elastin has been used as a target for molecular MRI, a 
significantly higher contrast enhancement in the perivascular regions in CCl4- treated fibrotic mice 
was observed as compared to healthy mice upon the administration of the Gd-containing elastin 
specific contrast agent, ESMA [282]. Similarly, Farrar and colleagues demonstrated that the Gd-
containing collagen I-specific contrast agent EP-3533 not only allowed for staging of liver fibrosis 
via 3D molecular MRI, but also enabled accurate therapy monitoring in mouse and rat models 
[110, 283]. 
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Besides MRI, also radionuclide-based imaging techniques such as SPECT and PET have 
been used for molecular imaging of liver fibrosis in preclinical setups. In case of SPECT, Li and 
colleagues reported on the use of 99mTc-labeled cyclic RGD penta-peptide for imaging hepatic 
stellate cells (HSC) in fibrotic rats [284]. The RGD peptide is known to have a high binding affinity 
to αvβ3 integrins, which are upregulated in hepatic fibrosis [285, 286]. Specifically, it was shown 
that the expression levels of αvβ3 integrins on HSC correlate with fibrosis stage, and that non-
invasive SPECT-based staging of liver fibrosis is possible with 99mTc-labeled cRGD [284]. In 
line with this, PET in combination with CT has been used for the imaging of translocator protein 
(TSPO) expression in progressive liver fibrosis. The TSPO is a convenient biomarker since it is 
mainly expressed by macrophages and HSC. The accumulation of the TSPO specific radiotracer 
18F-FEDAC correlated well with the severity of liver damage in rats exposed to CCl4 [287]. In 
order to facilitate clinical translation, further studies are needed to optimize molecular imaging 
probes and protocols which are specific for HSC [288] and other fibroblast-like cells, which e.g. 
express the platelet-derived growth factor receptor-β [289].  
In summary, significant progress has been made at the clinical level in anatomical and 
functional imaging of liver fibrosis. However, the abovementioned techniques and protocols entail 
multiple disadvantages and they do not really permit accurate fibrosis staging and treatment 
monitoring. At the preclinical level, molecular imaging of liver fibrosis via MRI, PET and SPECT 
has hinted towards more specific detection of changes in biomarker levels that correlate with 
disease progression and/or treatment responses, indicating that such probes and protocols may start 
impacting the diagnosis and treatment of liver fibrosis in the clinic in the near to distant future. 
Collagen type I is an important target for molecular imaging of liver fibrosis  since its 
accumulation is a characteristic of most types of chronic liver diseases (CLD) [290].  In this paper, 
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we report the development of a protein MRI contrast agent for molecular imaging of the collagen 
level (ProCA32.collagen1) extending the targeting capability of our recently reported ProCA32-
P40, a protein MRI contrast agent [83]. ProCA32.collagen1 with high dual relaxivity values for r1 
and r2 per Gd
3+ at both 1.5 and 7.0 T as well as strong collagen targeting capability enables the 
first robust detection of early and late stage of liver fibrosis as well as heterogonous expression of 
collagen by multiple molecular dynamic imaging. The development of collagen-targeted protein 
MRI contrast agent is expected to overcome the major clinical barriers in early diagnosis, 
noninvasive detection and staging of liver fibrosis, and have strong application in facilitating 
effective treatment and stop further progression toward major clinical consequences including 
cirrhosis, impaired liver function, and hepatocellular carcinoma. 
Chronic liver disease (CLD) is a major cause of morbidity and mortality worldwide[110, 
121, 161, 283]. Hepatic fibrosis can develop in patients with any type of chronic liver disease 
(CLD), including alcoholic liver disease (ALD), hepatitis C, hepatitis B, nonalcoholic fatty liver 
disease (NAFLD) and autoimmune hepatitis. The Centers for Disease Control (CDC) estimates 
that 19,388 people died in the US from alcohol related liver disease in 2014 [291]. Chronic liver 
disease originates from a variety of causes such as viral hepatitis, metabolic dysfunction, as well 
as alcohol abuse and autoimmune disease and almost all chronic liver injuries can cause liver 
fibrosis [291, 292].  
Biopsy coupled with histological analysis is the gold standard for diagnosis and staging of 
liver fibrosis as it relies on stage-dependent characteristic patterns of collagen expression. Collagen 
type I is heterogeneously accumulated in liver fibrosis depending on etiology which leads to 
fibrosis that disrupts liver cytoarchitecture and function [293]. Sequential histological grading of 
inflammation and staging of fibrosis based on collagen 1 are used to decide the risk of disease 
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progression. However, biopsy has many limitations such as sampling errors, high inter-observer 
variability with 33-50% error rate even for diagnosis of advanced stages of liver fibrosis such as 
cirrhosis likely due to heterogeneity [283]. Tremendous effort have been devoted into development 
of noninvasive imaging techniques based on stiffness associated with fibrosis such as ultrasound 
apparent diffusion coefficient (ADC), magnetic resonance elastography (MRE), T1, T2, relaxation 
in the rotating frame (T1ƿ) [294], magnetization transfer [295], and proton density fat fraction 
(PDFF). However, these techniques cannot provide accurate detection of early stage liver fibrosis 
and visualization of heterogeneity.  
A prerequisite for early detection and efficient treatment of liver fibrosis is a reliable non-
invasive diagnostic method to accurately stage fibrosis progression and response to therapy. MRI 
offers several unique advantages compared to other clinical imaging modalities with its deep tissue 
penetration, high spatial resolution, and coverage of the entire liver. Since MRI does not require 
the use of ionizing radiation, it is well suited for screening and monitoring the progression and 
regression of fibrosis [296, 297]. However, an early stage of patient liver fibrosis with regional 
heterogeneity cannot be ambiguously detected by MRI due to limitations of currently available 
MRI contrast agents. 
To differentiate “invisible” fibrotic cells from heterogeneous tissue background without 
clear boundary requires novel MRI contrast agents and imaging methodology to have a strong 
specificity for both organ and diseased cells as well as much improved relaxation properties. Iron 
oxide-based contrast agents such as ferumoxides create negative (dark) T2 /T2* effects that are 
reported to yield images with signal voids with very limited accuracy[278, 298]. Like all other 
approved Gd3+ MRI contrast agents,  Gd-BOPTA (Multihance) and Gd-EOB-DTPA (Eovist US; 
Primovist, Europe) have Gd3+ r1 relaxivity strong enough to lead to a positive (bright) imaging. 
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[299]. These two clinical agents have liver distribution and able to detect late stage fibrosis in vivo 
with r1 increase using T1-weighted sequence at a short arterial phase and a short hepatobiliary 
uptake phase [300, 301].  In addition, severity or the stage of fibrosis assessment is also necessary 
when making decision in diseases diagnosis, prognosis of chronic liver diseases and even while 
screening for various forms of HCC. Recent developments of collagen targeted contrast agent 
using approved DTPA (Magnivest) have shown to be able to image liver fibrosis with improved 
sensitivity and specificity but largely depending on the animal models[121], however, safety 
concerns about Magnevist underscore the pressing need of a safe MRI contrast agent with strong 
capability in detecting early stage fibrosis and delineating liver heterogeneity [302].  
We reasoned that precision dual imaging capability (r1 and r2) of stage-dependent 
characteristic expression patterns of collagen type I will lead us to differentiate “invisible” fibrotic 
cells from heterogeneous tissue background without clear boundary in early stage and extracellular 
matrix heterogeneity associated with late liver fibrosis depending on etiology, liver 
cytoarchitecture and function [293]. In this chapter, we report the development of a protein MRI 
contrast agent (ProCA) for molecular imaging of the collagen level (ProCA32.collagen1) in two 
models of liver fibrosis extending the targeting capability of our recently reported ProCA32-P40 
[83] (Fig. 5.2). ProCA32.collagen1 with high dual relaxivity values for r1 and r2 per Gd
3+ at both 
1.5 and 7.0 T as well as strong collagen targeting capability enables the first robust detection of 
early and late stage liver fibrosis as well as heterogonous expression of collagen by multiple 
dynamic molecular imaging properties. In addition, ProCA32.collagen1 is able to demonstrate 
vascular and architectural alterations during late stage fibrosis which has not been achieved before. 
The development of collagen-targeted protein MRI contrast agent is expected to overcome the 
major clinical barriers in early diagnosis, noninvasive detection and staging of liver fibrosis, and 
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have strong application in facilitating effective treatment and stop further progression toward 
major clinical consequences including cirrhosis, impaired liver function, and hepatocellular 
carcinoma. 
 
Figure 5.2 Development of ProCA32.collagen1 for molecular imaging of liver fibrosis.  
ProCA32.collagen1 was developed by linking collagen type I targeting moiety at its C-terminal to 
be applied in early detection of liver fibrosis as well as late stage liver cirrhosis. 
 Results 
5.2.1 Robust detection of early and late stages liver fibrosis with dual contrast property 
We tested whether molecular MR imaging with ProCA32.collagen1 is able to 
unambiguously and quantitatively detect early stage and late stage of liver fibrosis in vivo taken 
advantage of high r1 and r2 values (Fig. 5.3). Early and late stages of liver fibrosis of BALB/c mice 
were induced by injection of thioacetamide (TAA) and fed with 10% alcohol in drinking water 
either for 6 weeks or 12 weeks, respectively (Fig. 5.4). Fig. 5.3 shows R1 map inversion recovery 
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MRI images collected before and 24 hrs after intravenous (I.V.) injection of contrast agents (100 
µL, 5 mM) of ProCA32.collagen1, ProCA32-P40 (non-targeted), and Eovist. After 24 hours post 
injection, ProCA32.collagen1 demonstrates a dramatic increase in R1 to 2.4 (∆R1~ 0.78 s-1, about 
50% increase in liver area) in early stage fibrotic liver in mouse. Such change is increased with R1 
enhancement to ~ 2.85 s-1 (78 % increase) and ∆R1 to approximately 1.40 s-1 compared to pre-
injection for late stage fibrotic liver in mice. The R1 increase at 24-hour post injection is highly 
specific since it gradually decreased 48 hrs post injection due to excretion (Fig. 5.5). In contrast, 
this targeting agent does not result in a significant change for the mouse with normal liver (< 0.2 
s-1 and 10% increase in liver area) at 24-hour time point (Fig. 5.3).  In addition, ProCA32-P40 
without collagen binding capability does not result in any significant enhancement at this time 
point. On the other hand, clinical approved liver contrast agent, Eovist for the fibrotic liver, at the 
same stage (1A-Mild) and Ishak=3 did not result in any increase in R1 or ∆R1, 24 hrs after 
injection.  Consistent with R1 map, T2 map results also exhibit the same pattern at 24 hours for 
both early and late stages of fibrosis with higher changes for late stage than early stage of 
TAA/alcohol model (Fig. 5.6). Further quantitative analysis of R1 map and T2 map can be 
observed in Fig, 5.7.  
Taken together, these results demonstrate that the dual contrast property of 
ProCA32.collagen1 enables the first robust detection of early stage Ishak=3 mouse liver fibrosis 
with unprecedented sensitivity and quantification of both early and late stage liver fibrosis with 
significant enhancement in both ∆R1 and ∆R2 that correlate well with the severity of fibrosis (Fig. 
5.9).  
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Figure 5.3 Early and late stage liver fibrosis detection using ProCA32.collagen1. 
Demonstrates the R1 map of fibrotic (Ishak=3), normal (Ishak=0) and cirrhotic liver (Ishak=5) 
before and 24 hrs after injection of ProCA32.collagen1, ProCA32-P40 and Eovist. ΔR1 values of 
fibrotic (Ishak=3, and 5) and normal (Ishak=0) liver 24 hours after injection of 
ProCA32.collagen1, ProCA32-P40, and Eovist shows the targeting capability of 
ProCA32.collagen1 in differentiating different stages of liver fibrosis as the late stage shows the 
highest ΔR1 compared to early stage and normal liver. 
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Figure 5.4 TAA/alcohol-induced liver fibrosis animal model procedure 
 
 
Figure 5.5 R1 changes of liver over different MRI time points after injection of 
ProCA32.collagen1, ProCA32-P40 and Eovist. It shows the dynamic enhancement by 
ProCA32.collagen1 based on stage of fibrosis and its targeting capability. 
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Figure 5.6 T2 map MRI images of normal and fibrotic livers. 
T2 map MRI results are consistent with R1 map showing a significant decrease in T2 value 
(increase in R2) of late stage fibrotic liver (Ishak=5) after 24 hours post injection of 
ProCA32.collagen1, in addition, early stage fibrotic liver (Ishak=3) also shows decrease in T2 
which is more than normal liver but decrease is not as high as late stage. ΔR2 values shows that 
24 hrs is the time which demonstrates the significant difference between normal liver (Ishak=0), 
late (Ishak=5) and early stage (Ishak=3) fibrotic liver. 
5.2.2 Histological validation of early and late stage fibrosis and correlation with MRI 
Detailed histological analysis including H&E, alpha smooth muscle actin (SMA) levels 
(brown) and Sirius Red staining for collagen content (red) as well as quantitative analysis of CPA 
confirmed stage 3 in Ishak scoring system and late stage (Ishak=5). (Fig. 5.8).  
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Figure 5.7 Quantitative analysis of T1 and T2 map. 
 (A) Increase rates of liver (R1) values (%) for R1 map in TAA/alcohol induced mouse liver fibrosis 
compared to control showing different degree of increase based on contrast agent and time point. 
(B) T2 map values of normal and fibrotic livers with quantitative analysis. T2 map MRI results 
are consistent with R1 map showing a significant decrease in T2 value (increase in R2) of late 
stage fibrotic liver (Ishak=5) after 24 hours post injection of ProCA32.collagen1, in addition, 
early stage fibrotic liver (Ishak=3) also shows decrease in T2 which is more than normal liver but 
decrease is not as high as late stage. 
Furthermore, collagen proportional area (CPA) for TAA/alcohol and DEN model by 
pathologist confirmed early stage liver fibrosis (Mild-1A, zone 3, perisinusoidal) based on the 
NASH/CRN scoring. ProCA32.collagen1 distribution in normal and fibrotic liver is well-
correlated with the stage of the disease. The late stage of liver cirrhosis. SMA levels (brown) are 
much higher in later stage of liver fibrosis and CPA is 16% for Ishak= 5 (Fig. 5.8). 
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Figure 5.8 Histology validation of different stages of TAA/alcohol-induced liver fibrosis. 
Sirius red, H&E and αSMA staining of early and late stage fibrotic liver compared to normal liver 
confirms the stage of liver fibrosis, as more collagen and αSMA content and dead hepatocytes are 
the indications of the disease stage. 
 
 
144 
 
Figure 5.9 Correlation of MRI with histology analysis in detection of different stages of 
liver fibrosis.  
(A, B) Demonstrate the ability of ProCA32.collagen1 to distinguish early and late stages 
of liver fibrosis with ΔR1 and ΔR2 and its correlation with collagen proportionate area (CPA). 
(C) Collagen proportionate area analysis using ImageScope and its correlation with Ishak scoring 
system shows the stage of both early (Ishak=3) and severe fibrosis (Ishak=5) in TAA/alcohol 
induced mouse model. (D) Demonstrates a correlation between Gd3+ concentration in liver with 
A B 
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Ishak score. As the fibrosis becomes more severe, more Gd3+ as an indication of more 
ProCA32.collagen1 is in the fibrotic liver (* P < 0.05, student’s t-test).  
As Fig. 5.9 demonstrates, ProCA32.collagen1 is capable of distinguishing early stage 
fibrosis (Ishak=3) from normal liver (Ishak=0) and late stage fibrosis (Ishak=5) based on both R1 
and R2 mapping. With both ∆R1 and ∆R2 increasing based on the stage of the fibrosis, 
ProCA32.collagen1 can detect different stages with more confidence. Moreover, there is a strong 
correlation between Gd3+ concentration in liver with Ishak score. As the fibrosis becomes more 
severe, more Gd3+ as an indication of more ProCA32.collagen1 is in the fibrotic liver. 
5.2.3 Biodistribution and pharmacokinetics of ProCA32.collagen1 
Biodistribution analysis of ProCA32.collagen1 (Fig. 5.10) further supports the MRI results 
showing the targeting capability of the contrast agents. Severe fibrotic liver (Ishak=5) showed the 
highest concentration of Gd3+ and after that fibrotic liver (Ishak=3) supporting that the contrast 
agent targets based on collagen levels. Moreover, other organs did not show significant levels of 
contrast agent, all of them had less than %2 injection dosage per gram of tissue (Fig. 5.10). 
Detailed pharmacokinetic characteristic of ProCA32.collagen1 revealed that clearance of 
ProCA32.collagen1 was low and 0.36 mL/min/kg (less than 1% of liver blood flow of 90 
mL/min/kg) but more than 3 times higher than ProCA32-P40 and showed very high exposure (> 
100000 ng.h/mL blood). ProCA32.collagen1 has the terminal elimination half-life of 9.9 h that 
was slightly higher than ProCA32-P40 (8.09 h) with mean residence time of 14.51 h that was 
higher than 13.9 h of ProCA32-P40. In addition, volume of distribution (Vc) and volume of 
distribution at steady state (Vdss) were 1.53 and 1.77 L/kg, respectively, which were more than 2-
7 times higher than ProCA32-P40.  Taken together, these results demonstrate that the dual contrast 
property of ProCA32.collagen1 enables the first robust detection of early stage Ishak=3 mouse 
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liver fibrosis with unprecedented sensitivity and quantification of both early and late stage liver 
fibrosis with significant enhancement in both ∆R1 and ∆R2 that correlate well with the severity of 
fibrosis.  
 
A B 
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Figure 5.10 Biodistribution analysis of contrast agents using ICP-OES.  
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(A, B) Shows percent injection dosage and [Gd3+] of contrast agents, in different diseased livers. 
Sever fibrotic liver (Ishak=5) shows the highest Gd3+ concentration and injection dosage/g of 
tissue among other livers. (C) Shows percent injection dosage of ProCA32.collagen1 based on 
[Gd3+], in other organs. ProCA32.collagen1 does not have a brain deposit possible due to lack of 
penetration to blood barrier.  
5.2.4 Detection of vascular and architectural alterations with dynamic molecular imaging  
Here we report the first dynamic molecular imaging (DMI) as a function of time of collagen 
for both early and late stages of fibrosis to reveal intrahepatic angiogenesis (Fig. 5.11). The 
dynamic molecular imaging curve of collagen as a function of time for both early and late stage of 
fibrosis are very different at 3 and 24 hours (Fig. 5.5) despite the similarity for pre-injection and 
later time points 48-72 hrs due to excretion and washout of ProCA32.collagen1 at 48-hour post 
injection which both R1 and R2 enhancement for both early stage and late largely reduced to their 
initial values. Strikingly, at early blood pool phase 3-hour post injection of ProCA32.collagen1, 
R1 of cirrhotic liver increased dramatically to > 3.5 s-1 with ∆R1 > 2.0 s-1 (Fig. 5.11). Furthermore, 
the R1 increase rate of fibrotic liver was more than 120 % suggesting vascular distortion (Fig. 5.7 
A, 5.12, 5.13). Detailed histogram analysis of R1 map MRI images further shows in late stage 
fibrosis, different areas of the liver have heterogeneous enhancement reflecting these vessel 
changes at both 3 and 24 hrs post injection of ProCA32.collagen1 (Fig. 5.14). Normal liver has a 
symmetric Gaussian distribution of relaxivity plot consistent with sinusoid arrangement in the 
normal liver.  On the other hand, several bi-mode or multiple-mode distributions of relaxivity also 
consistent with the addition of intrahepatic angiogenesis with enlarged extracellular space (Fig. 
5.14). Consistently, the early stage liver fibrosis exhibits a small addition of R1. Significantly 
increased vessel formation stained by CD31 with quantitative analysis have also been observed 
148 
for late stage fibrosis supporting the first visualization of large vessel structure changes due to 
formation of severe fibrosis (Fig. 5.12, and 5.13).  We further show (Fig. 5.12) the existence of the 
portal hypertension associated with severe fibrosis in mouse liver (Ishak=5) reflecting the targeting 
ability of ProCA32.collagen1 with slow washout from the liver. Thus, we have achieved the first 
characterization of dynamic molecular contrast profiles to distinguish different stages of liver 
fibrosis with differential vessel structures and distortion of the hepatic vasculatures as well as 
collagen expression.   
 
Figure 5.11 Detection of vasculature structural changes during late stage fibrosis with 
ProCA32.collagen1. 
Demonstrates the R1 map of fibrotic (Ishak=3), normal (Ishak=0) and cirrhotic liver 
(Ishak=5) before and 3 hrs after injection of ProCA32.collagen1 and Eovist. ΔR1 values of fibrotic 
(Ishak=3, and 5) and normal (Ishak=0) liver 3 hours after injection of ProCA32.collagen1 and 30 
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min for Eovist shows the capability of ProCA32.collagen1 in detecting and revealing the vascular 
distortion occurring in severe fibrosis as ΔR1 has the highest value compared to early stage and 
normal liver. 
As it is observed from Fig. 5.12, normal liver sinusoidal endothelial cells (SEC) have 
fenestrae and express SE-1 marker but not CD31, however, in late stage of fibrosis, SEC upon 
activation lose fenestrae and these defenstrated SECs do not express SE-1 and they express CD31 
(Fig. 5.13). Defenestration of SECs lead to portal hypertension since the blood entering to the liver 
cannot go to central vein as the blood flow out of the liver is significantly lowered. In late stage 
fibrosis, intrahepatic angiogenesis occurs which does not increase blood flow, but blood has to 
flow through more capillaries to reach same central vein which still does not increase portal flow 
but creates more resistance, therefore after 3 hrs post injection, ProCA32.collagen1 is revealing 
sinusoidal remodeling, and portal-vein blood flow resistance which has not been reported by any 
MRI contrast agent before.   
 
Figure 5.12 Representative SEM images and ultrasound of sections from mice with normal 
and severe fibrotic liver (Figure provided by Ravi Chakra). 
Representative SEM images of sections from mice with late stage cirrhotic liver (Ishak=5). 
Quantitation of number and size of fenestrations of liver sinusoids in mice with late stage cirrhotic 
liver (Ishak=5) measured by manually counting/measuring number and the diameters of 
fenestration in the SEM images confirm vasculature structural changes detected by 
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ProCA32.collagen1. Fenestration size is average diameters (in micro Meter) of fenestrate from 
the SEM image analyses. Velocity of portal vein blood flow is measured by Doppler ultrasound 
imaging shows high portal hypertension detected at 3 hrs after injection of ProCA32.collagen1. 
The flow velocity is presented as mm per second. 
In Fig. 5.13, it is shown that CD31 is highly expressed in late stage fibrosis which is a 
confirmation for intrahepatic angiogenesis.  
 
 
IHC stains of liver tissue in mice with late stage cirrhotic liver (Ishak=5) confirming intrahepatic 
angiogenesis. The quantity of CD31 IHC is presented fold changes in CD31 stains compared to 
that of non-fibrotic mice (normal) (Figure provided by Ravi Chakra). 
 As Fig. 5.14 demonstrates, histogram analysis performed by MATLAB is showing 
different patterns of enhancement in normal liver and early and late stage fibrotic livers based in 
different time points (3 hrs, and 24 hrs) post injection of ProCA32.collagen1.  Furthermore, it 
shows heterogenous distribution of voxels across livers demonstrating a wide range of R1 values.  
 
 
 
Figure 5.13 Representative images of IHC stains of CD31 and quantitation of CD31. 
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Figure 5.14 R1 map histograms analysis of mouse livers. 
R1 map histograms analysis of early stage (Ishak=3), late stage fibrosis and normal liver 
(Ishak=0) pre (blue) and 3 hrs (red) and 24 hrs (green) post injection of ProCA32.collagen1 in 
TAA/alcohol-induced fibrosis mouse model demonstrates the dynamic ability of 
ProCA32.collagen1 in revealing both heterogeneity and vascular distortion of severe liver fibrosis 
5.2.5 Quantitative mapping of liver fibrosis heterogeneity 
Liver fibrosis heterogeneity can be regarded as one of the major limitations of liver biopsy 
and other imaging modalities since it has differential special distribution and also dependent on 
animal models and causes [303-306].  We then address liver fibrosis heterogeneity induced by 
both TAA and DEN byProCA32.collagen1 enabled molecular imaging (Fig. 5.15). This DEN-
induced late stage cirrhosis mouse model exhibits strong liver heterogeneity mimicking patient 
cirrhosis [307, 308]. Fig. 5.16 show that right segment of the mouse liver has CPA of 12% (Sirius 
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red staining) while left segment has CPA of 6.7%.   Consistent with TAA/alcohol model, both T1-
, T2-weighted and T1 inversion recovery images have enhancement of cirrhotic liver 3 and 24 
hours post injection of ProCA32.collagen1 with the maximum enhancement at 3 hours post 
injection specifically at the right segment of the liver confirming the histology data (Fig. 5.17). 
Histogram analysis of the MRI images show different heterogeneous distribution of voxels in MRI 
based on different pulse sequences (Fig. 5.18). In addition, R1 map data demonstrate further 
heterogeneity in the liver (Fig. 5.19.)  
 
Figure 5.15 Mapping liver cirrhosis heterogeneity with ProCA32.collagen1. 
T1, T2-weighted and T1 inversion recovery images of DEN-induced cirrhotic mouse liver before 
and 3 and 24 hrs post injection of ProCA32.collagen1 demonstrating heterogeneity of liver in the 
right segment. 
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Figure 5.16 Sirius red staining and collagen proportionate area analysis. 
Sirius red staining and collagen proportionate area analysis confirm that the right segment is 
more cirrhotic than the left region which correlates with MRI. 
 Contrast to noise ratio (CNR) analysis of different pulse sequences demonstrate the right 
segment enhancement compared to left segment which is in agreement with histology and CPA 
analysis. Moreover, as shown in Fig. 5.18, histogram analysis also confirms the heterogenous 
distribution of voxels in the liver correlating with MRI data.  
 R1 map analysis of DEN-induced liver cirrhosis also demonstrates heterogeneity of liver 
as shown in Fig. 5.19. In addition, histogram analysis performed for R1 map further confirms the 
data.  
 
Figure 5.17 Quantitative analysis of contrast to noise ratio of liver. 
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T1, T2-weighted and T1-inversion recovery images all demonstrate a higher contrast to noise ratio 
(CNR) of right segment of cirrhotic liver after 3 hours of ProCA32.collagen1 injection compared 
to left segment. 
 
Figure 5.18 Histogram analysis of DEN-induced cirrhotic liver. 
Histogram analysis of DEN-induced cirrhotic liver pre (blue), 3 hrs (red) and 24 hrs (green) post 
injection of ProCA32.collagen1. 
Taken together, further analysis of DEN-induced cirrhotic liver shows that 
ProCA32.collagen1 is capable of a time-dependent heterogenous enhancement of liver with 
specific areas of liver highlights at 3 hrs and 24 hrs and specific areas that remained enhanced or 
washed out at different time points. Similarly, detailed analysis of R1 map MRI images of 
TAA/alcohol model in late stage fibrosis, different areas of the liver have heterogeneous 
enhancement reflecting vessel changes at both 3 and 24 hrs post injection of ProCA32.collagen1. 
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(A) R1 map results showing heterogeneity in DEN-induced liver cirrhosis 3 and 24 hours post 
injection of ProCA32.collagen1. (B) Quantitative analysis of R1 values showing a significant 
increase in 3 hours post injection as well as showing heterogeneity.  (C) Histogram analysis of 
DEN-induced cirrhotic liver pre (blue), 3 hrs (red) and 24 hrs (green) post injection of 
ProCA32.collagen1 (* P < 0.05, student’s t-test).   
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Figure 5.19 R1 map analysis of DEN-induced liver cirrhosis. 
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Figure 5.20 Combination of STIR with long TE methodology with a T1-T2 MRI contrast 
agent. 
(A) T1 inversion recovery at different inversion times showing different heterogeneity of cirrhotic 
liver. (B) Schematic demonstration of STIR with long TE methodology with ProCA32.collagen1. 
ProCA32.collagen1 has high accumulation in the liver. As a result, liver has shortened T1, first, 
inversion time was used to suppress liver signal. Second, since liver also has short T2, we then use 
long TE to further suppress the liver signal. (C) Contrast to noise ratio (CNR) of cirrhotic liver 
before, 3 and 23 hours after injection of ProCA32.collagen1 at different inversion times (*P < 
0.05, student’s t-test).  
Figure 5.20 shows one of the advantages of combining T1 inversion recovery with a dual 
mode contrast agent like ProCA32.collagen1. We applied this pulse sequence which is STIR (short 
tau inversion recovery) with long TE and combined it with ProCA32.collagen1 and studied its 
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effects in contrast to noise ratio in DEN-induced mouse model of cirrhotic liver. It is observed that 
ProCA32.collagen1 combined with this imaging methodology can enhance different regions of 
cirrhotic liver at different time points (3 hrs and 24 hrs) by changing inversion times (TI) which 
can suppress the liver signal.  
5.2.6 Immunofluorescence staining of fibrotic liver 
In order to further confirm the targeting capability of ProCA32.collagen1, the contrast 
agent was co-stained with collagen type I in fibrotic liver.  For this purpose, frozen sections of 
liver tissues were collected. Then the tissues on slides were fixed with either ethanol or methanol 
in -20°C for 20 minutes to remove OCT which is a gel-like medium for embedding the tissues.   
After the tissues were dried, the blocking buffer is added for 2 hours at room temperature. 
Then the slides are washed with 1×TBST for once, and the primary antibody is added (Collagen 
type I) with 1:50 or 1:200 dilution and left for incubation in 4°C overnight. The slides are washed 
again with 1×TBST for three times, each time for 5 min. The second primary antibody is then 
added (ProCA32.collagen1) with 1:50 dilution for 2 hours at room temperature.  
In the next step, the slides are washed again three times, and secondary antibody is added 
for both of the primary antibodies (anti goat) and left for 1 hour at room temperature. Then DAPI 
is added to the slides and they are covered with glass and left at 4°C until they are dried.  
As Fig. 5.21 demonstrates, left picture shows fibrotic liver which was injected with 
ProCA32.collagen1. It is observed that ProCA32.collagen1 (red) is targeting collagen type I 
(green) in the liver, however, on the right picture, the fibrotic liver injected with ProCA32-P40 is 
shown. In this picture, there is no sign of the contrast agent which confirms its lack of targeting 
collagen type I.  
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Figure 5.21 Immunofluorescence staining of ProCA32.collagen1 and collagen type I in 
fibrotic liver tissues. Fibrotic liver injected with ProCA32.collagen1 clearly demonstrates that 
ProCA32.collagen1 (red) can target collagen type I (green) in liver, however, ProCA32-P40 does 
not show any targeting capability as it cannot be detected by Immunofluorescence staining in 
fibrotic liver.  
5.2.7 Treatment monitoring of liver fibrosis with ProCA32.collagen1 
Since liver fibrosis can be treated and reversed if detected early and several drugs are under 
development for treatment of liver fibrosis, and clinical contrast agents cannot follow up and 
monitor treatments, it is extremely crucial to design MRI contrast agents capable of treatment 
monitoring.  
Therefore, ProCA32.collagen1 was tested for treatment monitoring of late stage liver 
cirrhosis using ProAgio drug.  ProAgio is a protein-based drug derived from domain 1 of CD2 
protein developed by our collaborator Dr. Zhi-Ren Liu, and it has shown promising results for 
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reversal of late stage cirrhosis. We injected ProCA32.collagen1 to mice treated with ProAgio and 
mice with normal liver to assess the capability of the contrast agent in distinguishing drug treated 
liver from normal liver (Fig. 5.22).  
 
Figure 5.22 Liver cirrhosis treatment monitoring using ProCA32.collagen1. 
(A) ProAgio structure with M26C mutation for treatment of liver cirrhosis. (B) ProAgio can 
reverse liver cirrhosis as observed by decrease in liver weight. (C) R1 map MRI results before and 
3 and 24 hrs post injection of ProCA32.collagen1 is able to show the difference between ProAgio 
treated liver and normal liver at 3 hrs time point. (D) Quantitative analysis of ΔR1 at 3 and 24 hrs 
after injection of ProCA32.collagen1 is showing that normal liver has significant increase at 3-
hour time point, however ProAgio treated liver does not show any enhancement.  
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As Fig. 5.22 C and D are showing, at 3-hour time point, ProCA32.collagen1 is able to show 
the different between ProAgio treated liver and normal liver. At 3 hours post injection, 
ProCA32.collagen1 is causing a dramatic increase in ΔR1 values, however, drug treated liver does 
not show any increase suggesting that the contrast agent is being washed our rapidly from the liver. 
The normal liver R1 value increased to more than %25 at 3 hours but ProAgio treated liver 
increased only %2.   
5.2.8 Dynamic multi-color mapping of liver cirrhosis heterogeneity with ProCA32.collagen1 
Since we observed a dynamic property in ProCA32.colllagen1 in enhancement of DEN-
induced mouse liver cirrhosis, a multi-color heterogenous cirrhotic mouse liver was created in 
order to better reflect the liver enhancement at different time points (3 hrs and 24 hrs). For this 
purpose, MATLAB was used to create a multi-color map with voxel by voxel quantitative analysis. 
Since ProCA32.collagen1 has both r1 and r2 property and we scanned multiple pulse sequences, 
and this approach was used in both T2-weighted and T1 inversion recovery sequences. Two 
general color maps were generated for T2-weighted pulse sequence. First, a color map was created 
to summarize and demonstrate the voxels that enhanced 3 hrs and 24 hrs post injection of 
ProCA32.collagen1 and then a percentage of relative enhancement was calculated using this 
equation: Intensity (post) – Intensity (pre) / Intensity (pre). Figure 5.23 shows the T2-weighted 
color map 3 and 24 hrs post injection enhancement of ProCA32.collagen1.  Then a separate color 
map was generated to show the regions that stayed enhanced after 24 hrs and the areas that washed 
out after 24 hrs (Fig.5.24). In figure 5.24, the color bar shows the percentage of areas that 
maintained up to %200 and the regions that washed out completely within 24 hrs.  
The same procedure was performed for T1 inversion recovery and T1-weighted pulse 
sequences. 
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Figure 5.23 T2-weighted Multi-color map of 3 and 24 hrs enhancement in DEN-induced 
cirrhotic mouse liver.  
The color map demonstrates the dynamic enhancement of cirrhotic regions 3 (blue) and 24 (red) 
hrs post injection of ProCA32.collagen1. Right segment of liver is enhanced more at 3 hrs and left 
segment was enhanced more at 24 hrs. The bar on the right shows the percentage of relative 
enhancement.   
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Figure 5.24 T2-weighted Multi-color map of maintained vs washed out within 24 hrs of 
contrast agent injection in DEN-induced cirrhotic mouse liver. 
The color map demonstrates the dynamic enhancement of cirrhotic regions within 24 hrs, and the 
areas that the contrast agent remained in the liver are shown in a red color and the areas that the 
contrast agent is washed from the liver are shown in more blue color. The bar on the right shows 
the percentage of relative enhancement.   
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Figure 5.25 Quantitative analysis of T2-weighted cirrhotic liver enhancement post 
injection of ProCA32.collagen1. 
The bar on the right represents the voxel number which different parentage of increase at different 
time points. For instance, at 3 hrs, approximately, 1600 voxels had enhancement of less than %10.  
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Figure 5.26 T1-weighted Multi-color map and quantitative analysis of maintained vs washed out 
regions within 24 hrs of contrast agent injection in DEN-induced cirrhotic mouse liver. 
This is the summary of T1-weighted images demonstrating dynamic property of 
ProCA32.collagen1. At each time point, different regions of liver are enhanced.  
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Figure 5.27 T1 inversion recovery Multi-color map and quantitative analysis of 3 and 24 
hrs post injection of ProCA32.collagen1. 
The color map demonstrates the dynamic enhancement of cirrhotic regions 3 (blue) and 24 (red) 
hrs post injection of ProCA32.collagen1. In contrast to T2-weighted sequence, areas of 
enhancement at each time point are limited more to right or left segments of liver and are spread 
across the liver.   
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Figure 5.28 T1 inversion recovery Multi-color map of maintained vs washed out within 24 
hrs of contrast agent injection in DEN-induced cirrhotic mouse liver. 
The color map demonstrates the dynamic enhancement of cirrhotic regions within 24 hrs, and the 
areas that the contrast agent remained in the liver are shown in a red color and the areas that the 
contrast agent is washed from the liver are shown in more blue color. The bar on the right shows 
the percentage of relative enhancement.   
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 Discussion 
Liver fibrosis heterogeneity currently cannot be accurately detected by any methods. 
Spatial heterogeneity in fibrosis is one of the major limitations and challenges of liver biopsy and 
elastography-based techniques as they sample a small volume of liver which does not accurately 
reflect the overall extent and stage of fibrosis [306]. Collagen type I is an important target for 
molecular imaging of liver fibrosis since its accumulation is a characteristic of most types of 
chronic liver diseases (CLD) [290].   
5.3.1 Implication for early detection: Our developed contrast agent enabled novel imaging 
methodology for early detection of liver fibrosis.    
Early fibrosis can be reversed if it is detected early [309, 310]. However, current techniques 
including Fibroscan and MRE as well as MRI with clinical contrast agents in the market failed to 
detect fibrosis at early stage despite of rapid progress [311].   To overcome the limitation of small 
chelator-based contrast agents for detection of early stage fibrosis, targeting extracellular matrix 
(ECM) proteins with probes in molecular imaging techniques has attracted great attention for 
detection, monitoring disease progression as well as treatment [312]. Type I collagen is 
immediately secreted into the ECM as soon as the hepatic stellar cells are activated at the very 
early stage.  Its expression level and spatial distribution patterns play important role for the ECM 
remodeling and directly reflect fibrosis progression. Elastin, on the other hand, is more involved 
in the late stage fibrosis and cirrhosis [313]. Collagen targeting molecular magnetic resonance 
imaging demonstrates a unique application of MR technology to view biological processes at the 
cellular and molecular level. [314], [122], [315]. However, recent works reported that collagen 
targeting MRI contrast agents have more sensitive than other MRI techniques including using 
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endogenous relaxation times, diffusion, and magnetization transfer measurements [283], however, 
have limited capability in monitoring early stage of fibrosis in a rat DEN model. 
We have shown that early stage liver fibrosis (stage 3 based on Ishak and CPA analysis) 
can be detected using both R1 map and R2 (24 hours post injection). The detected MRI signals for 
both early and late stages are correlated well to those from histology analysis from CPA and further 
validated by Gd3+ contention detection with ICP-OES.  
Our developed protein-based MRI agent with collagen type I targeting moiety 
ProCA32.collagen 1 can have robust detection of early stage of liver fibrosis with large dynamic 
range with dramatic increased sensitivity. 
We have shown that ProCA32.collagen1 exhibits 5-fold increase in r1 relaxivity that 
clinical approved ones including Magnevist, and liver specific reagents such as MultiHance and 
Evoist. More importantly, ProCA32.collagen1 also has a high r2 value that enables application of 
several imaging methodologies including both T1 and T2 imaging to overcome the subtle changes 
of liver morphology without defined boundary at early stage liver fibrosis. More importantly, the 
precision is doubled. In contrast to the risk to trade off targeting capability and relaxivity reported 
by previously reported studies, here we demonstrate that we can further increase relaxivity 
properties for both r1 and r2 since ProCA32.collagen1 has higher relaxivity compared to ProCA32-
P40.  Previously we have shown that the addition of targeting moiety to ProCA32 does not have a 
reduction of the relaxivity, a problem associated with the addition of targeted capability [316]. 
Here, we attribute the additional contribution of water from outer-sphere to the relaxivity by 
PEGylation at nearby Lys sites to the increase of relaxivity of ProCA32.collagen1 compared to 
ProCA32-P40.  Second, ProCA32.collagen1 also exhibits the highest binding affinity to collagen 
type I (Kd of 1.4 µM) among all other imaging agents available [121] likely due to the proper 
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design of the targeting moiety. This strong binding affinity to collagen type I provides required 
sensitivity to detect early stage of secreted collagen in liver (1–20 nmolg-1) [313].  Third, 
ProCA32.collagen1 has a unique tissue penetration as revealed by its capability in distinguishing 
early and late stage fibrosis at 24-hour time point which correlates well with CPA quantification 
in histology.  
ProCA32.collagen1 has the organ distribution and retention time required by the new 
dynamic molecular imaging capability for temporal and spatial resolution of intrahepatic 
angiogenesis, portal hypertension and liver heterogeneity. The PK/PD studies have shown 
ProCA32.collagen1 has a relatively high volume of distribution and vascular confinement and very 
high exposure (> 100000 ng.h/mL of blood) which is superior than clinical contrast agents like 
Magnevist and even ProCA32-P40 demonstrating its targeting capacity. 
5.3.2 Implication for detection of heterogeneity, intrahepatic angiogenesis and portal 
hypertension 
Liver fibrosis heterogeneity and the process for the formation of liver fibrosis currently 
cannot be accurately detected by any methods. Spatial heterogeneity in fibrosis is one of the major 
limitations and challenges of liver biopsy and elastography-based techniques as the lack of whole 
liver volume coverage cannot accurately reflect the overall extent and stage of fibrosis[306]. 
Collagen type I is heterogeneously accumulated in liver fibrosis depending on etiology which leads 
to fibrosis that disrupts liver cytoarchitecture and function [293].  
Normal liver sinusoidal endothelial cells (SEC) have fenestrae and express SE-1 marker 
but not CD31, however, in late stage of fibrosis, SEC upon activation lose fenestrae and these 
defenestrated SECs do not express SE-1 and they express CD31. Defenestration as can be seen 
from SEM images lead to portal hypertension in late stage fibrosis since the blood entering to the 
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liver cannot go to central vein as the blood flow out of the liver is significantly lowered. In late 
stage fibrosis, vascular remodeling leading to capillarization of the sinusoids with generation of 
intrahepatic shunts creates hepatic angiogenesis which contributes to the progression of the 
disease[317]. Angiogenesis is also a key event in the emergence and recognition of early HCC and 
development of recurrence after potentially curative therapy and for the progression of liver cancer 
[318-320]. Observation of such process has only reported via histological staining and is not 
possible to be detected by any noninvasive methods.  Early studies reported that in most cases MRI 
can detect morphological characteristics of liver cirrhosis including surface nodularity, widening 
of fissures, expansion of the gallbladder fossa, notching and atrophy of the right lobe, and relative 
enlargement of the lateral segments of the left lobe and caudate lobe, in some cases however, 
cirrhotic liver can appear completely normal with confirmation of the diagnosis requiring biopsy 
[307, 308].  
Here we report that ProCA32.collagen1 is also able to detect intrahepatic angiogenesis, 
portal hypertension and map heterogeneity via DMI.  Dynamic contrast enhancement (DCE) is 
largely applied to report the cellular and tissue changes of various diseases and the responses upon 
drug treatment [321-323].  However, dynamic molecular contrast imaging was not achieved due 
to several major limitations of reported contrast agents. In addition to lack of targeted contrast 
agents with required sensitivity, DMI also requires targeted contrast agents to have adequate 
penetration and retention time to liver tissue to report the formation of new vascular structures.  
Detailed histological and PK/PD analysis revealed that ProCA32.collegen1 exhibits required 
targeting capability, sensitivity as well as the penetration capability.  Thus, vascular changes 
results from shunting of the portal and arterial blood supply directly into the hepatic outflow 
(central veins), compromising exchange between hepatic sinusoids and the adjacent liver 
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parenchyma causing fibrous portal-tract expansion, central-vein fibrosis and capillarization of the 
sinusoids [324] have been unambiguously detected by dual contrast property of 
ProCA32.collagen1. We further provided dynamic map of regions of cirrhotic liver with three 
distinguished vascular features.  ProCA32.collagen1 reveals sinusoidal remodeling, and portal-
vein blood flow resistance that has not been reported by any MRI contrast agent before.  We show 
that DEN- and TAA/alcohol-induced models exhibit differential map. Such information is 
essential for understanding molecular mechanism for fibrosis formation and treatment. It will also 
be very helpful for image-guided biopsy. Detection of angiogenesis as a promising therapeutic 
target by MRI contrast agents may be a useful noninvasive approach in follow-up of both disease 
progression and response to anti angiogenic therapies and even choosing treatment strategies 
[325].  
In this chapter, two different late stage cirrhosis models were used to test the contrast agent. 
First, late stage cirrhosis in TAA/alcohol model was tested to compare the ∆R1 values with early 
stage fibrosis. In late stage liver cirrhosis, the contrast agent shows its maximum effect in shorter 
time point of 3 hrs compared to 24 hrs of early stage.  The increase in ∆R1 is more than 2.0 s-1 and 
the R1 increase rate is more than %100 which shows the huge difference between ∆R1 and R1 
increase rate for early stage fibrosis at both 3 and 24-hour time point. This bigger enhancement 
displays the great capacity of ProCA32.collagen1 in staging different degrees of fibrosis from early 
to moderate to late stage.  After 24 hrs post injection, ∆R1 is decreasing due to fast washout of the 
contrast agent. It is worth mentioning that, ICP-OES analysis shows the highest accumulation of 
Gd3+ in late stage cirrhotic liver. In DEN-induced model, the highest enhancement in the liver was 
observed again at 3-hour time point after injection of the contrast agent. After injection of the 
contrast agent, a clear heterogeneity of cirrhotic liver due to heterogeneous increase in CNR of T1- 
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and T2-weighted and T1 inversion recovery images was observed. This result is significant 
compared to homogenous enhancement of liver in TAA/alcoholic model. Before injection of 
contrast agent, the liver looks homogenous which makes biopsy difficult in stage determination 
and even detection of the disease due to sampling error and small sample collection. Detecting 
liver heterogeneity after the injection ProCA32.collagen1 can facilitate the biopsy process and 
stage determination.  
ProCA32.collagen1 not only detects late stage fibrosis but also reveals vascular changes 
results from shunting of the portal and arterial blood supply directly into the hepatic outflow 
(central veins), compromising exchange between hepatic sinusoids and the adjacent liver 
parenchyma causing fibrous portal-tract expansion, central-vein fibrosis and capillarization of the 
sinusoids [324]. Furthermore, with dual contrast property of ProCA32.collagen1 different regions 
of cirrhotic liver is enhanced which helps the efficiency and facilitation of biopsy. 
5.3.3 Safety: Advantages of ProCA32.collagen1 Compared with Imaging Agents of Liver 
Fibrosis   
Increased evidences have demonstrated that the occurrence of nephrogenic systemic 
fibrosis (NSF) in renal impaired patients is associated with the release and accumulation of Gd3+ 
from the agent because of transmetallation [157, 206]. Recent concerns about Gd3+ depositions in 
animals and patients have led to withdrawn of four Gd3+ contrast agent from Europe by European 
Medicines Agency (EMA) [326].  Due to necessity for liver applications, Eovist and MultiHance 
remain in use. Our developed ProCA32.collagen1 represents a major leap in addressing concerns 
about metal toxicity and Gd3+ deposition associated with current contrast agents in several aspects. 
First, we have demonstrated that ProCA32.collagen1 can mitigate metal toxicity with largely 
reduced dose and strong resistance against transmetallation (104-1012-fold higher metal selectivity 
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for Gd3+ over Ca2+ and Zn2+) compared to existing contrast agents. In addition, we have not 
observed any brain depositions possibly due to its incapability in blood-brain barrier (BBB) 
penetration. Further, ProCA32.collagen 1 has strong liver preference and is able to specifically 
target molecular biomarkers, a property that lacks in all approved Gd3+ contrast agents. More 
important, ProCA32.collagen1 with high r1 and r2 relaxivity has very low injection dosage of 
0.0013 mmol.kg-1 projected in humans which is 20-200-fold lower than clinical contrast agents. 
Indeed, detailed clinical chemistry and tissue analysis demonstrate that no acute tissue toxicity 
have been observed.   
Our developed ProCA32.collagen1 represents a major leap in addressing concerns about 
metal toxicity and Gd3+ deposition associated with current contrast agents in several aspects. 
Administration of contrast agents helps with visualization of fibrosis at MRI. Specifically, majority 
of clinical Gd3+-based MRI contrast agents cause T1 shortening and signal enhancement on T1 
map images, however most of these agents have been linked to the occurrence of nephrogenic 
systemic fibrosis (NSF) in renal impaired patients due to release and accumulation of Gd3+ from 
the agent because of transmetallation [157, 206] . Furthermore, they are all based on small-
molecule chelates and have very low relaxivity (both r1 and r2) and sensitivity without targeting 
capability, therefore, they are only able to detect moderate and advanced stage of fibrosis, cirrhosis. 
The clinical contrast agents also use a high clinical injection dosage due to their low sensitivity 
with a short imaging window without the capability of enhancing the entire liver such as Eovist. 
ProCA32.collagen1 with high r1 and r2 relaxivity has very low injection dosage of 0.0013 mmol.kg
-
1 projected in humans which is 20-200-fold lower than clinical contrast agents. In addition, its high 
selectivity towards Gd3+ makes it a safer agent.   
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 Potential Application and Significance 
ProCA32.collagen1 with collagen type I targeting moiety was successfully developed and 
used in detection of liver fibrosis. Based on our results, the contrast agent is able to detect and 
distinguish different stages of the disease from early stage 3 (Ishak system) to late stage 5 liver 
fibrosis with high sensitivity. This sensitivity can be well demonstrated by increase in ∆R1 of 
fibrotic liver 3 and 24 hours after injection of ProCA32.collagen1 using R1 map MRI. 
Furthermore, this increase in ∆R1 is approximately 5-fold higher than Eovist, a clinical contrast 
agent. The early and late stage of fibrosis was further confirmed with histology analysis. 
Furthermore, ProCA32.collagen1 is capable of detecting cirrhosis heterogeneity in DEN-induced 
model which can significantly help other procedures such as biopsy for more accurate sample 
collection. To the best of our knowledge, this study describes the first early detection of liver 
fibrosis in the literature. This is a significant achievement since early fibrosis can be reversed if it 
is detected early, however, clinical contrast agents in the market have failed to detect fibrosis at 
early stage. Targeting capability of the contrast agent was further confirmed with ICP-OES and 
immunofluorescence staining as well as ELISA studies. The development of collagen targeting 
contrast agent is expected to have broad applications in detection and staging of fibrosis in chronic 
diseases and liver metastasis from various types of cancer and probing heterogeneous 
microenvironment changes upon disease progression and treatment. Furthermore, less injection 
dosage can be used to avoid toxicity as our results demonstrate. ProCA32.collagen1 combined 
with MRI can be used as a quantification and promising method for diagnosing stage specific 
chronic liver diseases. More results based on DEN-induced cirrhosis and HCC will be 
demonstrated in Chapter 7. Please visit Chapter 9 for results regarding nonalcoholic steatohepatitis 
detection.  
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 Summary 
Early diagnosis and noninvasive detection of liver fibrosis and its heterogeneity remain as 
major unmet medical needs for stopping further progression toward severe clinical consequences. 
We have developed a collagen type I targeting protein-based contrast agent (ProCA32.collagen1) 
(Kd of 1.4 M).  ProCA32.collagen1 possesses high relaxivities (r1 and r2 are 68 and 100 mM
-1⋅s-
1 at 1.4 T and 42.6 ± 1.0 and 217 ± 2.4 mM-1s-1 at 7T) per particle with a T1-T2 dual mode action. 
ProCA32.collagen1 enables the first robust detection of early (Ishak=3) and late stage of liver 
fibrosis and mapping liver fibrosis heterogeneity in animal models by its dynamic molecular 
imaging property by revealing vascular distortion during the late stage cirrhosis with largely 
reduced dose and strong resistance against transmetallation (104-1012-fold higher metal selectivity 
for Gd3+ over Ca2+ and Zn2+) compared to existing contrast agents.  
Based on our results, ProCA32.collagen1 with collagen type I targeting moiety can detect 
early stage 3 (Ishak system) with high sensitivity with dual mode r1 and r2 property and high 
collagen affinity which has not been achieved before. This sensitivity can be well demonstrated 
by increase in ∆R1 and ∆R2 of fibrotic liver 24 hours post injection of ProCA32.collagen1. 
Furthermore, during late stage fibrosis, ProCA32.collagen1 is capable of detecting heterogeneity, 
portal hypertension and intrahepatic angiogenesis in different animal models 3 hours post injection 
which can significantly help biopsy and treatment strategies for more accurate theranostics. It has 
no toxicity as demonstrated by clinical chemistry tests, tissue staining and injection dosage. To the 
best of our knowledge, this study describes the first early detection of liver fibrosis with high 
sensitivity as well as sinusoidal remodeling and portal hypertension during the late stage of the 
disease by any MRI contrast agent. The development of collagen-targeted protein MRI contrast 
agent is expected to overcome the major clinical barriers in early diagnosis, noninvasive detection 
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and staging of liver fibrosis, and have strong application in facilitating effective treatment and stop 
further progression toward major clinical consequences including cirrhosis, impaired liver 
function, and hepatocellular carcinoma. 
Furthermore, ProCA32.collagen1 is capable of detecting cirrhosis heterogeneity in DEN-
induced model which can significantly help other procedures such as biopsy for more accurate 
sample collection. To the best of our knowledge, this study describes the first early detection of 
liver fibrosis in the literature. This is a significant achievement since early fibrosis can be reversed 
if it is detected early, however, clinical contrast agents in the market have failed to detect fibrosis 
at early stage. Targeting capability of the contrast agent was further confirmed with ICP-OES and 
immunofluorescence staining as well as ELISA studies. The development of collagen targeting 
contrast agent is expected to have broad applications in detection and staging of fibrosis in chronic 
diseases and liver metastasis from various types of cancer and probing heterogeneous 
microenvironment changes upon disease progression and treatment. 
The development of collagen-targeted protein MRI contrast agent is expected to overcome 
the major clinical barriers in early diagnosis, noninvasive detection and staging of liver fibrosis, 
and have strong application in facilitating effective treatment and stop further progression toward 
major clinical consequences including cirrhosis, impaired liver function, and hepatocellular 
carcinoma. 
6 APPLICATION OF PROCA32.COLLAGEN1 IN IMAGING OF UVEAL 
MELANOMA LIVER METASTASIS 
 Introduction  
Liver as a vital organ in human body and determinant of survival from cancer is one of the 
major sites of metastasis such as gastrointestinal and extragastrointestinal cancers, melanoma, 
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breast, pancreatic, and renal cancer. The liver as the largest organ of the body has unique 
architecture for its diverse functions such as protein biosynthesis and detoxification of portal 
blood[327, 328]. Uveal melanoma as the most common intraocular malignancy typically 
metastasizes through blood and occurs in adults with an age-adjusted average of 5.1 per million 
[329]. Uveal melanoma accounts for 3.7% of all reported melanoma cases in the United 
States[330]. Approximately half of the patients with a primary uveal tumor will have 
metastasis[331]. Typically there is 40% chance of uveal melanoma to metastasize to the liver 
however, in hepatic metastasis cases, this chance is more than 90-95% in patients [329, 332]. 
Although the reported 5-year relative survival rate from diagnosis of a primary uveal melanoma is 
approximately 80% [329], the prognosis for patients with uveal melanoma liver metastases is poor, 
with a median survival of less than 6 months [333, 334]. Currently, the life expectancy of patients 
with metastatic UM is only 4-6 months since there are no highly effective treatments for these 
metastasis[332, 335]. 
Previous studies have shown that there are three stages of uveal melanoma metastasis to 
liver: In stage I: 50-μm-diameter micrometastasis occurs within the sinusoidal space; stage II: 
51- to 500-μm-diameter metastasis forms expanded collections of cells within the sinusoidal space; 
and stage III: 500-μm-diameter collections of cells will generate two distinctive patterns. These 
two patterns in stage III are called the “nodular” or “portal” and “infiltrative” or “lobular” patterns. 
The infiltrative pattern is an expansion of stage I to III intrasinusoidal growth, which has penetrated 
the portal lobule and is surrounded by fibrous septae (Fig. 6.1). In contrast, the nodular pattern 
appeared to efface, rather than infiltrate, the surrounding liver; it has been reported that the nodular 
pattern originates from the perivascular area of the portal triad with distinct clusters of tumor cells 
located around the portal venules [336]. 
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In the infiltrative pattern, tumor cells are supplied by blood vessels in the sinusoidal or 
pseudosinusoidal spaces, and angiogenesis is minimal [332], however, in the nodular pattern, the 
tumors are adjacent to portal venules and demonstrate angiogenesis as the metastatic focus grows 
with new tumor blood vessels formed and extend from branches of the hepatic arteriole [337]. 
It is vital to distinguish different UM tumor growth pattern characteristics in the liver in 
terms of diagnosis and therapy since their recognition in the liver has important clinical 
implications [334, 336]. In histological point of view, nodular and infiltrative pattern show 
differences in the host immune response. In infiltrative pattern, there are natural killer cells but in 
the nodular form cytotoxic T lymphocytes are the major cells [332].  
In previous studies, infiltrative and nodular patterns of metastatic UM have been 
distinguished by hepatic angiography and it was concluded that it can be used to predict response 
to hepatic arterial chemoembolization [338]. In addition, it has been reported that 
radioembolization can be effective in treating nodular liver metastases, but not infiltrative 
sinusoidal metastases[334]. In that particular study, nodular tumors in liver decreased in size with 
radioembolization without the infiltrative tumors responding to treatment[334].  Furthermore, it 
has been shown that patients with angiographically determined nodular tumor appearances 
survived longer than patients with infiltrative lesions (overall survival, 621 vs. 114 days) [339], 
therefore, distinguishing these patterns on any imaging modality is an important consideration 
when determining the treatment plan for patients with metastatic UM [339]. 
Current clinical imaging techniques have significant limitations in the early detection, 
diagnosis and differentiation of UM micrometastasis to liver as well as their different growth 
patterns. Magnetic resonance imaging (MRI) is a powerful technique for high-resolution 
visualization of the anatomic structure and function of soft tissues, including tumors without the 
179 
use ionizing radiation [340-342]. MRI offers several unique advantages compared to other clinical 
imaging modalities with its deep tissue penetration, high spatial resolution, and coverage of the 
entire liver. Since MRI does not require the use of ionizing radiation, it is well suited for screening 
and monitoring the progression and regression of different diseases [296, 297]. Existing methods 
such as apparent diffusion coefficient (ADC), magnetic resonance elastography (MRE), T1, T2, 
relaxation in the rotating frame (T1ƿ) [294], magnetization transfer [295], and proton density fat 
fraction (PDFF) cannot provide accurate detection of liver lesions, their patterns and heterogeneity.  
More than 35% of MRI scans require contrast agents [341]. Differentiation of 
micrometastasis from heterogeneous tissue background without clear boundary requires even more 
sensitive contrast agents and imaging methodology to have specificity for diseased cells as well as 
improved relaxation properties. Iron oxide-based contrast agents such as ferumoxides create 
negative (dark) T2 /T2* effects that are reported to yield images with signal voids and very limited 
accuracy[278, 298]. Two Gd3+-based contrast agents approved for liver imaging, Gd-BOPTA 
(Multihance) and Gd-EOB-DTPA (Eovist US; Primovist, Europe) have positive (bright) imaging. 
Along with all other approved Gd3+ MRI contrast  agents, they have per Gd3+ relaxivity (r1) values 
~5 mM-1.s-1 which is ~20-fold lower than a theoretical value [299]. Such low relaxivity limits their 
sensitivity for detecting small liver lesions. In addition, these agents are extracellular with r1 
increase using T1-weighted sequence at a short arterial phase and a short hepatobiliary uptake 
phase. Furthermore, a high injection dose of 0.025-0.3 mmol/kg is required to generate detectable 
contrast. Such high injection doses contribute to metal toxicity and have resulted in a black box 
warning.  
Small molecular Gd3+ agents that are routinely used for clinical cancer imaging to enhance 
image contrast by shortening the relaxation times of the surrounding water protons [47] are non-
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specific contrast agents and cannot differentiate tumor growth patterns or provide efficient 
detectable contrast in small tumors and micrometastasis. As a result, biomarker-specific molecular 
imaging reflecting tumor microenvironment can be an effective and sensitive approach towards 
the early detection and differential diagnosis of UM liver micrometastasis [343].  
Tumor microenvironment plays a vital role in tumor progression and metastasis [344, 345]. 
Extracellular matrix (ECM) is a major part of the microenvironment and collagen type I is the 
most abundant component [155]. Furthermore, Collagen as the major part of tumor 
microenvironment can affect its regulation of ECM remodeled by collagen degradation and re-
deposition, as well as promotion of tumor infiltration, angiogenesis, invasion and migration[155].  
Collagen has been extensively used as both imaging and therapeutic agents such as delivery 
systems for many kinds of bioactive proteins and drugs and engineered collagen hydrogels for the 
sustained release of biomolecules and imaging agents in various collagen-related diseases [346, 
347]. 
Since there are significant differences in the formation of collagen in these two distinctive patterns 
of UM micrometastasis [332] and differentiation can affect the choice of treatment regimens in the 
future, in this paper, we report the development of protein MRI contrast agents for molecular 
imaging of the collagen level (ProCA32.collagen1) extending the targeting capability of our 
recently reported ProCA32-P40, a protein MRI contrast agent [83]. ProCA32.collagen1 with high 
dual relaxivity values for r1 and r2 per Gd
3+ at both 1.5 and 7.0 T as well as strong collagen targeting 
capability enables the first robust early detection of stage II UM micrometastasis to the liver. 
Furthermore, for the first time, ProCA32.collagen1 is capable of differentiating nodular vs 
infiltrative pattern at this stage which has been achieved before (Fig. 6.2). The development of 
collagen-targeted protein MRI contrast agents are expected to overcome the major clinical barriers 
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in early diagnosis, noninvasive detection and staging of UM micrometastasis to liver, and have 
strong application in facilitating effective treatment toward major clinical consequences. 
 
Figure 6.1 . Schematic cartoon of metastatic UM to the liver [332].  
Melanoma arises in the choroid of the eye, extravasates into tumor blood vessels, and then travels 
via the systemic circulation as circulating melanoma cells with tumor stem cell–like properties, 
where it enters the liver as single cells. These single cells likely arise from hepatic arterioles and 
seed the sinusoidal space causing the infiltrative pattern of growth, which progresses to stage I 
(0-50 μm) micrometastases, stage II (51-500 μm) intermediate metastases, which are bathed by 
serum in the sinusoidal space, and eventually stage III (500 μm) metastases, which replace the 
hepatic lobule.  
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Figure 6.2 Precision imaging with progressive molecular MRI contrast agent, 
ProCA32.collagen1. 
Schematic illustration of ProCA32.collagen1 capability in early detection and differentiation of 
UM tumor growth patterns micrometastasis in liver. Nodular pattern showing different pattern 
and higher levels of collagen compared to infiltrative.  
 
 Results 
In order to assess the application of ProCA32.collagen1 with collagen type I targeting 
moiety in detection of small lesions of micrometastasis, the contrast agent was used in different 
animal models of uveal melanoma liver metastasis.   
6.2.1 Molecular imaging of implanted mouse Uveal Melanoma in liver  
In order to test our contrast agent capability for in vivo imaging of the tumor, mouse uveal 
melanoma (B16LS9) was implanted in the liver. Then, the PEGylated contrast agent (100 µL, 5 
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mM) has been injected in the mice in the tail vein. Fig. 6.4 A illustrates the tumor in the liver of 
the mice. T1-weighted, T2-weighted and inversion recovery MRI images of the tumor in the liver 
were collected using a 7.0 T MRI instrument. T1-wighted images showed approximately 6-fold 
enhancement in the relative contrast of the tumor 40 hours post injection of ProCA32.collagen1. 
Fig. 6.4 A and B show the T1-weighted images and quantitative analysis of the tumor enhancement 
after injection. T2-wieghted images also showed about 4-fold enhancement in the relative contrast 
of the tumor 40 hours post injection of ProCA32.collagen1 compared to pre-injection. Fig. 6.4 A 
demonstrated the T2-wieghted images. 
An inversion recovery pulse sequence was also used for molecular imaging of the tumor 
in the liver. In this method, both liver and tumor signal were suppressed in order to achieve a high 
contrast between liver and tumor. As can be seen in Fig. 6.4 A and B summarize the results using 
different techniques. In these techniques, tumor images can appear as both bright and dark spots 
depending on the type of signal suppression. Fig. 6.3 demonstrates the procedure in which the liver 
signal is suppressed with the use of inversion recovery pulse sequence combined with 
ProCA32.collagen1. 
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Figure 6.3 Demonstration of STIR with long TE sequence for the double suppression of 
liver signal for tumor imaging. 
After injection of ProCA32.collagen1 for about 3 hours, contrast agent has high accumulation in 
the liver than tumor. As a result, liver has shortened T1, while tumor T1 doesn’t change much. 
This sequence has two steps to suppress liver signal. First, we will use inversion time to suppress 
liver signal. Second, since liver also has short T2 compared with tumor, we further using TE to 
further suppress the liver signal, while tumor signal still can be detected due to long T2. 
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Figure 6.4 MRI images of B16LS9 mouse implanted UM tumor before and after injection 
of ProCA32.collagen1 in liver.  
(A) T1-weighted, T2-weighted, and T1 inversion recovery images (B) Quantitative analysis of 
relative contrast of tumor before and 40 hours after injection of ProCA32.collagen1 demonstrates 
a great enhancement in tumor post injection of the contrast agent in T1-weighted, T2-weighted, 
and T1 inversion recovery with different inversion times. 
 
Figure 6.5 T2 map MRI images of B16LS9 mouse implanted UM tumor.  
(A) T2 map MRI images of B16LS9 mouse implanted UM tumor before and 24 and 40 hours post 
injection of ProCA32.collagen1. (B) T2 map analysis of tumor before and 24 and 40 hours post 
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injection of ProCA32.collagen1 shows the contrast agent is penetrating into the tumor causing a 
noticeable decrease in T2 post 24 hrs. 
 In addition to those three mentioned pulse sequences, T2 maps of liver with implanted 
tumor was also collected before and 24 and 40 hours post injection of ProCA32.collagen1. Fig. 
6.5 A and B demonstrate the results with quantitative analysis of T2 values. As it is observed from 
Fig. 6.5 B, tumor T2 value was significantly decreased from 0.13 s (pre) to 0.08 s (24 hours) post 
injection of ProCA32.collagen1. This result is an indication of targeting capability and tumor 
penetration of ProCA32.collagen1. The T2 value then gradually increased at 40 hours since the 
contrast agent is being washed out. The liver T2 value slightly decreased at 24 hours post injection 
and deceased more at 40 hours post injection but the majority of T2 reduction occurs at tumor site.  
6.2.2 Immunofluorescence and collagen staining  
In order to further confirm the targeting capability of ProCA32.collagen1, the liver frozen 
sections with tumor were stained for collagen and contrast agent with Sirius red and rabbit 
antibody, respectively.  For this purpose, for contrast agent staining, frozen sections of liver tissues 
were collected. Then the tissues on slides were fixed with either ethanol or methanol in -20°C for 
20 minutes to remove OCT which is a gel-like medium for embedding the tissues.   
After the tissues were dried, the blocking buffer is added for 2 hours at room temperature. 
Then the slides are washed with 1×TBST for once, and the primary antibody is added 
(ProCA32.collagen1) with 1:50 dilution and left for incubation in 4°C overnight. The slides are 
washed again with 1×TBST for three times, each time for 5 min.  
In the next step, the slides are washed again three times, and secondary antibody is added 
for the primary antibody (anti goat) and left for 1 hour at room temperature. Then DAPI is added 
to the slides and they are covered with glass and left at 4°C until they are dried.  
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As Fig. 6.6 demonstrates, A is showing heart tissue without any collagen present and B is 
liver with tumor exhibiting large packs of collagens in pink color and C is showing the liver with 
implanted tumor. D and E are uveal melanoma tumors in the liver showing two distinctive patterns 
demonstrated by collagen (blue). F is immunofluorescence staining of ProCA32.collagen1 
showing the contrast agent is targeting the liver with tumor.  
 
Figure 6.6 Immunofluorescence and collagen staining 
(A)  Heart as a negative control showing no signs of collagen. (B) Liver tissues with tumor show 
collagen packs in pink color. (C) Image of liver with implanted uveal melanoma tumor. (D, E) 
Liver with two different uveal melanoma tumor growth patterns showing different in collagen 
pattern as well. (F) Immunofluorescence staining of ProCA32.collagen1 in liver with uveal 
melanoma implanted tumor shows the heterogenous distribution of the contrast agent. 
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6.2.3 Molecular imaging of M15 Uveal Melanoma metastasized to the liver   
Human UM M20 orthotopic mouse model metastasized to the liver was generated and 
PEGylated contrast agent (100 µL, 5 mM) was injected in mice in the tail vein. T1-weighted, T2-
weighted and inversion recovery MRI images of the tumor in the liver have been collected using 
a 7.0 T MRI instrument. Fig. 6.7 shows the T1 inversion recovery of mouse liver before and after 
injection of ProCA32.collagen1 at different inversion times. The mouse model is M20 with human 
uveal melanoma tumor metastasized to the liver from the eye. As it can be seen from MRI images, 
tumors are showing up 24 hours after injection of ProCA32.collagen1 based on the inversion time 
used. The same results can be observed in T1- and T2-wieghted MRI images. Inversion recovery 
pulse sequence was also used in this experiment with different inversion times. The best MRI 
image with tumors lighting up in the dark background of the liver can be obtained in the optimized 
inversion time of 0.01s (Fig. 6.7). Inversion time of 0.12 s surprisingly did not show any tumors 
in the liver. Different inversion times at 48-hour time point was also tested to identify the best 
inversion time for better contrast of the tumor. 
Therefore, inversion time of 0.01 s can provide the best enhancement of tumors 24 hours 
post injection of ProCA32.collagen1.  Other contrast agents such as non-targeted agent, ProCA32-
P40 and Eovist were tested later in 0.01 s inversion time to assess the targeting ability of 
ProCA32.collagen1.  
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Figure 6.7 Imaging of UM Tumor with different inversion times. 
Different invasion times of 0.01, 0.12 and 0.23 seconds were tested in inversion recovery pulse 
sequence in order to obtain the best enhancement for tumors. Inversion times of 0.01 s and 0.23 s 
were able to show tumors; however, inversion time of 0.12 s did not show any tumors, therefore, 
0.01 s was used for further analysis.  
 We have used other contrast agents such as ProCA32-P40, and Eovist to test the targeting 
efficiency of ProCA32.collagen1. As Fig. 6.8 demonstrates, Eovist, a liver specific clinical 
contrast agent cannot show any tumors in the liver although histology analysis confirmed the UM 
metastasis to the liver. Moreover, ProCA32-P40 which has also good relaxivity and sensitivity but 
lacks collagen type I targeting capability failed to show any tumors. These results exhibit the 
advantage of having a targeting moiety in ProCA32.collagen1. 
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Figure 6.8 T1 inversion recovery (IT=0.01 s) MRI images of mouse livers with M15 UM 
metastasis model.  
Only ProCA32.collagen1 can show UM micrometastasis 24 hrs post injection confirmed with 
histology. Eovist and ProCA32-P40 cannot show any tumors in the liver after injection despite the 
presence of tumors in histology.   
6.2.4 Correlation of MRI with histology of Uveal Melanoma  
Hematoxylin and eosin stain or hematoxylin and eosin stain (H&E stain or HE stain) is one 
of the principal stains in histology. It is the most widely used stain in medical diagnosis and it is 
often the gold standard. In M20 model, the liver tissues were stained with H&E and tumors were 
correlated with MRI image (inversion recovery at 24-hour time point). As it can be seen in Fig.6.9 
A, total number of six isolated tumors with nodular and infiltrative patterns along the portal vein 
were detected by H&E staining. The same tumors were detected in MRI by injecting 
ProCA32.collagen1 contrast agent considering that tumors with nodular pattern have high levels 
of collagen type I surrounding them. Most importantly, the contrast agent is able to detect the 
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nodular pattern of tumors which has significant clinical implications. The tumors in the MRI can 
be well correlated with H&E staining of liver tissue. Fig 6.9 B shows the good correlation between 
tumor size in histology and tumor size in MRI. Moreover, the limit of detection has been 
significantly lowered with the use of ProCA32.collagen1 as tumor as small as 0.250 mm2 was 
detected. Tumor heterogeneity can also be observed after injection of the contrast agent as shown 
in Fig 6.9 C. Contrast to noise ratio analysis of tumors show the significant enhancement of tumors 
24 hours post injection of ProCA32.collagen1. A 14-fold increase was observed in the CNR (24 
hour) compared to pre (Fig. 6.9 D).  
In addition, the tumors were stained with collagen type I antibody to confirm that collagen 
type I is surrounding the tumors. Collagen type I in Fig.6.10 A can be seen in brown color and can 
be correlated with H&E staining at the same time.  
In Fig. 6.10 A, brown colors can be seen that are surrounding the UM tumor in dark purple. 
In addition, the tumors in the liver were stained with S100 antibody staining to confirm the Uveal 
Melanoma tumor in the liver. The result can be seen in Fig. 6.10 B. Fig. 6.10 C and D are 
demonstrating Sirius red staining for collagen in uveal melanoma tumors. These images are 
showing two different patterns of UM with different collagen levels and patterns (red). It can be 
seen that nodular pattern has more collagen levels compared to infiltrative pattern, furthermore, 
collagens in nodular pattern are present both inside and outside of the tumor, however, in 
infiltrative pattern collagens are surrounding the tumor. 
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Figure 6.9 MRI and histology correlation of UM tumor detected by ProCA32.collagen1. 
(A) H&E staining of 6 tumors with different patterns corresponds with MRI image demonstrating 
the high sensitivity of ProCA32.collagen1 in early detection and distinguishing of UM patterns. 
Tumor numbers 1-4 showing infiltrative pattern and tumor number 5 and 6 are representing the 
nodular pattern. Based on histology, stage II, nodular and infiltrative patterns can be detected by 
the contrast agent using T1 inversion recovery (TI=IT=0.01 s). (B) Histology results showing 
correlation with MRI image. Tumors area in mm2 in MRI is very close to the area of tumors in 
H&E. (C) Contrast to noise ratio (CNR) calculations showing a 14-fold increase in tumor after 
injection of ProCA32.collagen1. 
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Figure 6.10 Histology confirmation of UM tumor and collagen expression. 
(A) UM nodular tumor in liver with collagen type I surrounding it in brown color. (B) S100 
antibody staining confirms the Uveal Melanoma tumor in the liver. (C) Sirius red staining of 
infiltrative pattern UM tumor in liver showing collagen (red) surrounding the tumor. (D) Sirius 
red staining of nodular pattern UM tumor in liver showing collagen (red) surrounding the tumor 
as well as inside the tumor. The collagen pattern is clearly different based on tumor pattern. 
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6.2.5 ICP-OES organ distribution 
The Gd3+ concentration in different organs were measured post injection of contrast agents 
using ICP-OES. Based on the measurements, the Gd3+ concertation in liver with uveal melanoma 
48 hours post injection of ProCA32.collagen1 was approximately 0.08 mol/g. Overall, liver 48 
hours after injection of ProCA32.collagen1 showed the highest Gd3+ concentration among other 
organs including the liver injected with non-targeted contrast agent, ProCA32 (ProCA32-P40), 
which demonstrates the targeting capability of ProCA32.collagen1 towards collagen type I in liver 
with uveal melanoma. The Gd3+ injection dosage per gram of tissue in liver with 
ProCA32.collagen1 was approximately 3-fold higher than ProCA32-P40. Further results in Fig. 
6.11 A and B show that the Gd3+ content is much lower in other organs compared to liver. 
 
Figure 6.11 Gd3+ concentration measurements showing contrast agent distribution in 
different organs 48 hours post injection of ProCA32.collagen1. 
(A) Gd3+ concentration measurements in (µmol/g) in different organs using ICP-OES. (B) 
Injection dosage of contrast agents per gram of tissues in different organs using ICP-OES. 
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 Discussion 
We have developed a protein-based MRI agent with collagen type I targeting moiety 
attached to its C-terminal. In order to meet the requirements for MR imaging of liver metastasis, 
the targeting peptide was added to the C-terminal to avoid any alterations in the protein structure 
and its metal binding affinities which is very different from other approaches. We have 
demonstrated that it is possible to increase relaxivity by addition of a targeting moiety to a protein 
MRI contrast agent without sacrificing relaxation and metal binding properties, such as affinity 
and metal specificity. 
ProCA32.collagen1 as an MRI contrast agent has several advantages over clinical contrast 
agents based on small chelators such as Gd-DTPA in functional and molecular imaging 
applications. First, it greatly increases the CNR and SNR. Second, it improves dose efficiency with 
reduced metal toxicity. Three, it prolongs the tissue retention time, which enables imaging of 
different stages of the disease that requires prolonged tissue enhancement; and fourth, it functions 
as a protein carrier that can conjugate target-specific ligands to collagen 1 for targeted molecular 
MR imaging. Although the diffusion rate of a protein with proper size (3-5 nm) is slower than that 
of small chelators, ProCA32.collagen1 has the capability to diffuse to the target. 
One of the most important characteristic of an MRI contrast agent specifically for liver 
metastasis is its sensitivity. An MRI contrast agent with high relaxivity determines the sensitivity 
and limit of detection of the agent capable of detecting a disease. This is extremely crucial for liver 
metastasis since the early stage of the disease cannot be detected by MRI due to small sizes of 
micrometastasis. In addition, clinical contrast agents do not have the capacity to detect UM tumor 
growth patterns (nodular vs infiltrative) in order to make a difference in treatment strategies. Given 
the fact that collagen type I is an important biomarker in assessing the growth patterns of UM 
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tumors, ProCA32.collagen1 was designed and developed to overcome the major limitations of 
clinical contrast agents. ProCA32.collagen1 with targeting capability is able to not only detect 
small UM micrometastasis in liver at early stage but also has the ability to distinguish nodular and 
infiltrative tumor patterns and therefore, facilitate the treatment of these tumors.   
6.3.1 Advantages of ProCA32.collagen1 Compared with Imaging Agents of Liver Metastasis   
Administration of contrast agents helps with visualization of tumors using MRI. 
Specifically, majority of clinical Gd3+-based MRI contrast agents cause T1 shortening and signal 
enhancement on T1 map images, however most of these agents have been linked to the occurrence 
of nephrogenic systemic fibrosis (NSF) in renal impaired patients due to release and accumulation 
of Gd3+ from the agent because of transmetallation [157, 206] . Furthermore, they are all based on 
small-molecule chelates and have very low relaxivity (both r1 and r2) and sensitivity without 
targeting capability, therefore, they are only able to detect late stages of UM when the tumor sizes 
are in cm. The clinical contrast agents also use a high clinical injection dosage due to their low 
sensitivity with a short imaging window without the capability of enhancing the entire liver such 
as Eovist. 
Several research-based probes and Gd3+-based contrast agents targeting extracellular 
matrix (ECM) proteins have been evaluated in animal models of breast cancer in the past several 
years. Zhou et al has developed penta-peptide conjugated to Gd-DOTA to target fibrin–fibronectin 
complexes in tumor microenvironment[343]_ENREF_49. All of these MRI contrast agents have 
low relaxivity values for both r1 and r2 and rely only on their T1 property. ProCA32.collagen1 with 
high r1 and r2 values allow both T1 and T2 imaging to increase the confidence of MRI scans. 
ProCA32.collagen1 enhances the entire liver for at least 3 h, which substantially widens the MRI 
detection window for high-quality imaging of liver, allowing us to introduce both T1 and T2 
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property of the contrast agent since the small tumor micrometastasis are usually not well visualized 
during the arterial and early venous phases, upon the administration of clinical contrast agents. In 
addition, tumor growth pattern cannot be visualized either. 
6.3.2 Noninvasive Biomarkers of Uveal Melanoma Liver Metastasis 
Uveal melanoma (UM) has high tendency to metastasize to the liver [348, 349]. Although 
the local treatment of the intraocular tumor has progressed, the survival rate of UM patients 
remained unchanged or changed little over the past few decades. Since UM metastatic tumor 
burdens are typically high when detected by changes in liver function tests or even different 
imaging modalities, there is no reliable and effective treatment [350, 351]. In the past, 
oncologists were dependent on the measurement of liver enzymes levels in order to raise 
the suspicion of metastases, however a significant tumor size is sometimes needed to increase liver 
enzymes, therefore, sometimes patients have normal liver enzymes with diffuse hepatic metastases 
[352]. As a result, there is an unmet medical need to develop sensitive biomarkers to detect early 
metastatic UM as well as its growth patterns. 
A broad variety of molecules synthesized or in the blood have been proposed as markers 
of cutaneous melanoma tumor progression [353]. These markers include melanin-related 
metabolites and enzymes (Alpha-MSH, tyrosinase), adhesion molecules (ICAM-1, PECAM-1, 
CD-44) and cytokines (IL-8, IL-10, IL-2R). The currently available diagnostic tests to detect 
cutaneous melanoma- associated molecules include LDH as introduced by the AJCC (American 
Joint Committee on Cancer), S-100β [354], NSE (neuron specific enolase ), LASAP (lipid bound 
sialic acid) and melanoma-inhibitory activity (MIA) [355].  
In cutaneous melanoma, a study demonstrated that serum S-100β can be an independent 
prognostic maker for Stage II of the disease [356, 357]. It was reported that S-100β serum level 
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changes can be of predictive value for a positive response to chemotherapy and immunotherapy 
[357], however, there is not enough information about the clinical value of S-100β in patients with 
UM. In addition, two serum markers reported to correlate with the presence of hepatic metastases 
from uveal melanoma are tumor-associated antigen known as melanoma inhibitory activity (MIA) 
and osteopontin (OPN) [355, 358-360]. 
Collagen type I as a tumor stroma-derived biomarker is important in variety of cancers 
since it reflects the tumor microenvironments changes, therefore, as a direct marker is a perfect 
target for molecular MR imaging compared to other ECM components such as elastin. 
Specifically, in UM, collagen type I is not only present in early stages of the disease and small 
micrometastasis but also an indication of tumor growth pattern difference in the liver which is 
indispensable for treatment choices. Furthermore, collagen targeting molecular magnetic 
resonance imaging demonstrates a unique application of MR technology to view biological 
processes at the cellular and molecular level.  
Development of an MRI contrast agent to target collagen type I can be an ideal way to take 
advantage of combination of an imaging modality with a direct biomarker to detect UM in liver at 
early stage and the growth pattern differences. ProCA32.collagen1 with high binding affinity of 
1.4 M to collagen type I among agents targeting the ECM is an ideal contrast agent since it is 
well within the range of the natural collagen type I concertation in liver (1–20 nmolg-1), in addition, 
this concentration will increase as the tumor develops or changes its pattern. ProCA32.collagen1 
with high relaxivity it very sensitive to these changes for early detection and pattern distinction in 
UM in liver.  
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6.3.3 Nodular vs infiltrative growth pattern distinction using ProCA32.collagen1 
Patients with UM metastasis rarely survive more than a few years after initial detection of 
the metastasis. The median survival time after diagnosis of metastasis in the largest published 
series of unselected patients with metastatic uveal melanoma was 3.6 months [361]. Cumulative 
actuarial survival in this series was 20% at 1 year, 13% at 2 years, 5% at 3 years, 2% at 4 years, 
and less than 1% at 5 years [335]. The liver is usually the first site of metastasis of UM, and is the 
only single organ involved in 60%–80% of UM patients[362]. The median survival of patients 
with liver metastasis is 2–7 months despite aggressive therapy, [363] and the clinical course of 
these patients is highly dependent on disease progression in the liver [364, 365]. 
Recognizing the different growth patterns of metastatic UM in the liver has important 
clinical implications. Histologically, nodular and infiltrative types exhibit differences in the host 
immune response: there are natural killer cells in the infiltrative form, whereas the nodular form 
contains cytotoxic T lymphocytes [332]. There are also discrepancies in the formation of collagen, 
angiogenesis, and other factors that distinguish these 2 histologic growth patterns [366]. The 
choice of treatment regimens in the future may be altered because of these differences. Dayani et 
al distinguished between infiltrative and nodular patterns of metastatic UM on hepatic angiography 
and noted that it can be used to predict response to hepatic arterial chemoembolization. Halenda 
et al[338] also noted that radioembolization was effective in treating nodular liver metastases, but 
not infiltrative sinusoidal metastases[334]. In that particular study, a patient had a mixture of 
nodular and infiltrative liver metastases demonstrated by MRI. The nodular liver metastases 
decreased in size with radioembolization, but the infiltrative metastases did not respond to 
treatment and the patient’s condition ultimately progressed. Sharma et al[339] showed that patients 
with angiographically determined nodular tumor appearances survived longer than patients with 
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infiltrative lesions (overall survival, 621 vs. 114 days)[339]. Differentiating between these patterns 
on scans is an important consideration when determining the treatment plan for patients with 
metastatic UM. It is possible that the nodular pattern on imaging may represent an earlier pattern 
of disease that transforms into the infiltrative pattern as the tumor escapes from the portal triad. 
ProCA32.collagen1 is the only contrast agent developed so far with the capability of differentiating 
UM growth patterns in liver which is significant when choosing treatment strategies for patients 
to prolong the survival. 
6.3.4 Transmetallation of ProCA32.Collagen and Clinical MRI Contrast Agents 
The chemical instability of a Gd3+-based contrast agent can lead to exchanges with other 
metal ions such as zinc, copper, and calcium which can, in turn, have biological consequences. 
These consequences include accumulation of Gd3+ in bones, interference with colorimetric serum 
determination of calcium and hence spurious hypocalcaemia, interaction with scintigraphic 
procedures, increased zincuria, interaction with metal-dependent biological systems such as 
metalloenzymes, etc. Free gadolinium is highly toxic and the ionic radius of Gd3+ (107.8 pm) is 
close to that of Ca2+ (114 pm) and this element is an inorganic blocker of many types of voltage-
gated calcium channels at nano- to micromolar concentrations, therefore, it cab inhibit those 
physiological processes which depend upon Ca2+ influx.  
Generally, there are two structurally distinct categories of gadolinium chelates exist: (a) 
The ‘macrocyclic’ chelates such as Gd-DOTA (Dotarem), where Gd3+ is ‘caged’ in the pre-
organized cavity of the ligand. (b) The ‘linear’ chelates such as Gd-DTPA (Magnevist) or Gd-
DTPA-BMA. The toxicity of gadolinium complexes actually depends on their ability to release 
free Gd3+ ions. Transmetallation: is a type of organometallic reaction that involves the transfer of 
ligands from one metal to another. Several cations such as Fe3+, Cu2+, Zn2+ or Ca2+ compete with 
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the Gd3+ cation and a number of other anions such as PO4
3- , CO3
2- , OH- can compete with the 
ligands for the Gd3+. Generally the stability of contrast agents has the following order: Macrocylic 
ionic  Macrocylic non-ionic  linear di-ionic  linear non-ionic  cyclic-linear-charge.  
In order to further support the kinetic stability and metal selectivity of ProCA32.collagen1 
for Gd3+ over Zn2+ compared to other clinical contrast agents, 55 µM and 110 µM of 
ProCA32.collagen1 was used along with 100 µM Gd3+, 100 µM Zn2+ in 1.2 mM PO43- buffer. For 
clinical contrast agents, 2.5 mM of contrast agents (Omniscan, Eovist, Mganevist and MultiHance) 
with 2.5 mM Zn2+ in 30 mM PO43- was used in buffer.  The relaxation rate (R1) was measured for 
each contrast agent over time.  To normalize the data, R1(t)/R1(0) was calculated. Figure 3f 
demonstrates the relaxation rates change of clinical contrast agents (Eovist, Magnevist, Ominiscan; 
ProHance, MultiHance and Dotarem) and ProCA32.collagen1 (loaded with Gd3+ to at 
approximately 1:1 ratio and 1:2 ratio) in phosphate buffer supplemented with ZnCl2 for different 
length of time. As it can be concluded form Fig. 3f, Omniscan has the highest decrease in relaxation 
rate after 4000 min incubation with zinc (91.2%). ProCA32.Collagen (1:1) along with Dotarem 
and ProHance did now show significant decrease in relaxation rate. 
In addition, 250 µM of contrast agent as the final concentration was used in the human 
serum and incubated at 37C for 13 days. Ponceau S solution and Coomassie brilliant blue were 
used for staining. As it can be seen in Fig. 8c, ProCA32.collagen1 is stable up to 10 days. These 
experiments further support the conclusion that ProCA32.colagen1 has significantly higher kinetic 
stability and metal selectivity for Gd3+ over Zn2+ than those of Omniscan, Eovist, Magnevist and 
MultiHance. In addition, ProCA32.collagen1 has a strong proteolytic stability, as revealed by its 
structural integrity for 10 days of incubation in human serum. These two experiments also showed 
that high concentration of Zn2+ is not able to compete with Gd3+ in ProCA32.collagen1.  
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 Potential Application and Significance  
Based on the results described in this study, ProCA32.collagen1 is capable of detecting 
early stage II UM tumor liver metastasis with high sensitivity which has not been achieved before 
by any clinical or research-based MRI contrast agent. In addition, for the first time, an MRI 
contrast agent is able to differentiate UM tumor growth patterns (nodular and infiltrative) in the 
liver resulting in important clinical consequences in terms of choosing the best treatment for UM. 
Detection of liver metastasis can make significant difference in patient treatment outcome and 
survival. In addition, noninvasive detection of tumor heterogeneity using ProCA32.collagen1 can 
provide important information regarding the population of different cell types (inflammatory or 
tumor cells). 
Since of ProCA32.collagen1 has higher relaxivity values for both r1 and r2 compared to 
other contrast agents, different imaging sequences can be applied to increase the detection 
confidence. Furthermore, less injection dosage can be used to avoid toxicity as our results 
demonstrate.     
 Summary and Conclusion 
The MRI images suggest that the contrast agent has the capability of enhancing the tumor 
signal in much longer times post injection (24 hours) in both T1- and T2-weighted images. In 
addition, inversion recovery technique was successfully applied for the deigned contrast agent 
which led to 6-fold increase in the relative contrast of the mouse implanted tumor compared to 
pre-injection image. Furthermore, MRI images in metastatic model (M20) studies showed the 
heterogeneous distribution of the contrast agent in tumors which further prove the targeting 
capability. Gd3+ biodistribution results strongly correlates with tissue staining studies. Picro-Sirius 
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Red staining results suggest that collagen pattern and level difference based on tumor pattern 
difference and the capacity of ProCA32.collagen1 in distinguishing them. 
Transmetallation data suggest that ProCA32.collagen1 with (1:1) ratio of Gd3+ and protein 
has the highest kinetic stability among other clinical contrast agents. Furthermore, the contrast 
agent is stable in human serum up to 10 days. ProCA32.collagen1 can be considered as a promising 
agent in early detection of uveal melanoma metastatic liver tumor as well as distinguishing pattern 
difference. In addition, based on the literature, collagen has different expression levels depending 
on the type of the tumor, therefore, our contrast agent can be used to distinguish the originality of 
the metastatic tumor.  
Collagen expression and changes are major diagnostic biomarker and therapeutic target for 
many chronic diseases including chronic liver diseases, many types of cancers and metastasis, 
heart failure, and pulmonary fibrosis. Uveal melanoma, the most common primary intraocular 
tumor, has a 40% risk of metastasizing to the liver that results in death in almost all cases. To date, 
there is no reliable noninvasive imaging method for early detection and staging of primary liver 
cancer and hepatic metastases with high sensitivity and specificity. MRI has several unique 
advantages for monitoring slow progression and detection of metastasis with high resolution 
without using radiation. There is a pressing unmet medical need to develop MRI contrast agents 
with desired sensitivity and collagen specificity to overcome high heterogeneous background as 
well as proper in vivo properties and reduced toxicity.   In this study, we report the success in 
designing a protein-based MRI contrast agent, ProCA32.collagen1 with collagen type I targeting 
capability to diagnose and stage the metastasis of uveal melanoma. ProCA32.collagen1 exhibits 
the highest relaxivity values for r1 and r2 per Gd
3+ at both 1.5 and 7.0 T and are 14-20-fold higher 
than clinically used contrast agents. The uniqueness of both high r1 and r2 relaxivity values enable 
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us to achieve both T1 and T2 imaging after a single injection of ProCA32.collagen1. More 
important, we can significantly improve dynamic range in detection with a 6-fold enhancement in 
the relative contrast for the implanted liver uveal melanoma tumor in mouse taken advantage of 
both relaxation property and imaging methodology. In addition, ProCA32.collagen1 is able to 
differentiate M15 uveal melanoma metastasized to the liver with nodular pattern from infiltrative 
with 14-fold increase in contrast to noise ratio (CNR) which has not been achieved using clinical 
contrast agent.  Distinguishing different patterns of uveal melanoma has significant clinical 
implications in terms of choosing the most effective treatment. Based on MRI correlation with 
histology analysis, ProCA32.collagen1 is capable of detecting tumors as small as 0.250 mm2 which 
is much smaller than not only the current detection limit of 10–20 mm but also tumors previously 
detected by ProCA32-P40. We have further shown that the addition of targeting moiety does not 
reduce its strong metal binding affinity to Gd3+ and 1011-fold higher selectivity towards Gd3+ over 
Zn2+ than Eovist. The development of collagen targeting contrast agent is expected to have broad 
applications in detection and staging of liver metastasis from various types of cancer and probing 
heterogeneous microenvironment changes upon disease progression and treatment.  
7 APPLICATION OF PROCA32.COLLAGEN1 IN DETCTION OF 
HEPATOCELLULAR CARCINOMA (HCC) 
 Introduction  
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. 
Worldwide, approximately 500,000 new patients are diagnosed with HCC each year, often 
associated with poor prognosis [367]. It is the fifth most frequent neoplasm and ranks third on the 
list of most lethal cancers [368, 369]. The highest incidence of HCC is found in Asia and sub-
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Saharan Africa. Most cases of HCC develop in a background of chronic liver damage such as 
cirrhosis or hepatitis [370]. 
Cirrhosis from any cause predisposes to hepatocellular carcinoma (HCC) and hence can be 
considered a premalignant condition. Indeed, the majority of patients worldwide with HCC have 
underlying cirrhosis [371]. With the exception of some areas of the world where hepatitis B virus 
(HBV) infection is endemic and the role of other oncogenic agents (ie, aflatoxin) may be important, 
[372] it is uncommon to find HCC in the absence of cirrhosis. On a global basis, longitudinal 
studies indicate that cirrhosis related to either hepatitis C virus (HCV) or hepatitis B virus (HBV) 
infections represent the major known risk factors for HCC [370, 373, 374]. 
7.1.1 HCC in Cirrhosis  
HCC is a common cause of death among patients with compensated cirrhosis. European 
cohort studies have reported that, among persons who died of a liver- related cause, HCC was the 
responsible cause in 54% 6 to 70% [375] of patients with compensated cirrhosis of different 
etiologies and in 50% of patients with HCV-related cirrhosis [376]. Data from one of the 
longitudinal studies, which involved 112 cirrhotic patients with HCC detected during ultrasound 
surveillance, showed that tumor progression was the cause of death of 63% of patients with HCC 
who died during the first 4 years of surveillance (1987–1991), of 69% who died during the second 
4-year period (1992–1996), and of 83% who died during the third period (1997–2001) [374]. 
Recent epidemiologic data indicate that, in the United States as well as in some European 
countries, the mortality rate from HCC is increasing [377-379]. Conversely, cirrhosis-related 
mortality not due to HCC declined into the early 1990s in the same areas, [380-382] although, 
subsequently, remained stable in the United States between 1995 and 1998 [383]. A similar trend 
was noted in Italy, between 1969 and 2000, where the mortality rates of cirrhosis showed a clear 
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decline while the mortality rates for HCC slowly increased. A possible explanation for these 
findings is that medical management of non-HCC complications of cirrhosis, such as prevention 
and treatment of variceal bleeding and management of ascites, has improved, as has the availability 
of alcoholism treatment, leading to longer survival of patients with cirrhosis, who in turn are at 
greater risk over time of developing HCC. A recent report of a decrease in the mortality rate of 
alcohol-related cirrhosis supports this hypothesis [384, 385]. 
7.1.2 Benign versus malignant hepatic nodules in HCC 
According to the currently used nomenclature, there are only two types of hepatocellular 
nodular lesions: regenerative lesions and dysplastic or neoplastic lesions. Regenerative nodules 
include monoacinar regenerative nodules, multiacinar regenerative nodules, cirrhotic nodules, 
segmental or lobar hyperplasia, and focal nodular hyperplasia. Dysplastic or neoplastic nodules 
include hepatocellular adenoma, dysplastic foci, dysplastic nodules, and hepatocellular carcinoma 
(HCC) [386-388].  
Many of these types of hepatic nodules play a role in the de novo and stepwise 
carcinogenesis of HCC, which comprises the following steps: regenerative nodule, low-grade 
dysplastic nodule, high-grade dysplastic nodule, small HCC, and large HCC (Fig. 7.1). 
During the past 2 decades, MR imaging has emerged as an important imaging modality for 
assessing cirrhosis and its complications, such as hepatic nodules [386]. For assessment of hepatic 
nodules, MR imaging is more useful than any other imaging modality currently available [386]. 
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Figure 7.1 Different steps in generation of carcinogenesis for HCC in cirrhosis[387]. 
 
Although arterial enhancement with delayed washout, increased T2-weighted signal 
intensity, delayed capsular enhancement, restricted diffusion, and tumor thrombus are typical 
features, not all lesions demonstrate these findings. The radiologist must be familiar with these 
typical imaging characteristics, and less common appearances and associated findings of HCC, 
and must be able to differentiate them from those of lesions that mimic HCC. Knowledge of 
therapeutic options and how those are related to imaging findings is imperative to assist clinicians 
in managing these patients [386]. 
Accordingly, researchers have aimed to derive target genes and drug candidates for HCC; 
however, the development of targeted drugs has not yet significantly improved outcomes [389, 
390]. Lately, the paradigm in cancer biology  has shifted from the study of the genetics of tumor 
cells alone to the complicated crosstalk between cancer and the tumor microenvironment (TME) 
[391, 392]. The TME is the cellular environment in which the tumor exists, including the 
surrounding blood vessels, immune cells, fibroblasts, other cells, signaling molecules, and the 
extracellular matrix (ECM). Recent studies have shown that the stromal cells in HCC have a 
dynamic and flexible function in tumor proliferation, invasion, and metastasis, and that the cells 
of the TME can regulate the response of cancer cells to chemotherapy [393-395]. Hepatic stellate 
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cells (HSCs) play critical roles in diverse aspects of liver physiology, including liver organo- 
genesis, regeneration, and HCC. HSCs are found in the space of Disse between the sinusoidal 
endothelial cells and hepatic epithelial cells [396]. 
Hallmarks of HSC activation are reduced levels of intracellular lipid drop- lets, increased 
expression of α-smooth muscle actin (α-SMA) and ECM production, as well as morphological 
changes [397, 398]. Additionally, the interaction between HCC and activated HSCs forms a pro-
angiogenic microenvironment by the overexpression of VEGF-α and matrix metallopeptidase 9 
(MMP9) [399-401]. 
ECM-related proteins in the TME play important roles in liver function in health and 
disease. Abnormal ECM composition and structure in solid tumors are the major obstacles for the 
penetration of anticancer drugs.  Among ECM proteins, collagens and specially collagen type I are 
the most abundant structural protein in the liver. A disproportionate concentration of collagen type 
I results in altered cell phenotypes and architectural distortion with abnormal blood flow in the 
liver. Moreover, a high collagen type I content is a key barrier for interstitial drug penetration 
among ECM-related proteins [402] and thereby reduces the efficacy of chemotherapeutics. 
Because HCC is developed from chronically damaged tissue that contains a large amount of 
inflammation and fibrosis, further knowledge of the crosstalk between HCC and their TME is 
essential for achieving a better understanding of tumor development, progression, and 
chemoresistance in HCC [402, 403]. 
 
7.1.3 The challenges in diagnosis of hepatocellular carcinoma 
The aim of early detection plans in patients at risk of hepatocellular carcinoma (HCC) is to 
detect the tumor at an evolutionary phase, when a cure with long-term disease-free survival is 
209 
highly likely [404]. Accordingly, the goal is to detect and diagnose tumors when they are smaller 
than 2 cm in size, the so-called BCLC stage 0. Beyond this cutoff, the prevalence of satellites 
and/or microvascular invasion is significantly increased and treatments such as resection, 
transplant, and ablation will be plagued by recurrence due to dissemination prior to treatment 
[404]. 
While this goal is easy to frame, establishing accurate diagnosis in such small nodules is a 
major clinical challenge. Tumor markers, including alpha-fetoprotein and novel ones such as 
glypican or PIVKA, have no major usefulness for screening and diagnosis [404], and thus, as in 
most other cancer types, diagnosis would require a positive biopsy. Nevertheless, biopsy is known 
to have a suboptimal sensitivity (around 60–70 %) [405]. It provides a limited amount of tissue, 
and the fact that such small HCCs are usually well differentiated makes it difficult to confidently 
distinguish HCC from dysplastic or regenerative nodules. Even expert pathologists would not have 
a 100 % agreement without false positives and false negatives in such small malignant nodules. 
Immunohistochemical staining for glypican 3, heat-shock protein 90, or survivin may reinforce 
HCC suspicion, but they do not increase the diagnostic rate. Diagnostic signatures based on gene 
expression have also been proposed but have not been validated, and such molecular diagnosis is 
not yet in clinical practice. Even if biopsy would have 100 % sensitivity, it would not be feasible 
in some patients because of the location or the presence of clotting disorders. 
All these comments explain the development of imaging criteria for the non-invasive 
diagnosis of HCC [405]. The increased arterial blood supply that characterizes HCC provides the 
basis for the increased contrast uptake in the arterial phase of dynamic techniques, such as 
computed tomography and magnetic resonance. This is a hallmark of malignancy and, if it is 
followed by hypointensity in the venous/delayed phases, the profile is specific for HCC [405]. 
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This hypointense appearance of the hypervascular focal lesions known as ‘‘wash-out’’ is due to 
the venous supply being less prominent in HCC as compared to the surrounding liver, and, thus, 
the arrival of contrast through the portal vein, so that the liver intensity is enhanced as compared 
to the tumor. Several studies have validated such a profile as almost 100 % specific for HCC [406, 
407]. Interestingly, while intrahepatic cholangiocarcinoma may display increased arterial blood 
supply, it does not show washout and this is key for the distinction between these two entities, 
which have a sharply different prognosis and treatment [5, 6]. It is important to note that 
intrahepatic cholangiocarcinoma (ICC) incidence is on the rise and cirrhosis is a major risk for it. 
Thus, differentiation between HCC and ICC is not futile. Nevertheless, as happens with biopsy, 
the diagnostic sensitivity of CT or MR for small HCC (~2 cm) is far from 100 %. Increased arterial 
blood supply appears along tumor growth and, currently, just 60–70 % of HCC\2 cm can be 
confidently diagnosed by imaging techniques [407]. 
7.1.4 Limitations of current clinical contrast agents in HCC diagnosis  
All these limitations explain the need to further improve the diagnostic accuracy of imaging 
techniques in order to set a non-invasive diagnosis avoiding the request for a positive biopsy. The 
use of organ-specific contrast agents such as gadoxetic acid (GA or Eovist) or aims to fulfill this 
goal.  
Eovist is a combined hepatobiliary (HB) and Gadolinium-chelates contrast agent, suitable 
for regular dynamic multiphasic studies, that offers the possibility to obtain both the conventional 
arterial and venous phases, but also a 20-min delayed HB phase. At this delayed time point, the 
hepatocytes have taken up the 50 % of the administered dose [278, 408-410]. Therefore, non-
hepatocyte focal lesions and those with non-functional hepatocytes, such as most HCCs, should 
not accumulate contrast. This results in low signal intensity foci relative to the intensity of the liver 
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parenchyma in the HB phase of Eovist-enhanced MR. While this background would make Eovist-
MRI an optimal technique, there are a number of issues that need active research. 
Several studies suggest a potential diagnostic value [411-415], but no robust prospective 
study has defined its added diagnostic value in the clinical setting. Very early HCC with well-
preserved hepatocyte function may show GA uptake and offer false negative results. In addition, 
as previously mentioned, ICC may also emerge in a cirrhotic liver, and likely this opens a potential 
for false positive diagnosis. Finally, the technicalities for the optimal use of GA for an adequate 
reading of the arterial and venous phases of MRI as done currently with gadolinium chelates are 
not well established. The injection rate of the small amount of contrast injected for GA-MRI may 
limit the proper recognition of the contrast uptake in the arterial phase and, thus, impair the use of 
the already validated criteria based on the recognition of arterial uptake followed by wash-out. 
Even wash-out recognition in such nodules may be impaired, as uptake of GA in the biliary phase 
may overlap with the delayed venous one. Accordingly, the injection of higher volumes or the use 
of different injection rates have been proposed to optimize the information offered by GA-MR. 
Prior studies have evaluated the impact of injection rate and the amount of contrast injected 
with controversial results. Zech et al. [416] compared in an experimental study the influence of 
regular to double doses and different rates of injection (1–2 mL/s) on the enhancement of liver 
vasculature in GA-MR and Gd-DTPA. They found that the arterial enhancement in GA-MR 
injected at 1 mL/s was comparable to Gd-DTPA. Haradome et al. [417] reported in a retrospective 
study on 216 patients that fluoroscopic triggering GA-MR and slow rate injection provide proper 
arterial phase images. Schmid-Tannwald et al.  [418]compared two injection rates (1 and 2 mL/s) 
for GA-MR dynamic studies in 80 patients and reported higher enhancement in the aorta in the 
arterial phase with the lower injection rate. Feuerlein et al. [419] compared the enhancement 
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characteristics of liver parenchyma, portal vein, and the portal vein to liver contrast with two HB 
contrast agents in 70 patients. The authors found that contrast in the arterial and portal venous 
phases was lower when GA was used compared to Gd-BOPTA. 
It is important to note that such studies do not include patients with liver tumors. Such 
information is the focus of the manuscript by Chen et al. [420] published in this issue of 
Hepatology International. The authors describe that, in hypervascular HCCs, the enhancement in 
the arterial and portal phases is lower than that observed when using the conventional non-specific 
gadolinium. The authors found that the relative contrast difference between the liver and HCC was 
significantly less when using GA as compared with a nonspecific gadolinium, but, interestingly, it 
was increased in the portal phase. This resulted in a better definition of the hypointense lesions 
that may be due to the overlap of the delayed venous phase and the early HB uptake of GA by the 
nontumoral liver. 
All these studies suggest that clinical MRI contrast agents have considerable weaknesses 
for the diagnosis and staging of patients with suspected or proven HCC and major clinical research 
is needed to develop more sensitive MRI contrast agents for the proper management of patients 
diagnosed with HCC. In this Chapter, our efforts to apply ProCA32.collagen1 in MR detection of 
HCC tumors in DEN-induced mouse model will be discussed.  
 Results  
7.2.1 DEN-induced HCC 
For these studies first, the HCC animal model was generated. For all of our studies, we 
employed female and male mice with C57BL/6 genetic background. Experiments involving 
animals were conducted in accordance with the NIH Guide for the Care and Use of Laboratory 
Animals and were approved by the Georgia State University IACUC. Animals were housed in a 
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pathogen-free animal facility under a 12 h light/dark cycle and fed a standard rodent chow and 
water ad libitum. In order to induce liver tumor development, 14-day-old mice were treated with 
a single dose of DEN (Sigma–Aldrich # N0756) given dissolved in saline at a dose of 25 mg/kg 
body weight by i.p. injection. Mice in one randomly pre-assigned group were killed 10 months 
after DEN administration for histological and biochemical analyses. Mice were randomly 
distributed in various groups having equal males and females.  
Immediately after euthanizing, livers were removed, weighed and the numbers of visible 
tumors on the liver surface were counted macroscopically. The largest lobes were fixed in formalin 
and embedded in paraffin. Sections were stained with hematoxylin and eosin and examined 
microscopically. 
Two mice with HCC were selected for MRI scan and after scan they were sacrificed, and 
livers were collected and weighted for HCC assessment (Fig. 7.2). As it can be seen from the 
images multiple tumors have developed in the liver which shows the large volume of the liver 
compared to normal liver.  
 
 
Figure 7.2 HCC mouse livers after treatment compared to normal liver. 
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7.2.2 MRI results of DEN-induced HCC mouse 
The mice with HCC tumors were tail-vein injected with ProCA32.collagen1 and T2-
wighted, T1-weighted, T1 map inversion recovery and T2 maps were collected before and 3 and 
24 hrs post injection of ProCA32.collagen1. As Figures 7.3 to 7.6 show, after injection of 
ProCA32.collagen1 at both 3 and 24 hrs, there is enhancement in the tumor areas as well as 
cirrhotic regions.  
 
Figure 7.3 T2-weighted images of HCC mouse post injection of ProCA32.collagen1 
 
215 
 
Figure 7.4 T2-weighted images of HCC mouse post injection of ProCA32.collagen1 in a 
different slice of liver 
 
Figure 7.5 T2-weighted MRI images in slice 12 of HCC mouse liver 
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Figure 7.6 T2-weighted MRI images in slice 13 of HCC mouse liver.  
Areas in orange circle shows the enhancement in tumor and areas in blue circle is showing the 
cirrhotic areas. ProCA32.collagen1 is able to detect both tumors and cirrhotic areas.  
 Figure 7.6 is a clear demonstration of mixture of HCC and cirrhosis in the mouse liver 
observed by ProCA32.collagen1. In 3 hrs post injection of the contrast agent, a significant 
enhancement is observed in the cirrhotic areas (blue circle), and after 24 hours the contrast agent 
is washed out, therefore the enhancement is decreasing. Moreover, ProCA32.collagen1 can 
demonstrate HCC tumor 3 and 24 hrs post injection as shown by orange circle.  
 Further analysis of another HCC mouse (Fig. 7.7) confirms the results and show the same 
phenomenon.  
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Figure 7.7 T2-weighted MRI images of another HCC mouse liver before and 3 and 24 
hrs post injection of ProCA32.collagen1 
 As Fig. 7.7 demonstrates, the left segment of liver is more cirrhotic and right segment has 
possibly two large tumors as defined by their boundaries. After injection of ProCA32.collagen1 at 
3 hrs, a significant enhancement is observed in the two large tumors as well as left segment of liver 
showing cirrhotic region.  
 Fig. 7.8 shows the R2 map analysis after injection of ProCA32.collagen1. As it is observed 
from the figure, T2 map results further confirm the T2-weighted results (Fig. 7.7). After 
quantitative analysis of T2 values, both left and right tumors in the right segment of liver showing 
decrease in T2 and increase in R2 (MRI image). Furthermore, left down segment of liver showing 
increase in R2 and decrease in T2 as indication of cirrhotic regions.  
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Figure 7.8 T2 map analysis of HCC tumors and cirrhotic areas in DEN-induced HCC 
mouse liver. R2 map MRI images showing enhancement in tumors and quantitative analysis of T2 
values showing decrease in both tumors and cirrhotic regions in the liver.  
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Figure 7.9 T2-weighted MRI images of slice 2 of DEN-induced HCC mouse liver before 
and 3 and 24 hrs post injection of ProCA32.collagen1.  
Left segment of liver has significant enhancement 3 hrs post injection of ProCA32.collagen1 (blue 
circle) demonstrating cirrhotic regions and after 24 hours the contrast is washed out. Right 
segment of liver which was significantly enhanced after 3 hours showing HCC tumor (orange 
circle).  
These results are consistent with results from previous HCC mouse (Fig. 7.7) which show 
that results are reproducible with the injection of ProCA32.collagen1. Moreover, R2 map MRI 
results are complimentary to T2-weighted results showing the same pattern for cirrhotic areas and 
tumor regions (Fig. 7.10).  
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Figure 7.10 R2 map MRI images and quantitative T2 analysis of slice 2 of DEN-induced 
HCC mouse liver before and 3 and 24 hrs post injection of ProCA32.collagen1. 
 
Figure 7.11 T2-weighted MRI images of slice 4 of DEN-induced HCC mouse liver before 
and 3 and 24 hrs post injection of ProCA32.collagen1. 
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Since our ProCA32.collagen1 has both r1 and r2 property, we scanned these HCC mice 
with multiple pulse sequence to further increase the confidence level of detection. Therefore, T1-
weighted MRI was also used assess the tumor and cirrhotic regions of HCC mice.  
 
Figure 7.12 T1-weighted MRI images of another HCC mouse liver before and 3 and 24 
hrs post injection of ProCA32.collagen1. 
T1-weighted MRI images showing different regions of liver enhanced consistent with T2-weighted 
images in Fig. 7.7 in the same slice.  
 Figures 7.13 and 7.14 show the significant enhancement of liver and cirrhotic regions 3 
hrs post injection of ProCA32.collagen1 in T1-weighted MRI image. 
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Figure 7.13 T1-weighted MRI images of slice 4 of HCC mouse liver before and 3 and 24 
hrs post injection of ProCA32.collagen1. 
 
Figure 7.14 T1-weighted MRI images of slice 5 of HCC mouse liver before and 3 and 24 
hrs post injection of ProCA32.collagen1. 
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7.2.3 Histology results of DEN-induced HCC mouse liver 
In order to confirm the presence of tumors and collagen in HCC mouse livers, H&E and 
Sirius red staining were performed on paraffin embedded section of mouse liver.  
 
Figure 7.15 Sirius red (left) and H&E (right) staining of mouse HCC liver.  
Left picture showing Sirius red staining of collagen (red) in liver and right picture demonstrating 
H&E. The areas with darker pink show HCC tumors as it is observed from their boundaries.     
 Further analysis is required to completely correlate each specific tumor from histology 
with MRI and it is currently being studied.  
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Figure 7.16 Sirius red (left) and H&E (right) staining of mouse HCC liver. 
 
 
Figure 7.17 Sirius red (left) and H&E (right) staining of mouse HCC liver. 
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 Summary  
In summary, ProCA32.collagen1 was successfully applied in detection of DEN-induced 
HCC mouse model in the liver. ProCA32.collagen1 is able to enhance both cirrhotic and tumor 
areas in the model as confirmed by several pulse sequences. One of the advantages of using 
ProCA32.collagen1 in detection of HCC is that because of both r1 and r2 property, T1- and T2-
weighted and T1 and T2 maps can be used to increase the level confidence for the detection and 
avoid observing artifacts in the MRI. Moreover, based on MRI images, ProCA32.collagen1 is able 
to show heterogeneous enhancement in both cirrhotic and tumors areas which reflect the 
heterogeneous collagen expression in these areas. Distinguishing collagen patterns and 
arrangement in HCC tumor from collagen patterns in cirrhotic areas can be a significant 
achievement in the clinical imaging field. These differences can shed light on how cirrhosis can 
progress to HCC and help with treatment strategies and even distinguishing different tumor 
subtypes in HCC. Further studies and correlation between MRI images and histology results are 
needed to achieve this goal. 
8 APPLICATION OF PROCA32.COLLAGEN1 IN DETECTION OF THORACIC 
AORTIC ANEURYSM (TAA)  
 Introduction  
Aortic aneurysms exhibit permanent luminal expansion of the aorta that portends rupture 
and usually leads to death. This disease occurs in both abdominal and thoracic aortic regions, 
which are termed as abdominal aortic aneurysms (AAAs) and thoracic aortic aneurysms (TAAs), 
respectively. Due to an incomplete understanding of molecular mechanisms and pathophysiologic 
processes, there is no proven medical therapy that can prevent expansion or rupture of either type 
of aortic aneurysms.  
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Patients with suspected dissection of the thoracic aorta require immediate diagnostic 
evaluation so that urgent therapeutic interventions can begin. Detailed information on associated 
findings, such as the extent of the dissection, the location of the entry site, the formation of 
thrombus in the false lumen, and evidence of pericardial effusion or aortic regurgitation may be 
helpful in selecting the best management plan and assessing the patient's prognosis [421-425]. The 
established diagnostic procedures, including aortography, [426, 427] contrast-enhanced x-ray 
computed tomography (CT), [428-433] and two-dimensional transthoracic color-flow Doppler 
echocardiography (TTE), [434-438] all have inherent procedural or diagnostic shortcomings. 
Transesophageal echocardiography (TEE) [439-441] and magnetic resonance imaging (MRI) 
[442, 443] are recent advances in noninvasive imaging technology that have been useful in 
assessing the thoracic aorta [444, 445].  
The degradation of the extracellular matrix (ECM) in the medial wall in aorta is key in the 
formation, progression and rupture of TAA [446]. Particularly, the turnover of collagen, an 
essential component of the ECM, is known to be responsible for the remodeling that occurs in the 
adventitia. Recent studies indicate that perturbations in collagen micro-architecture and networks, 
probably as a result of collagen degradation and inappropriate collagen deposition, may alter vessel 
wall response to mechanical load and lead to vessel wall failure [447]. Therefore, imaging collagen 
in AAA and TAA might provide valuable information about the state of aneurysm development 
and the identification of AAAs and TAAs prone to severely progress or rupture. 
8.1.1 Animal model of TAA and AAA 
Since it is difficult to acquire patient samples and perform experiments in humans directly, 
research focusing on defining mechanisms of AAAs has been frequently extrapolated from animal 
models. A commonly used animal model is subcutaneous infusion of angiotensin II (AngII) into 
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mice. Compared to other surgical approaches for inducing AAAs in mice, such as intra-aortic 
elastase perfusion or peri-aortic application of calcium chloride that require laparotomy [448, 449], 
this method does not require entry into the body cavity and requires minimal surgical expertise 
[450, 451]. 
Subcutaneous infusion of AngII through osmotic pumps to induce AAAs and TAAS was 
initially reported in low density-lipoprotein (LDL) receptor -/-mice fed a saturated fat-enriched 
diet [450], and subsequently in apo E -/- mice fed a normal laboratory diet [451]. Many recent 
studies have also demonstrated that AngII induces AAAs in normolipidemic mice [452-454]. The 
approach of infusing AngII has been applied to induce AAAs and explore molecular mechanisms 
as well as development of potential therapeutic strategies [455] since this model recapitulates many 
features observed in human AAAs. For example, risk factors of human AAAs such as smoking, 
aging, and male gender also augment AngII-induced AAAs in mice [456, 457]. The association of 
hypercholesterolemia with AAAs in humans requires clarification. However, it has been consistent 
that hypercholesterolemia augments AngII-induced AAAs in mice [458, 459]. Pathologies of 
AngII-induced AAAs in mice are highly heterogenous and are characterized by profound 
macrophage infiltration, collagen degradation, thrombotic formation and resolution, and 
neovascularization [460]. In contrast to the most common infrarenal aortic location of AAAs in 
humans, AngII-induced AAAs in mice occur in the suprarenal aortic region. Another ubiquitous 
feature of AngII-induced AAAs is the transmural medial break, leading to transmural thrombosis. 
It is unclear whether transmural elastin rupture occurs in humans since pathological development 
of AAAs in humans has not been exclusively studied due to lack of aneurysmal tissues from earlier 
stages. AngII infusion into mice also leads to profound expansion of the thoracic aortic region, 
that is predominantly restricted to the ascending aorta which is the most common region for TAAs 
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in humans [461, 462]. Similar to AngII-induced AAAs, TAAs induced during AngII infusion also 
recapitulate many features of human TAAs [463]. However, in contrast to AngII-induced AAAs, 
AngII-induced TAAs are not associated with hypercholesterolemia and do not have gender 
differences. The overall goal of subcutaneous AngII infusion into mice is to study pathological 
features and molecular mechanisms of AAAs and TAAs.  
In this Chapter, we first explored the use of multi-sequence high-field MRI to study the 
development of TAA in the animal model with subcutaneous infusion of angiotensin II (AngII) 
into mice. Then, we applied our recently developed protein-based collagen targeted MRI contrast 
agent, ProCA32.collagen1 with collagen-targeting capability to identify presence of collagen in 
the aneurysmal wall in aorta with molecular MRI.  
 Results 
8.2.1 MRI procedure for cardiac gating 
The fundamental challenges of cardiac MRI imaging is that movement of the heart 
throughout the cardiac cycle and the movement of the lungs during the respiratory cycle produce 
motion artifacts in the image. Respiratory motion can be alleviated with breath holding during 
imaging. The problem of heart motion can be solved with the use of ECG gated imaging. ECG 
gating allows for stop motion imaging by acquiring data only during a specified portion of the 
cardiac cycle, typically during diastole when the heart is not moving. The R wave of the ECG is 
used as a reference point with data acquisition being initiated following a given delay after the R 
wave. Images are created from data collected over a series of cardiac cycles (R to R intervals) (Fig. 
8.1 and 8.2) [464]. 
ECG electrodes are placed over the mouse’s chest right under the skin in both hands (Fig. 
8.1) using either a three or four lead configuration. Lead are positioned such to accentuate the R 
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wave and minimized the T wave. If the procedure is being used in humans, patients with a 
prominent T wave often prove difficult to image as misgating can occur from triggering off the T 
wave rather than the R wave. Artifacts also occur when there are differences in the length of the R 
to R interval, such as occurs in cardiac dysrhythmias. ECG gating may be impaired in people with 
a low ECG signal. A low ECG signal results from geometries that decrease signal to the ECG 
leads, such as in barrel chested patients with COPD. Large pericardial effusion can also decrease 
the ECG signal. A common gating artifact, known as the magnetohydrodynamic effect, occurs 
when ions within the blood are transported through a magnetic field, inducing a voltage and 
distorting the ECG recording. This artifact can often be overcome by vectorcardiogram gating 
(VCG), which can distinguish electrical activity of the heart from ions in the blood. In cases where 
ECG gating is unsuccessful, pulse triggering can be employed using a pulse oximeter with the 
systolic upstroke as the trigger for the pulse sequence. This technique is not very successful in 
patients with a delayed pulse upstroke relative to heart contraction [464]. 
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Figure 8.1 ECG gating procedure in mouse with TAA 
 
 
Figure 8.2 Cardiac and respiratory gating diagrams and module in mouse with TAA 
 
As it is observed in Fig. 8.2, there are two diagrams conducting the gating in 7.0 T MRI, 
one indicating the ECG gating by monitoring the mouse beat per minute (BPM) number and the 
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other one that is monitoring the mouse respiratory by breath per minute number. The MRI is signal 
is collected in between these signals.     
8.2.2 MRI pulse sequence  
For MRI scan of heart, several pulse sequences were used. Black blood T1-weighted and 
black blood proton density are one of the most common pulse sequences used for heart imaging 
as they show blood vessels as dark images. In black blood T1-weighted, TR of 13.82 ms and TE 
of 3.11 ms were used. For black blood proton density which has both T1 and T2 property, TR of 
250 ms and TE of 7 ms were used. For both of the pulse sequences, a total of 7 slices were collected 
with matrix size of 128×128, FOV= 35 mm with no gap. 
Dark Blood MR is vascular imaging strategy wherein the signal from flowing blood is 
suppressed (rendering it "black") rather than enhanced as it is in conventional Bright Blood MRI 
techniques.  Rapidly flowing or turbulent blood has a naturally low signal because of phase-
dispersion and time-of-flight signal losses. These effects may be further accentuated by application 
of flow-spoiling gradients, saturation bands, and/or inversion pulses. The well-recognized vascular 
"flow voids" seen on routine MR imaging represent a crude form of dark-blood MRI. 
8.2.3 MRI images of mouse with TAA 
After performing the ECG and respiratory gating and using the mentioned pulse sequences, 
MRI images of TAA and control mice were collected before and 16 and 24 hours post injection of 
ProCA32.collagen1. Several slices of MRI were collected focused on the aortic arch or thorax-I as 
shown in Fig. 8.3. Figure 8.4 shows the whole field of view of MRI which has the aorta shown in 
black hole at the center of the image (red circle). 
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Figure 8.3 Graphic image of different sections of aorta 
 
 
Figure 8.4 Black blood T1-weighted images of TAA mouse before and post injection of 
ProCA32.collagen1. 
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Figure 8.5 MRI images of black blood proton density-weighted of TAA-1 mouse before 
and post injection of ProCA32.collagen1. 
The black hole encircled in red in all images represent the aorta in the thorax region and the white 
area surrounding the aorta shown by red arrows is collagen surrounding the wall of aorta.   
Figure 8.5 shows the focused images on the aorta region before and 16 and 20 hrs post 
injection of ProCA32.collagen1 in mouse with TAA in black blood proton density-weighted 
images.   
 
Figure 8.6 MRI images of black blood T1-weighted of TAA-1 mouse before and post 
injection of ProCA32.collagen1. 
 
 
 
234 
 
Figure 8.7 MRI images of black blood proton density-weighted of normal mouse before 
and post injection of ProCA32.collagen1. 
 
Figure 8.8 MRI images of black blood T1-weighted of normal mouse before and post 
injection of ProCA32.collagen1. 
As it is observed from the above figures, white regions surrounding the aorta is enhanced 
20 hrs post injection of ProCA32.collagen1 which might be an indication of collagens surrounding 
the aorta.  
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Figure 8.9 MRI images of black blood proton density-weighted of TAA-2 mouse before 
and post injection of ProCA32.collagen1. 
As Fig. 8.9 demonstrates, clearly there is an enhancement in proton density MRI images 
16 hrs post injection of ProCA32.collagen1 which is possibly due to presence of collagen outside 
of aorta walls.  
 
Figure 8.10 MRI images of black blood T1-weighted of TAA-2 mouse before and post 
injection of ProCA32.collagen1. 
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Figures 8.9 and 8.10 are showing black blood MRI images of another TAA mouse which 
shows the areas of enhancement aroud16 hours post injection of ProCA32.collagen1. This might 
be an indication of presence of collagen around the aorta walls.  
8.2.4 Histology results of TAA and normal mice 
After MRI data collection, the mice were sacrificed and whole aorta was collected as 
shown in Fig. 8.11 and then they were sliced in paraffin embedded sections.  
 
Figure 8.11 Aortic images (ex vivo) from mice infused with AngII (TAA) and normal mouse 
(control). The area pointed with red arrow is where the MRI images where collected. 
Trichrome Stains (Masson) was used to study the presence of collagen fibers in the aorta 
walls. This procedure is intended for use in the study of connective tissue, muscle and collagen 
fibers. Trichrome Stain reagents are for ‘‘In Vitro Diagnostic Use’’. Trichrome stains are used 
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primarily for distinguishing collagen from muscle tissue. In general, they consist of nuclear, 
collagenous and cytoplasmic dyes in mordants such as phosphotungstic or phosphomolybdic acid. 
The procedure described here is using aniline blue as a collagen stain instead of a green dye. Tissue 
sections are treated with Bouin’s solution to intensify the final coloration. Nuclei are stained with 
Weigert’s iron hematoxylin, and cytoplasm and muscle are then stained with Beibrich scarlet-acid 
fuchsin. After treatment with phosphotungstic and phosphomolybdic acid, collagen is 
demonstrated by staining with aniline blue. Rinsing in acetic acid after staining renders the shades 
of color more delicate and transparent. 
 
Figure 8.12 Masson's trichrome stain of aorta in normal mouse.  
In the slide, nuclei are shown in black, cytoplasm is shown in red, muscle fibers are shown in red 
and collagen fibers are shown in blue. 
 Fig. 8.12 is showing the control mouse have some collagen fibers (blue) surrounding the 
muscle of aorta. Masson's trichrome stain was also performed for two TAA mice. The results are 
shown in Fig. 8.13 and 8.14.  
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Figure 8.13 Masson's trichrome stain of aorta in TAA-1 mouse. 
 
 
Figure 8.14 Masson's trichrome stain of aorta in TAA-2 mouse. 
 
As shown in Fig. 8.14, the amount of collagen fibers is relatively higher compared to TAA-
1 mouse and control mouse which confirms the enhancement in Figures 8.9 and 8.10. 
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 Summary  
In conclusion, ProCA32.collagen1 was used to image collagen fibers surrounding aorta 
wall in both normal and two Ang II mice with TAA. Black blood T1-weighted and proton density-
weighted MRI images were used to suppress the bright signal from the blood vessels to facilitate 
the visualization of aorta and its surroundings. Based on literature, collagen should appear as a 
bright signal in black blood pulse sequences. MRI images before and 16 and 20 hrs post injection 
of ProCA32.collagen1 demonstrate signal enhancement post injection around the aorta wall. 
Furthermore, based on histology analysis, TAA-2 mouse has more collagen fibers (blue) as shown 
by Masson's trichrome stain. Therefore, it can be concluded that ProCA32.collagen1 is capable of 
imaging collagen in mouse with thoracic aortic aneurism.  It is worth mentioning that, TAA and 
AAA models in a much later stage will have significant collagen expression and fibrosis which 
will be used in our future studies.   
9 APPLICATION OF PROCA32.COLLAGEN1 IN DETECTION OF 
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
 Introduction  
Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat is stored in 
the liver. This buildup of fat is not caused by heavy alcohol use. When heavy alcohol use causes 
fat to build up in the liver, this condition is called alcoholic liver disease. Two types of NAFLD 
are simple fatty liver and nonalcoholic steatohepatitis (NASH). Simple fatty liver and NASH are 
two separate conditions. People typically develop one type of NAFLD or the other, although 
sometimes people with one form are later diagnosed with the other form of NAFLD.  
Non-alcoholic fatty liver disease (NAFLD), defined as excess accumulation of fat in the 
liver, has become the most common cause for chronic liver disease in the Western world and is 
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estimated to impact at least 30% of Americans [465, 466] or Chinese [467] with the prevalence 
appearing to rise in recent years [468, 469]. Non-alcoholic steatohepatitis (NASH) is a subset of 
NAFLD, estimated to affect 2–5% of Americans, in which increased liver fat is accompanied by 
cellular injury, inflammatory infiltrate and, subsequently, liver fibrosis, which can progress to 
cirrhosis with it associated complications [470]. 
Nonalcoholic fatty liver disease is characterized by hepatic steatosis, without a history of 
excessive alcohol use, in the absence of other known liver diseases [471-474]. Nonalcoholic fatty 
liver disease is categorized into 2 subtypes: nonalcoholic fatty liver (NAFL), which is usually 
nonprogressive, and NASH, which is often progressive and can lead to cirrhosis and HCC [475]. 
Nonalcoholic fatty liver and NASH have traditionally been considered 2 separate clinical entities, 
rather than 2 points on a disease continuum [476]. Recent studies evaluating sequential liver 
biopsies are challenging this notion [477] .A systematic review and meta-analysis of paired biopsy 
studies found that both patients with NAFL and NASH have the potential to develop progressive 
liver disease [478]. The fibrosis progression rate from stage 0 to stage 1 for NAFL vs NASH is 14 
years vs 7 years, providing suggestive evidence that NAFL, NASH, and fibrosis progression are a 
continuum rather than separate diagnoses [478]. 
Patients with NAFL and mild lobular inflammation, without ballooning, had an increased 
risk of disease progression as compared with those without inflammation. Another retrospective 
study evaluated serial liver biopsies in 108 patients and found no significant difference in the 
proportion of fibrosis progression between patients with NAFL and those with NASH at index 
biopsy (37% vs 43%; P=.65). Similarly, a recent study analyzing paired liver biopsies over time 
found that even patients with bland steatosis can progress to NASH, especially in the setting of 
metabolic risk factors [479]. 
241 
For reasons that are not completely clear, NAFLD is more common in men than women 
and precise estimates of incidence rates for NAFLD are uncertain (because of difficulties with 
establishing a precise diagnosis during sequential follow-up) current incidence rates are 
approximately 20/10,000 person-years, peaking in the sixth decade of life. Current population-
based prevalence of NAFLD is approximately 30–40% in men and 15–20% in women and is even 
higher in people with type 2 diabetes mellitus (T2DM), occurring in up to 70% of this group of 
patients [480]. 
Establishing an accurate diagnosis of NASH is of major clinical importance. A histologic 
diagnosis of NASH is associated with cardiovascular disease and more rapid progression of liver 
disease. To accurately distinguish NASH from NAFL requires liver biopsy. Nonalcoholic fatty 
liver is defined as bland steatosis with minimal or no inflammation, whereas NASH is 
characterized by macrovesicular steatosis, ballooning, and mixed lobular inflammation with or 
without zone 3 perisinusoidal fibrosis [481, 482].   
Although fatty liver by itself is associated with other features of the metabolic syndrome 
such as obesity, diabetes mellitus type 2, hypertension and dyslipidemia, increased liver-related 
mortality is essentially limited to patients with NASH [483].  
Increased triglyceride deposition in the liver reflects an input/output imbalance of hepatic 
free fatty acid (FFA) metabolism. In obesity-associated NAFLD, there is an increase of FFA 
delivery to the liver, especially during the fed state, due to adipose tissue insulin resistance [484, 
485]. In addition, de novo lipogenesis is increased, [486] driven by the hyperinsulinemia as well 
as excess availability of carbohydrates. Compensatory increase in very low-density lipoprotein 
(VLDL) secretion is not sufficient to overcome the excess formation of triglycerides [487] while 
it is unclear whether β-oxidation is increased or decreased in these subjects [488]. 
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The accumulated triglycerides in steatosis appear to be relatively inert with benign 
outcome; hepatocellular injury is driven by lipotoxicity from FFAs and their derivatives, [489] as 
well as overloading of mitochondrial capacity. This initial metabolic stress activates multiple cell 
stress pathways, including generation of reactive oxygen species, endoplasmic reticulum stress 
and apoptosis. Injury signals from stressed or dying hepatocytes, lipids and chemokines activate 
an immune response, including recruitment and activation of variety of immune cells, further 
increasing cellular injury. Key mediators are the Kupffer cells and macrophages, which are further 
activated by bacterial products from the gut microbiome. Hepatocellular injury and immune cell 
activity converge to activate hepatic stellate cells, causing a change in their phenotype and 
deposition of collagen, resulting in increased fibrosis and hepatic architectural distortion. 
Although the injury patterns are common and conserved, there is variability between 
patients with NAFLD in the degree of activation of each individual pathway, likely accounting for 
the heterogeneity of clinical phenotypes and severity. This may be secondary to different external 
stimuli (ie, dietary composition), genetic components and modulation by the gut microbiome, 
among other factors. 
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Figure 9.1 Schematic representation of the putative mechanisms underlying the 
contribution of NAFLD to the increased risk of cardiovascular and kidney chronic diseases. 
Although there are no Food and Drug Administration-approved medications for NASH, 
there are several medications that have shown benefits in clinical trials. Prompt diagnosis, timely 
referrals, and effective treatments are necessary to improve the long-term outcomes of patients 
with NAFLD and NASH in the setting of primary care and general gastroenterology 
practices[490].  
NAFLD affects a substantial proportion of the population worldwide. Only a minority of 
subjects who have the condition develop liver-related complications. Predicting which patients 
will develop progressive disease is problematic. Currently, there is no available noninvasive test 
demonstrated to be simple, reproducible, and valid for disease staging in patients with NAFLD. 
Liver biopsy remains the gold standard investigation to distinguish between patients with NASH 
and those without NASH or bland steatosis, and to determine disease prognosis based on fibrosis 
staging [491].  
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Figure 9.2 Epidemiology of NAFLD. 
 
In this chapter, our efforts in extending the application of ProCA32.collagen1 in early 
detection of NASH will be discussed. Furthermore, liver cirrhosis induced by NASH diet has been 
imaged with ProCA32.collagen1. Based on our results, we have demonstrated that 
ProCA32.collagen1 can detect liver fibrosis even at a much earlier stage of nonalcoholic 
steatohepatitis where liver has a mixture of steatosis and fibrosis. Based on histology analysis, 
ProCA32.collagen1 can detect Ishak stage 1 of 6 or 1A Mild in NASH/CRN scoring systems.  
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 Results 
9.2.1 NASH animal model 
Two different groups of mice (n=4 in each group) on NASH diet were chosen for our 
studies in detection of NASH in NAFLD mice. First group, they had a liver-specific Comparative 
Gene Identification-58 (CGI-58) knocked out (LivKO) and second group were wild type (WT) 
mice. Both groups were fed with a western diet (D12079B) and fructose in drinking water (42g/L) 
starting from 6-week old. They were also fed with ASO with dose of 25g/kg per injection. IP 
injection was done twice a week. Fructose in drinking water was autoclaved and changed twice a 
week. They were on western diet all the time. 
9.2.2 Analysis of LivKO group 
ProCA32.collagen1 was injected through tail vein and MRI images of mouse livers of 
LivKO group were collected before and 3 and 24 hrs post injection of the contrast agent. Then the 
mice were sacrificed and their livers were collected and examined for histology analysis.  
 
Figure 9.3 Liver images of four LivKO mice with severe NASH and fibrosis. 
 
As it is seen from Fig. 9.3, livers are fatty and weights are much larger than normal livers. 
The liver weights were ranging from 5.0-5.9 grams.    
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9.2.3 MRI results of LivKO mice 
Similar to our previous MRI experiments, several pulse sequences were used to image 
LiveKO mice livers. Heavy T2-wrighted, T1 weighted, T1 map, and T2 map sequences were 
collected for all four mice and quantitative analysis was performed on the liver signal. Figures 9.4 
to 9.7 demonstrates the heavy T2-weighted MRI images of liver before and 3 and 24 hrs post 
injection of ProCA32.collagen1.   
 
Figure 9.4 Heavy T2-weighted MRI images of mouse 1 with significant fibrosis due to fatty 
liver before and 3 and 24 hrs post injection of ProCA32.collagen1.  
Regions shown in green, yellow and red are livers which show significant enhancement after 
injection of the contrast agent.  
MRI images are shown in both gray scale and color map to illustrate the amount of increase 
in the liver after injection of ProCA32.collagen1. The regions in the border of the images are fat 
that show a high intensity signal under MRI (red color).  
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Figure 9.5 Heavy T2-weighted MRI images of mouse 2 with significant fibrosis due to 
fatty liver before and 3 and 24 hrs post injection of ProCA32.collagen1.  
 
Figure 9.6 Heavy T2-weighted MRI images of mouse 3 with significant fibrosis due to 
fatty liver before and 3 and 24 hrs post injection of ProCA32.collagen1. 
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Figure 9.7 Heavy T2-weighted MRI images of mouse 4 with significant fibrosis due to 
fatty liver before and 3, 19 and 24 hrs post injection of ProCA32.collagen1. 
 
Figure 9.8 Contrast to noise ratio (CNR) analysis of fibrotic livers pre- and 3 and 24 hrs 
post injection of ProCA32.collagen1.  
A significant increase in CNR of livers was observed post injection of ProCA32.collagen1. The 
value almost doubled after the injection (n=4, * P < 0.05, student’s t-test). 
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9.2.4 Analysis of WT group 
ProCA32.collagen1 was injected through tail vein and MRI images of mouse livers of WT 
group were collected before and 3 and 24 hrs post injection of the contrast agent. Then the mice 
were sacrificed and their livers were collected and examined for histology analysis.  
 
Figure 9.9 Liver images of four WT mice with mild NASH and fibrosis. 
 
As it is seen from Fig. 9.9, livers are fatty and weights are larger than normal livers. The 
liver weights were ranging from 2.1-3.4 grams which are lighter than KO mice which is an 
indication of milder NASH and fibrosis.     
9.2.5 Comparison of heavy T2-weighted MRI results of WT and KO groups 
In order to study the ability of ProCA32.collagen1 in distinguishing between different 
stages of fatty liver, heavy T2-weighted MRI images of KO and WT mice were collected and 
compared before and 3 and 24 hrs post injection of the contrast agent. Contrast to noise ratio (CNR) 
analysis was also used to show the MRI signal enhancement different between livers after injection 
of ProCA32.collagen1. The results can be observed in Fig 9.10. As it is observed, CNR of both 
WT and KO mice increased 3 hrs post injection of the contrast agent, however, this increase is 
much higher for KO mice which might be an indication of portal hypertension existence in this 
group. In 24 hrs, the targeting ability of the contrast agent is visible as the KO mice with severe 
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NASH and fibrosis have larger CNR compared to WT mice. Moreover, CNR of WT mice has 
increased significantly compared to CNR at 3 hrs which confirms the targeting capability of 
ProCA32.collagen1.  
 
Figure 9.10 Heavy T2-weighted MRI images of WT and KO livers before and 3 and 24 
hrs after injection of ProCA32.collagen1 along with CNR their corresponding CNR.  
CNR of both WT and KO mice increased 3 hrs post injection of the contrast agent, however, this 
increase is much higher for KO mice which might be an indication of portal hypertension existence 
in this group. In 24 hrs, the targeting ability of the contrast agent is visible as the KO mice with 
severe NASH and fibrosis have larger CNR compared to WT mice. Moreover, CNR of WT mice 
has increased significantly compared to CNR at 3 hrs which confirms the targeting capability of 
ProCA32.collagen1.  
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9.2.6 Comparison of R1 map MRI results of WT and KO groups 
Since ProCA32.collagen1 has both r1 and r2 properties, T1 map MRI images of mouse 
livers from these two groups were also scanned to further confirm the results observed by heavy 
T2-wighted images. Using MATLAB software, T1 map data were processed and analyzed (Fig. 
9.11). Consistent with results in Chapter 5 where late stage liver cirrhosis (Ishak=5) and portal 
hypertension was detected in TAA/alcohol-induced mice, R1 has significantly increased at 3 hrs 
for KO group which has severe fatty liver. In addition, targeting process of ProCA32.collagen1 
was observed in 24 hrs time point.  
 
Figure 9.11 R1 map analysis of KO and WT Mice with fatty liver before and after 
injection of ProCA32.collagen1. 
R1 of both WT and KO mice increased 3 hrs post injection of the contrast agent, however, this 
increase is much higher for KO mice which might be an indication of portal hypertension existence 
in this group. In 24 hrs, the targeting ability of the contrast agent is visible as the KO mice with 
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severe NASH and fibrosis have larger R1 compared to WT mice. Moreover, CNR of WT mice has 
increased significantly compared to CNR at 3 hrs which confirms the targeting capability of 
ProCA32.collagen1. Moreover, ∆R1 analysis shows the highest enhancement for KO mice at 3 hrs 
and targeting at 24 hrs.   
9.2.7 Histology results of NASH mice 
After MRI analysis, detailed histology consisting of Sirius red stain for collagen and 
hematoxylin and eosin (H&E) for fat cells were performed to confirm the stage of fatty liver for 
these two groups. As the results demonstrate in Fig. 9.12 and 9.13, there is a distinctive  difference 
in liver structure among WT and KO groups showing the WT mice have mild fatty liver and KO 
mice have sever fatty liver disease.  
 
Figure 9.12 Sirius red staining collagen (red) of fatty mouse liver in KO and WT groups. 
Collagen networks in red color can be observed for both KO and WT groups, however, in KO mice 
much higher collagen levels can be observed which is an indication of the severity of fatty liver 
compared to WT which has milder fatty liver.  
 
 
253 
 
Figure 9.13 Hematoxylin and eosin (H&E) staining of fatty mouse liver in KO and WT 
groups. Microvesicular steatosis can be observed in both images, however KO mice has much 
higher degree of steatosis.  
 Summary 
ProCA32.collagen1 has proved that it has the capacity to detect early stage fatty liver 
disease and distinguish late stage from early stage NASH using both r1 and r2 property with high 
confidence. Moreover, at 3 hrs time point, ProCA32.collagen1 is able to show the vascular 
structural changes during late stage of NASH white at 24 hrs time point, the targeting capability 
occurs. Both R1 map and CNR analysis exhibit the higher enhancement in KO group liver 
compared to WT mice. Sirius red and H&E staining both confirmed the early stage of NASH in 
WT mice and late stage of NASH in KO mice.  
10 MAJOR FINDINGS AND FUTURE DIRECTION 
To achieve “Precision Diagnostics” in molecular imaging of chronic liver and heart 
diseases, first, we need to identify and validate biomarkers of early disease which may likely to be 
different than those of late stage disease. Second, we need to develop new high throughput methods 
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to develop imaging agents targeted to these new biomarkers. Third, we need to develop more 
sensitive, high-resolution imaging technologies that can multiplex signals.  
Monitoring different disease biomarkers in patients with invasive methods such as biopsy 
has so many disadvantages such as its invasiveness, high costs and sampling error, 
intra/interobserver variability, hospitalization in 1–5% of cases, mortality in 0.01–0.1% of cases, 
lack of accuracy due to substantial sampling error, cost associated morbidity, pain and bruising at 
the biopsy site, prolonged bleeding, infection of the biopsy site, and pneumothorax and 
hemothorax. For instance, there is a 33% error in diagnosis of liver cirrhosis which severely affect 
the patient outcomes. With its unique capacity to generate reproducible and non-invasive 
assessment of biological/disease processes of different organs at various time points, molecular 
imaging of disease biomarkers using MRI can be an important and ideal diagnostic tool to facilitate 
the understanding of the disease, monitoring disease progression and drug treatment and activity 
during preclinical and clinical application. However, one of the major limitations of MRI is lack 
of sensitive contrast agents with targeting capability.  
Disease biomarkers, are important indicators of disease formation and progression. Disease 
biomarkers have been extensively applied in the disease diagnosis for the identification of disease, 
prediction of disease progression and follow the effects of drug treatment. Image and quantify 
these biomarkers provides valuable information for the disease evaluation and treatment. Although 
huge progress has been made during the past few decades, immunohistochemistry after biopsy is 
still the major approach to evaluate biomarkers. Unfortunately, biopsy is an invasive technique; 
patient suffers huge pain during this process. Moreover, only limited samples can be collected by 
biopsy which could easily lead to false positive and false negative results. Therefore, non-invasive 
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imaging techniques, which enables image the biomarker in the whole disease tissue, are in urgent 
need for the disease diagnosis, especially cancer diagnosis and evaluation. 
Collagen type I is an appealing target for molecular imaging of a variety of diseases such 
as liver fibrosis, liver metastasis, breast cancer, pancreatic cancer and aortic aneurysms. In organ 
fibrosis and different cancers, collagen accumulation as well as its concentration increases by the 
disease progression. In addition, collagen type I is an extracellular protein which makes it 
accessible for any agent. Collagen type I meets the criteria for an ideal biomarker since its 
concentration can increase with disease progression to provide a quantitative level for disease stage 
(Early vs Late). In addition, its extracellular location can make it readily accessible by the probe. 
Collagen has different patterns which can reflect the disease cause and stage as well as providing 
information on the disease microenvironment to reflect the mechanism. Collagen type I is also 
responsive to treatment (Monitoring treatment) and it is specific in determining the disease state. 
In order to address major barriers in the field of clinical diagnostics, we have developed a 
collagen type I-targeted MR contrast agent, ProCA32.collagen1 to act as an agent to image chronic 
heart and liver diseases. We have successfully applied the contrast agent in a variety of mouse 
models with liver and heart disease.  
As discussed in Chapter 1, there is pressing need to develop more sensitive imaging agents 
for early diagnosis of different chronic liver and heart diseases. We have shown in Chapter 4 that 
ProCA32.collagen1 has improved sensitivity and targeting capability and superior biophysical 
characteristics compared to other previously developed contrast agents in our lab and clinically 
available contrast agents.  
The contrast agent has very high relaxivity at both 1.4 T (clinical magnetic field) and 7.0 
T compared to all clinically used contrast agents and majority of research-based agents. It has very 
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good Gd3+ binding affinity as well as high selectivity in the presence of other physiological metal 
ions such as Ca2+ and Zn2+. ProCA32.collagen1 has shown no signs of toxicity and has improved 
safety properties. It is very stable in serum and has strong resistance against transmetallation. 
ProCA32.collagen1 has low injection dosage given its high relaxivity as well as good collagen 
type I binding affinity, the highest reported for a collagen-targeted MRI contrast agent (Figure 
10.1). ProCA32.collagen1 has better collagen I affinity compared to EP-3533 (Kd = 1.4 µM) which 
is a research-based contrast agent based three Magnevists.  
 
Figure 10.1 Collagen type I binding affinity comparison between ProCA32.collagen1 
and EP3533. 
In Chapter 5 and 9, we have successfully applied ProCA32.collagen1 in early detection of 
alcohol induced mouse liver fibrosis and nonalcoholic steatohepatitis using both r1 and r2 property. 
ProCA32.collagen1 enables the first robust detection of early stage (Ishak stage 3 of 6) liver 
fibrosis and nonalcoholic steatohepatitis (Ishak stage 1 of 6 or 1A Mild) in animal models via dual 
contrast modes. ProCA32.collagen1 also provides the first non-invasive mapping of intrahepatic 
angiogenesis associated with vascular distortion during late-stage cirrhosis and heterogeneity via 
dynamic molecular imaging (DMI). 
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Figure 10.2 Animal Models of Liver Fibrosis. 
 
In Chapter 6, ProCA32.collagen1 was successfully used for early detection of human uveal 
melanoma tumors metastasis to mouse liver. ProCA32.collagen1 can detect UM tumors in liver in 
both implanted and metastatic mouse models. ProCA32.collagen1 can demonstrate tumor 
heterogeneity in metastatic model with 14-fold increase in contrast to nose ratio and has improved 
sensitivity compared to non-targeted agent (ProCA32-P40) and Eovist which could not detect any 
tumors. The contrast agent is able to show both UM patterns in liver (Nodular and Infiltrative). 
Based on MRI correlation with histology analysis, ProCA32.collagen1 is capable of detecting 
tumors as small as 0.250 mm2 which is much smaller than not only the current detection limit of 
10–20 mm but also tumors previously detected by ProCA32-P40. The dynamic range in detection 
was significantly improved with a 6-fold enhancement in the relative contrast for the implanted 
liver uveal melanoma tumor in mouse taken advantage of both relaxation property and imaging 
methodology 
In Chapter 7, we have used ProCA32.collagen1 in detection of hepatocellular carcinoma 
(HCC) in liver in DEN-induced mouse model. ProCA32.collagen1 has shown promising results in 
distinguishing cirrhotic regions in liver from HCC tumors, and finally, in Chapter 8, we have 
described our attempt in extending the application of ProCA32.collagen1 in imaging collagen in 
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mouse model of thoracic and abdominal aortic aneurysm (TAA/AAA) with subcutaneous infusion 
of angiotensin II (AngII) from implanted osmotic pump.  
 
Figure 10.3 Summary of application of ProCA32.collagen1in diagnosis of chronic diseases. 
Overall, by developing ProCA32.collagen1, we have tried to address several challenges in 
clinical diagnostics field and facilitate precision diagnostics. We have addressed early diagnosis 
to facilitate treatment or reversal of the disease. We have successfully imaged disease 
heterogeneity by monitoring spatial and temporal changes of biomarker (Collagen) to facilitate 
biopsy. We were also able to monitor drug treatment in liver fibrosis. The development of collagen 
targeting contrast agent is expected to have broad applications in detection and staging of various 
chronic diseases and probing heterogeneous microenvironment changes upon disease progression 
and treatment in different organs. This work will have broad applications in early diagnosis of 
chronic diseases as shown in Figure 10.2. 
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APPENDICES  
Appendix A. Identification of Calmodulin Binding Domain in Cx43 Gap Junction Protein 
Appendix A.1. Introduction  
Cellular communication is an important aspect in maintaining homeostasis within 
multicellular organisms. Processes such as hormone signaling, neural transmission, and cell-tocell 
adhesion have provided animals with a wide variety of communication mechanisms that operate 
with very high specificity. In addition to these mechanisms of cellular communication, individual 
cells also contain numerous protein channels that allow communication with the extracellular 
environment. In fact, membrane proteins can pass a large number of ions and metabolites across 
the cell membrane in very short time periods. With such numerous possibilities of cellular 
communication, it may appear that the direct connection between the intracellular environments 
of two adjacent cells provided by gap junctions would be redundant [492]. 
Multicellular organisms require various means of cellular communication to respond to 
internal and environmental stimuli. One method of communication is through the use of gap 
junctions, which allow the exchange of ions, nutrients and small metabolites from one cell to 
neighboring cells [493]. Gap junctions consist of the intercellular channels that mediate the cell-
to cell transfer of small molecules, including metabolites, second messengers, and ions, in 
mammalian cells [494]. Gap junctions are composed of two hemichannels (termed connexons) 
with each composed of six connexin (Cx) 3 subunits. The connexon from one cell joins in mirror 
symmetry with another connexon of the opposing cell. Currently, at least 20 connexin genes have 
been identified in the human genome, with connexin 43 (Cx43) the most ubiquitous connexin 
[495]. 
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Connexins (Cx) are proteins encoded by a multigene family that typically form cell-cell 
channels. To date, 21 Cx genes have been identified in the human genome and most of their Cx 
orthologues have been described in other vertebrate species. The assembly of connexins into gap 
junction channels (GJC) occurs in two main stages. Connexins first oligomerize into hexameric 
hemichannels (HC) in the Golgi apparatus, from where they are transported to the cell surface in 
vesicles and they fuse to the plasma membrane in an exocytotic process [496]. 
The number of HCs delivered to the plasma membrane can be represent only the 4-15% of 
total Cx protein [497]. Subsequently, hemichannels presented by adjacent cells make contact and 
dock to form a complete intercellular channel. During the docking process, the channel interior 
becomes isolated from the extracellular environment and the newly formed channel opens, 
allowing the direct exchange of ions, second messengers and metabolites between the interior of 
the two cells. New intercellular channels aggregate to form plaque-like structures, while older 
channels are endocytosed as double-membrane gap junction structures by one of the two 
contributing cells, indicating that the hemichannels remain docked during gap junction 
degradation. It was previously thought that hemichannels remained closed until docking during 
channel formation. However, the opening of undocked hemichannels has been demonstrated in 
solitary Xenopus oocytes expressing the lens Cx46 [498] and in isolated horizontal cells of the 
catfish retina [499]. Twenty years later, there is now evidence that HCs composed of different 
connexins can be electrically and chemically activated [500], and in native cells these HCs can 
mediate the rapid flow of ions across the cell membrane to regulate ionic homeostasis, and to 
facilitate the release of ATP, NAD+, glutamate or prostaglandins involved in autocrine/paracrine 
signaling [501], as well as the transfer of nitric oxide [502]. 
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Both Ca2+ and H+ play a role in chemical gating of gap junction channels, but, with the 
possible exception of Cx46 hemichannels, neither of them is likely to induce gating by a direct 
interaction with connexins. Some evidence suggests that low pHi affects gating via an increase in 
[Ca2+]; in turn, Ca2+ is likely to induce gating by activation of CaM, which may act directly as a 
gating particle. Each Cx43 monomer consists of four highly conserved transmembrane segments, 
a short N-terminal cytoplasmic region, one intracellular and two extracellular loops, and a C-
terminal tail. Variability in sequence homology across different connexin types is greatest in the 
intracellular loop and C terminus. Efforts to map the potential CaM-binding sites in Cx43 have led 
to conflicting results [503]. 
This protein family is related with many diseases, like skin disease, tooth, and heart 
diseases (Figure 3). The first inherited abnormality of a gap junction protein was reported in 1993 
with mutations in Cx32 in individuals with X-linked charcot-marie-tooth disease [504]. Then in 
1997, mutations in Cx26 were identified in case of deafness [505], a finding that led to the 
significant discovery that mutations in Cx26 are in fact a common cause for several forms of 
deafness. Later, mutations have been discovered in seven Cxs: Cx30, 30.3, 31, 40 43, 46 and 50 
to be related with different diseases. Among them, four connexins are associated with skin 
diseases, Cx26, Cx30, Cx30.3, Cx31. Cx46 and 50 have been shown to underlie cases of cataract. 
Gap junctions play an important role in maintaining cell and tissue function and 
homeostasis, and loss of function of connexin43 mutations has been linked to several serious 
human diseases. Cx43 is the most abundantly expressed human connexin. Recently, a CaM 
binding site was assigned to the second half of the cytoplasmic loop (CL) domain of Cx43, Cx44, 
and Cx50 and confirmed using surface plasmon resonance, circular dichroism, fluorescence 
spectroscopy, and nuclear magnetic resonance. Gap junctions have been shown to be regulated by 
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[Ca2+] and also mediated by CaM interacting directly with the connexin proteins. Zhou et al. 
indicated that the 136–158 amino acids of Cx43 bind with CaM with 1:1 stoichiometry in a Ca2+- 
dependent manner [506]. 
 
Appendix 1. Molecular organization and schematic topology of a gap-junctional plaque 
 
Recently, CaM binding sites have been identified on the cytoplasmic loop (CL) of at least 
three Cxs in the α family. It has been shown that the Ca2+ regulation of Cx43 gap junctions is 
blocked by CaM inhibitors. It is proposed that the carboxyl-terminal part of the Cx43 in the 
cytoplasmic loop (Cx43136–158) domain is essential in regulation of Cx43 gap junction by CaM 
in a Ca2+-dependent manner and eventually closure of Cx43 gap junction. The Cx43 CaM binding 
domain follows the 1–5-10 CaM-binding mode subclass with hydrophobic residues at positions 1, 
5, and 10 which is similar to the CAMBD of Ca2+/CaM-dependent kinase II (CaMKII). Ca2+-bound 
CaM induces a conformational change in cytoplasmic loop of Cx43 or a combination of both steric 
hindrance mechanisms cause the closure of the channel. Furthermore, it has been shown that, the 
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addition of CaMKII inhibits CaM-Cx43 cytoplasmic loop interaction which causes a subsequent 
transition of the channel from close to open state. 
Connexin43, which is a CaM target protein, is a membrane protein. Therefore, it is difficult 
to study the complex due to the challenges associated with the membrane proteins such as; 
difficulty in expression and purification, low solubility and conformational flexibility. Therefore, 
the intracellular regions of Cxs are largely “invisible” in the reported X-ray structures. Thus, the 
molecular mechanisms for CaM regulation of Cx43 are not well established. 
In this section, we have described a strategy to further study the binding between CaM and 
Connexin43 and possible role of transmembrane residues in CaM binding to Cx43 (Figure 5). In 
this approach, two fusion proteins with the sequences of Cx43(99-154) and Cx43(88-164) were 
designed and expressed. A peptide that contains the entire intercellular loop (Cx43, 99-154) was 
designed to study the interaction of CaM with the entire loop. Another peptide that contains the 
entire intercellular loop and also parts of the transmembrane domains (Cx43, 88-164) was designed 
to study the importance of the transmembrane domain to the interaction of CaM with intercellular 
loop. Initial studies between D-CaM and the two proteins suggest that there is an interaction 
between Cx43(88-164) + Fusion protein, however, the peptides are not purified yet. In order to 
purify the peptides TEV protease and thrombin used as enzymes to cleave the rest of the protein 
and produce only sequences of Cx43 (99-154) and Cx43 (88-164). Different cleavage conditions 
were used to test whether TEV protease can cleave the protein or not. 
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Appendix 2 CaM binding sites in gap junction. 
 
Appendix A.2. Expression and purification of His-tagged Cx43 (99-154) 
The vector carrying the sequence of thioredoxin protein fused at N-terminal which contains 
a histag before the sequence of the Cx43 (99-154) was transformed into BL21(DE3) Green E-coli 
cell strain. M9 medium was used for the expression of the protein. (Carbenicillin was used instead 
of ampicillin because of better stability). First the protein was expressed in small scale (200 mL) 
and the bacterium was grown over night at 37°C, 200 rpm. Then the solution was induced into 2L 
of M9 medium and the bacteria was allowed to grow at 37°C until its optical density reached 0.6-
0.8, then 200 μL of IPTG was added for over expression of the protein and then the temperature 
was immediately decreased to 28°C and it was allowed to grow over night. Then in the morning 
the cell debris was collected. Figure 13 shows the full sequence map of Cx43(99-154) with fusion 
protein and TEV cleavage site. Figure 14 demonstrates SDS-page results for expression of 
Cx43(99-154).  
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Appendix 3 Mechanism of Cx43 purification with TEV protease. 
 
 
Appendix 4 SDS-page results for expression of Cx43(99-154). 
 
After centrifuge and collecting the cell debris, the following buffer was used: 25 mM 
HEPES, 500mM NaCl, 1% sarkosyl, pH=7.2, and after that 5 to 10 mL of the buffer was added 
and then Lysozyme was added to the final concentration of 150 μg/mL and the solution was 
incubated for 30 min at 37°C. Then it was sonicated 3 times for 30 seconds, and 5 min rest between 
each sonication, and then it was centrifuged. The same buffer was used to wash the cell debris for 
the second time. For the third time 2M of Urea, 20 mM Tris-HCl, 0.5 M NaCl, and 2% Triton X-
100 (pH=8) was used to wash and lysate the cell debris and denature the protein in order to make 
it more soluble. Finally, after centrifuge and collecting the cell debris, it was washed with 6 M 
Guanidine hydrochloride, 1 mM 2-mercaptoethanol, 20 mM Tris-HCl, 0.5 M NaCl, 5 mM 
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Imidazole (5 mL), and then let it stir for 1 hour at room temperature, and then it was centrifuged 
at 4°C, 7000 rpm, 20 min. The reason for washing with this buffer is again to make the protein 
more soluble by denaturing it. Only 5 mL of the last buffer was used to wash the cell debris for 
FPLC injection. 
Appendix A.3. FPLC Purification of Cx43 (99-154) using His-tag Column 
First the column was washed with EDTA to remove any positively charged ions. Then, 
FPLC column was charged with Nickel ions, so that the desired protein which has six consecutive 
histidine residues can bind to the column. Then the column was washed with high concentration 
of Urea (20 mM Tras-HCl, 0.5 M NaCl, 20 mM imidazole, 1mM 2-mercaptoethanol, 6 M of Urea) 
to unfold the protein and then it was washed with 0M of Urea (20 mM Tras-HCl, 0.5 M NaCl, 20 
mM imidazole, 1mM 2-mercaptoethanol, 0 M of Urea) to refold the protein back again. In order 
to equilibrate the column, the buffer with high concentration of guanidine (6M) was used to wash 
the column. Since imidazole forms a strong complex with nickel, finally high concentration of 
imidazole was used to elute the protein out of the column. These two buffers were used for the 
purification in the FPLC column. The buffer which has lower concentration of imidazole was used 
to equilibrate the column (Buffer A: 20 mM Tras-HCl, 0.5 M NaCl, 20 mM imidazole, 1mM 2- 
mercaptoethanol, pH=8.0). (Buffer B: 20 mM Tras-HCl, 0.5 M NaCl, 500 mM imidazole, 1mM 
2-mercaptoethanol, pH=8.0). After elution, a large peak came out from the column and samples 
were taken from the peak fractions for SDS-page to confirm that the protein is pure. As it is shown 
in Appendix 5, fractions 28 to 41 contain single band which confirms they contain our protein 
based on the molecular size. 
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Appendix 5 Purification of Cx43(99-154) with Fusion Protein. 
 
The column was washed with high concentration of Urea (20 mM Tras-HCl, 0.5 M NaCl, 
20 mM imidazole, 1mM 2-mercaptoethanol, 6 M of Urea) to unfold the protein and then washed 
with 0M of Urea (20 mMTras-HCl, 0.5 M NaCl, 20 mM imidazole, 1mM 2-mercaptoethanol, 0 M 
of Urea) to refold the protein back again. After the purification, in order to remove the imidazole, 
desalting column was used and the protein solution was passed through the column, and then the 
protein was dialyzed against 10 mM Tris in pH of 8.0. After that the concentration and yield of the 
protein was calculated. Appendix 6 indicates the FPLC results for desalting column, and Appendix 
7 corresponds to concentration and yield of the protein. 
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Appendix 6 Imidazole removal from the protein using desalting column. 
 
 
Appendix 7 Cx43 (99-154) concentration calculation based on UV absorbance. 
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Appendix A.4. Testing TEV Protease Cleavage Conditions with Purified Cx43(99-154) 
with fusion protein 
After the protein was purified, in order to see whether direct addition of the enzyme cleaves 
the protein or not, different amounts of the enzyme were directly added to the purified protein. For 
this purpose, two sets of experiments were designed. First, the factor of time was changed, and 
second, the amount of the enzyme was changed. Appendix 8 summarizes these two sets of 
experiments. 
 
Appendix 8 SDS-page results for testing different cleavage conditions of TEV protease, 
C1 and C2 correspond to protein and the enzyme, respectively. 
For experiment set No.1 (1 to 4), the amount of the enzyme was changed and the time was 
kept constant at 4°C overnight for 2 days. As you can see, the more enzyme is added the more 
cleavage of the protein occurs and it results in two products: 1. Fusion protein with histag which 
is 16.9 kD and 2. The peptide fragment which is 6.5 kD and corresponds to Cx43 (99-154), 
therefore, it can be concluded that amount of the enzyme plays a role in the cleavage. In experiment 
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set No.2 (1’ to 3’), only the time was changed to 2h, 4h and 6h at room temperature. Based on 
SDS-page results, no cleavage occurred during the tested times. We can conclude that if the 
cleavage occurs at room temperature, TEV protease will degrade and autolysis happens which 
result in a dramatic reduction in the enzyme activity, therefore no cleavage will carry out. 
Appendix 9 shows the cleavage products of Cx43(99-154) with fusion protein. 
 
Appendix 9 The cleavage products of Cx43(99-154) with fusion protein. 
 
Appendix A.5. New method for Purification of Cx43 (99-154) 
After adding the pure enzyme to pure fusion protein, everything that is in the solution has 
histidine tag except our desired peptide, therefore, we have come up with a new purification 
protocol. In this procedure, after letting the cleavage reaction complete, nickel beads were added 
to the mixture, and they were mixed with the solution for 2 hours at 4°C, then the mixture was 
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centrifuged and the supernatant was separated from the beads. Theoretically, the peptide should 
be in the supernatant and the enzyme, cleaved fusion protein, and uncleaved protein will bind to 
nickel beads. After performing the mentioned experiment, the Cx43 (99-154) was successfully 
purified from the mixture. Figure 20 shows the experiment steps for purification of Cx43 (99-154) 
peptide. 
 
Appendix 10 The enzyme, uncleaved protein, and cleaved fusion protein have histidine tag 
therefore, nickel beads can be used to separate the peptide from the mixture after cleavage. 
After obtaining the supernatant, SDS-page was run to make sure the peptide is pure. 
Appendix 11 shows the pure peptide after cleavage with molecular weight of 6.5 kDa. 
The final concentration of peptide was calculated to be 993 μM with the final yield is 4 mg 
L-1. 
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Appendix 11 Pure Cx43 (99-154) after Purification.  
 
Appendix A.6. Monitoring the Interaction between Cx43 (99-154) and Calmodulin 
After obtaining the pure peptide, steady-state and anisotropy fluorescence spectroscopy 
was used to monitor the interaction between CaM and Cx43 (99-154) peptide. For this purpose, in 
steady state fluorescence spectroscopy, 4 μM of dansylated CaM was used, and the signal of dansyl 
chloride was monitored during the interaction. Different volumes of the peptide were titrated to 
CaM. The titration was continued until the total concentration of the peptide in the solution reached 
30 μM. After adding different volumes of the peptide no increase in the signal was observed 
suggesting there is no interaction between the peptide and dansyl CaM. To further prove there is 
no interaction, fluorescence anisotropy was used. Fluorescence anisotropy can be used to measure 
the binding constants and kinetics of reactions that cause a change in the rotational time of the 
molecules. If the fluorophore is bound to a small molecule, the rate at which it tumbles can 
decrease significantly when it is bound tightly to a large protein. If the fluorophore is attached to 
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the larger protein in a binding pair, the difference in polarization between bound and unbound 
states will be smaller (because the unbound protein will already be fairly stable and tumble slowly 
to begin with) and the measurement will be less accurate. The degree of binding is calculated by 
using the difference in anisotropy of the partially bound, free and fully bound (large excess of 
protein) states measured by titrating the two binding partners. After performing the experiment, 
again no interaction was observed proving our previous steady state fluorescence experiment. 
Appendix 12. Illustrates the mentioned experiment. 
 
Appendix 12 Fluorescence Steady State and Anisotropy of Dansyl-CaM and Cx43(99-
154). 
Appendix A.7. Purification of Cx43 (88-163) Peptide 
Using the same procedure discussed in section 2.12, another peptide with transmembrane 
residues was purified. This peptide consists of the same resides that Cx43 (99-154) peptide had 
with additional transmembrane residues at both ends. Figure 23 demonstrates the SDS-page results 
for purification of Cx43 (88-163) peptide. 
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Appendix 13 The purified Cx43 (88-163) peptide. 
 
After obtaining the other peptide, a preliminary study was performed using steady-state 
fluorescence spectroscopy. As you can see in figure 24b, after titrating the peptide to dansyl-CaM, 
an increase and blue shift was observed which suggests the possible binding of CaM to Cx43(88- 
163) peptide. Appendix 14 illustrates the interaction and comparison between the two peptides and 
their interaction with Dansyl-CaM. 
 
Appendix 14 Comparison between the interactions of two peptides with dansyl-CaM. 
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Appendix A.8. Summary and conclusion  
Based on the new purification technique that we used, two peptides one consisting of the 
whole loop of Cx43 (99-154) and another one which has loop with transmembrane residues were 
successfully purified. Fluorescence steady-state and anisotropy were used to monitor the 
interaction between Cx43 (99-154) and Cx43 (88-164) peptides with dansyl-CaM. Based on the 
preliminary results, Cx43 (88-163) binds to dansyl CaM, however, Cx43(99-154) does not show 
any increase or blue shift in the signal of dansyl-CaM which suggests there is not interaction 
between them. 
 
 
